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 ABSTRACT 
Prescription stimulant use for neurocognitive enhancement is a significant 
problem among college students with and without ADHD. The primary reason 
students report misusing stimulant medication is to enhance academic functioning. 
Given that increasing numbers of students are misusing prescription stimulants, it is 
critical to explore whether empirical findings support neurocognitive benefits of 
prescription stimulants. Hence, the primary purpose of this meta-analytic study was to 
examine the potential effects of prescription stimulants on cognitive functioning of 
adults with and without ADHD. A systematic search and retrieval process resulted in 
the calculation of effect sizes from 91 studies. Fourteen meta-analyses were conducted 
across three levels of constructs, ranging in scope from broad to narrow. Findings 
indicated significant, but small effect sizes for cognition (g = 0.15), as well as the 
broad cognitive constructs of abilities of focused behavior (g = 0.14), learning and 
memory (g = 0.10), and executive function (g = 0.13). Small effect sizes were also 
revealed for the narrow cognitive constructs of inhibitory control, working memory, 
processing speed, declarative learning and memory, and self-regulation. Effects were 
the greatest for declarative long-term memory (g = 0.50) that was assessed 1 to 7 days 
following drug administration and learning, suggesting that ADHD medication may 
proffer academic benefits for college students. Studies investigating the effects of 
ADHD medication on measures of non-declarative memory and planning and 
decision-making, however, resulted in effect sizes that approached zero. Furthermore, 
23 variables (e.g., study design, participant characteristics, medication type) were 
assessed as potential moderators, but the majority of analyses did not reveal significant 
differences between outcomes. Of particular note, differences between the 
 neurocognitive effects of ADHD medication on adults with and without ADHD were 
not supported. These findings suggest that ADHD medication may indeed act as a 
neurocognitive enhancer, but only for specific domains of cognition. Considering that 
college students are already engaging in illegal use of prescription stimulants for 
academic enhancement, as well as the potential for stimulant misuse to have serious 
side effects and adverse outcomes, these results point to the glaring need for public 
policy concerning the misuse of prescription stimulant medications.  
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CHAPTER 1: BACKGROUND 
Statement of the Problem 
The efficacy of prescription stimulant and prostimulant medications for the 
reduction of Attention-Deficit/Hyperactivity Disorder (ADHD) symptomatology 
among adults and children has been well documented through clinical trials and meta-
analyses (Faraone, 2012; Faraone & Biederman, 2002; Faraone & Buitelaar, 2010; 
Faraone and Glatt, 2010). Prescription stimulant use for cognitive enhancement, 
however, as opposed to ADHD symptom management, is a growing problem among 
college and non-college students with and without ADHD (Babcock & Byrne, 2000; 
Dupont, Coleman, Bucher, & Wilford, 2008; Dussault & Weyandt, 2013; Hall, Irwin, 
Bowman, Frankenberger, & Jewett, 2005; Janusis & Weyandt, 2010; Judson & 
Langdon, 2009; Low & Gendaszek, 2002; McCabe, Knight, Teter & Wechsler, 2005; 
Novak et al., 2007; Pilkinton & Cannatella, 2012; Rabiner et al., 2009; Verdi, 
Weyandt, & Zavras, 2014; Weyandt et al., 2009; Weyandt et al., 2013a). Given the 
consistent finding that college students report enhancing academics as their primary 
reason for misusing stimulant medication (Advokat, Guidry & Martino, 2008; Bossaer 
et al., 2013; DeSantis, Noar & Webb, 2008; Garnier-Dykstra et al., 2012; Habibzadeh 
et al., 2011; Rabiner et al., 2009; Teter et al., 2005; White et al., 2006; Weyandt et al., 
2009), and adults with ADHD have indicated productivity as a motivation for 
stimulant misuse (Novak et al., 2007), it is important to examine the potential effects 
of prescription stimulant medications on cognitive enhancement. While two reviews 
have assessed the effect of prescription stimulants on cognition in adults with and 
without ADHD, and have concluded that the effects of stimulant medications on 
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cognitive enhancement vary according to population and task (Advokat, 2010; Smith 
& Farah, 2011), these reviews relied on studies that were underpowered and varied in 
design, potentially impeding comparisons across studies. Indeed, Smith and Farah 
(2011) stated that although larger clinical studies assessing the cognitive effects of 
stimulants are warranted, such studies are unlikely to be funded given “cognitive 
enhancement falls between the two stools of research funding” (i.e., disease-oriented 
and pharmaceutical funders) (p. 736). Additionally, in their meta-analysis examining 
prescription stimulant efficacy for ADHD symptoms, Faraone, Biederman, Spencer, 
and Aleardi (2006) reported that comparing effect sizes and results across prescription 
stimulant studies without using statistical techniques to account for study differences 
(e.g., meta-analysis) would result in biased conclusions. Therefore, a meta-analysis 
examining the efficacy of prescription stimulant medications for cognitive 
enhancement in adults with and without ADHD, accounting for medication type, 
medication dose and study design, would greatly contribute to the literature.  
To date, no systematic meta-analyses concerning ADHD medication for 
neurocognitive enhancement including adults with and without ADHD have been 
conducted. Furthermore, previous meta-analytic studies (Ilieva, Hook, & Farah, 2015) 
have only explored the effects of amphetamine (AMP) and methylphenidate (MPH) on 
working memory, episodic memory and inhibitory control, but no studies have 
conducted meta-analyses concerning the effects of ADHD medication on the cognitive 
behaviors related to vigilance, processing speed, non-declarative memory, planning 
and decision-making, or self-regulation. Findings from such a study will provide 
important implications for the use and misuse of prescription stimulants as a “smart 
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pill” (Smith & Farah, 2011, p. 717) for adults seeking to enhance their cognitive 
functioning and college students hoping to improve their academic outcomes. 
Therefore, this meta-analytic study will examine whether prescription stimulants play 
a role in multiple domains of cognitive functioning of adults with and without ADHD. 
The primary hypothesis is that prescription stimulant and prostimulant medications 
will demonstrate general positive effects on cognition among adults with and without 
ADHD. Secondary hypotheses are that the greatest benefits will be found for a) 
samples of adults receiving the highest stimulant and prostimulant doses, b) samples 
of adults within studies that time the administration of stimulant and pro-stimulant 
medication to peak during learning, c) samples of adults with lower cognitive baseline 
functioning, and d) samples that include adults with ADHD. 
Attention-deficit/hyperactivity disorder (ADHD) 
Attention-deficit hyperactivity disorder (ADHD) is a childhood-onset 
neurodevelopmental disorder characterized by clinical levels of inattention, 
impulsivity, and/or hyperactivity (American Psychiatric Association, 2013) with 
genetic, environmental, and biological bases (Biederman, 2005; Weyandt, 2006). 
Although symptoms of ADHD were previously believed to attenuate by adulthood, 
studies examining adults with ADHD have demonstrated that clinical levels of 
inattention, impulsivity, and hyperactivity may persist into adulthood for a majority of 
individuals (Biederman, 2005; Faraone et al., 2000; Wilens, Faraone, & Biederman, 
2004). In particular, symptoms of ADHD in adults may manifest as internal 
restlessness, difficulty with relaxation, excessive talking, excessive fidgeting, and 
difficulty with sitting for long periods (Kooij et al., 2010; Weyandt, et al., 2003; 
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Weyandt, Hays & Schepman, 2005). Prevalence rates of ADHD have been estimated 
to approximate 5% among children and adolescents and between 2.5 and 4% among 
adults (American Psychiatric Association, 2013; Kessler et al., 2006). Negative long-
term consequences, such as school dropout, lower likelihood of college completion, 
and decreased levels of work productivity and performance, have been associated with 
ADHD (Adamou et al., 2013; Barkley et al., 2002). Furthermore, college students with 
ADHD have demonstrated impaired neuropsychological, social, emotional, academic 
and psychological functioning compared to college students without ADHD (Weyandt 
et al., 2013b). 
Pharmacotherapy Treatment for ADHD 
Recommended treatment of ADHD in adults is similar to that of children, 
involving a multimodal approach including psycho-education, pharmacotherapy, 
coaching, cognitive behavior psychotherapy, and/or family therapy (Kooij et al., 
2010). First-line psychopharmacotherapy treatments for adults with ADHD include 
approximately ten types of stimulant medications, such as long acting oros-
methylphenidate, mixed amphetamine salts (MAS), and dexmethylphenidate (d-
AMP), as well as lisdexamfetamine dimesylate (LDX), a prostimulant (Kooij et al., 
2010). The most commonly prescribed stimulant medications among adults, however, 
include methylphenidate (MPH), with trade names of Ritalin or Concerta, and 
amphetamine (AMP), generally prescribed in the form of MAS composed of d-AMP, 
with the trade name of Adderall (Arnold, 2000; Heal, Cheetham & Smith, 2009; Smith 
& Farah, 2011). Specifically, MPH and MAS have been estimated to make up 34.5% 
and 43.4% respectively of ADHD medication prescriptions for adults (Castle et al., 
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2007). Additional pharmacotherapies include non-stimulant medication, such as 
atomoxetine (ATX), which potentially has a lower abuse potential given its chemical 
structure. ATX is a selective inhibitor of norepinephrine (NE) (or noradrenaline) 
transporters and is believed to increase dopamine (DA) and NE concentrations in the 
prefrontal cortex (PFC) (Marquand et al., 2011; Swanson et al., 2006). Nonstimulant 
medication, as well as medications such as long-acting bupropion, modafinil, and 
guanfacine, may be effective for patients unresponsive to stimulants or who have 
conditions that contraindicate stimulant use (e.g., cardiac conditions, addiction) (Kooij 
et al., 2010).   
All of the catecholaminergic stimulant medications approved by the FDA for 
use by adults with ADHD contain either MPH or AMP (Weisler & Childress, 2011). 
Although stimulants as a class are believed to enhance neurotransmission of both DA 
and NE throughout the central nervous system, the underlying mechanisms of action 
vary according to stimulant type and are not completely understood (Arnold, 2000; 
Faraone & Buitelaar, 2010; Heal et al., 2009; Weyandt, 2006). For instance, some 
studies suggest that MPH blocks DA transporters, with higher doses resulting in 
higher occupancy of DA transporters (Volkow et al., 1998) and does not involve other 
presynaptic activity (Arnold, 2000). AMP, however, is thought to increase the release 
of DA and NE, in addition to blocking DA reuptake (Arnold, 2000; Weisler & 
Childress, 2011). LDX also results in increased DA and NE neurotransmitters and 
blocking of DA reuptake because it is a long-acting prodrug that when absorbed into 
the bloodstream is hydrolyzed into d-AMP and L-lysine, a naturally occurring amino 
acid (Heal et al., 2009; Pennick, 2010; Rowley et al., 2014). Limited by their half-life, 
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short-acting agents last between two to five hours and long-acting agents may last 
between six and 12 hours; therefore, in adults, a combination of both immediate and 
extended release stimulants may best help control symptoms of ADHD throughout a 
12-16 hour day (Weisler & Childress, 2011). Stimulant medications, e.g., MPH, are 
believed to improve ADHD symptoms because of their effects on the 
catecholaminergic neurotransmission in fronto-subcortical circuits that are associated 
with cognitive processes, such as goal-driven behaviors, attentional processes, and 
response inhibition (Britton, 2012; Weyandt, 2006). 
Efficacy of Prescription Stimulant and Prostimulant Medication 
ADHD Symptoms 
While the efficacy of pharmacotherapy for the reduction of ADHD symptoms 
has been clearly established among samples of children and adolescents with ADHD, 
fewer studies have examined effects among adults (Wilens et al., 2004). Still, a 
plethora of studies demonstrating the positive effects of both stimulant and 
prostimulant medications with adult populations exist (e.g., Adler et al., 2008; Adler et 
al., 2009; Bouffard, Hechtman, Minde, & Iboni-Kassab, 2003; Faraone, 2012; Jain et 
al., 2007; Kooij et al., 2004; Spencer et al., 2005; Spencer et al., 2007; Spencer, Adler, 
Weisler, & Youcha, 2008; Stein et al., 2011; Weisler et al., 2006).  A recent meta-
analysis conducted by Faraone and Glatt (2010) revealed that both short-acting and 
long-acting stimulants yielded greater effects for the improvement of symptoms 
related to ADHD compared to the effects of non-stimulants (e.g., ATX, Bupropion, 
and Modafinil). 
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Cognition 
High school students with ADHD have been found to be less likely to 
graduate, less likely to attend and graduate from college, and perform worse 
academically than students without ADHD (Adamou et al., 2013; Advokat, Lane, & 
Luo, 2011; Barkley et al., 2002; Barkley, Fischer, Edelbrock, & Smallish, 1990; 
Bussing et al., 2012; Faraone et al., 1993). Although deficits in academic performance 
are associated with behavioral tendencies such as disruptive behavior, inattention, and 
difficulty remaining seated (Barkley, 2006; Danforth, Connor, & Doerfler, 2014; 
Faraone et al., 1993), deficits in cognitive functioning are often assumed to be 
precursors to symptoms of ADHD (although some researchers are criticizing this 
assumption) (Coghill et al., 2013). In fact, improvements in cognition, defined as 
multiple processes of knowing that involve attention, memory and reasoning (Gerrig 
& Zimbardo, 2014), are generally a perceived benefit of stimulant medication by 
stimulant misusers (DeSantis et al., 2008; Rabiner et al., 2009).  
Children, Adolescents, and Adults. Studies and reviews examining the 
cognitive effects of prescription stimulant medication on children and adolescents 
have suggested these medications may indeed act as neurocognitive enhancers in some 
domains of cognition, although with only modest effects. Coghill and colleague’s 
(2013) recent review and meta-analysis examined the effects of MPH on cognitive 
functions in children and adolescents with ADHD and found that MPH showed small 
to moderate positive effects compared to placebo for memory, reaction time, reaction 
time variability, and response inhibition. Results were based on findings from 36 
studies using psychometrically sound instruments to measure executive and 
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nonexecutive neurocognitive outcomes. Furthermore, Repantis and colleagues (2010) 
conducted a systematic meta-analysis examining the effects of MPH and Modafinil for 
neuroenhancement among healthy children, adolescents and adults and found a 
positive effect of MPH for memory, but not for attention, mood, or executive function 
(Repantis et al., 2010). Furthermore, one review (Weyandt et al., 2013a) found overall 
improvements related to attention, impulsivity, memory and response inhibition for 
children and adults with ADHD. Most recently, in their systematic review of the 
effects of prescription stimulants and stimulant misuse among adolescents and adults, 
Weyandt et al. (2014) found that prostimulants associated with improvements in 
executive function tasks and some domains of cognition for college students and 
adults, including performance productivity in adults between the ages of 18 to 45.  
Adults. Regarding the potential for ADHD medication to be used as a 
cognitive neuroenhancer for adults specifically, two reviews have reported mixed 
findings related to the effects of prescription stimulant medication on cognition among 
adults with ADHD (Advokat, 2010) and without ADHD (Advokat, 2010; Smith & 
Farah, 2011). Additionally, one meta-analysis (Ilieva et al., 2015) suggests that MPH 
and AMP may have small effects on cognition in healthy adult populations.  
In their review on the effects of stimulant medications on cognition, Smith and 
Farah (2011) concluded that stimulant medication may have positive effects on 
learning for healthy adults between the ages of 18 and 45. Cognitive effects were 
assessed via both declarative and non-declarative learning tasks, with effect sizes 
ranging from small to large. The findings related to other components of cognition 
from Smith and Farah’s review, however, were mixed. Specifically, studies examining 
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effects on working memory demonstrated mixed results, with significant findings 
ranging from small to large effects. Studies examining cognitive control, i.e., cognitive 
processes involving the resisting of impulses, yielded more null findings than 
significant findings, yet the reported effect sizes were generally large, with greater 
enhancement for individuals performing worse prior to treatment. 
Advokat (2010) reported similar results in a review of studies examining the 
effects of MPH and AMP on cognition in children and adults with and without 
ADHD. Specifically, Advokat reported that while studies exploring the effects of 
stimulants on cognition generally demonstrated improvements in focused attention 
among adults without ADHD, a worsening of selective attention and distractibility 
may occur as evidenced by increased errors on tests of cognitive flexibility and set-
shifting (e.g., IDED, WCST) (Dyme et al., 1982; Rogers et al., 1999), as well as 
decreased response latencies (i.e. increased impulsivity) (Dyme et al., 1982; Elliott et 
al., 1997). Advokat concluded that although short-term acquisition does not improve 
and may actually be worsened by prescription stimulants, when prescription stimulants 
are acting during a period of memory consolidation they may improve long-term 
retention of information among adults without ADHD. These positive effects on 
memory acquisition, however, may differ according to baseline functioning (i.e., those 
with lower functioning may benefit more). Unfortunately, the effects of stimulants 
may also impede other types of performance requiring ‘cognitive flexibility,’ perhaps 
because of increased arousal leading to more impulsivity in individuals with higher 
baseline performance compared to individuals with lower baseline performance 
(Advokat, 2010, p. 1262). Among adult samples with ADHD, Advokat reported that 
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prescription stimulants have led to improvements in sustained attention  (e.g., 
Barrilleaux and Advokat, 2009; Wilson, Cox, Merkel, Moore, & Coghill, 2006) and 
positive effects on verbal memory performance over 3-6 months (Kurscheidt et al., 
2008). Advokat (2010) noted, however, that some studies have reported inconsistent 
and null effects from prescription stimulants on tests of distractibility, i.e., interference 
in reaction time, and planning.  
A recent meta-analysis (Ilieva et al., 2015) investigating prescription stimulant 
effects on inhibitory control, working memory, and episodic memory supported many 
of the conclusions drawn by Advokat (2010) and Smith and Farah (2011). 
Specifically, Ilieva et al.’s findings revealed significant, but small effects of AMP and 
MPH on inhibitory control, working memory, and short-term episodic memory, as 
well as moderate effects on delayed episodic memory. The latter finding, however, 
was qualified with an indication for publication bias, leading the researchers to 
conclude these larger effects may not be an accurate representation for delayed 
episodic memory.  
Although there is evidence that healthy individuals perceive cognitive 
enhancement and may receive small, but significant cognitive benefits from taking 
prescription stimulant medications, a number of alternative reasons may explain their 
self-perceived and small effects of enhanced cognition; i.e., placebo effects, altered 
perception of quality of work, or enhanced energy and motivation to improve 
productivity (Hildt, Lieb, & Franke, 2014; Ilieva et al., 2015; Smith & Farah, 2011). 
Furthermore, limitations related to study designs (e.g., insufficient power to detect 
statistical significance, poor psychometric properties of outcome measures, doses of 
 11
 
medication that are too low to proffer effects) likely contribute to the mixed findings 
of prescription stimulant effects on cognition. A systematic meta-analysis examining 
individual components of cognition in addition to memory and inhibitory control, 
taking into account variability across studies, will help to elucidate whether and how 
prescription stimulants play a role in cognitive functioning of adults. 
Stimulant Misuse 
The research examining the efficacy of stimulant medication among 
populations with ADHD is relatively clear regarding reductions in ADHD symptoms, 
but less clarity exists regarding cognitive effects. Yet, non-medical stimulant use, 
which involves using prescription stimulant medication for reasons outside the scope 
of a prescription (Weyandt et al., 2013a), is a growing problem among college 
students who report misusing stimulants primarily to enhance academic functioning 
(e.g., Bossaer et al., 2013; Garnier-Dykstra et al., 2012; Verdi et al., 2014; Weyandt et 
al., 2013a). Weyandt and colleagues (2013a; 2014) conducted systematic reviews of 
stimulant misuse among college students and found the most common reasons 
students reported engaging in stimulant misuse related to increased concentration, 
studying, and performing well on tests. In fact, students engaging in stimulant misuse 
have reported perceiving enhanced cognition (DeSantis et al., 2008; Rabiner et al., 
2009) and shown less concern towards the ethical and safety ramifications of stimulant 
misuse (Judson & Langdon, 2009).  
Stimulant misuse is especially concerning given both AMP and MPH are 
classified as a schedule II drug by the FDA, indicating these drugs have a high 
potential for abuse that could lead to physiological and/or psychological dependence 
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(Kollins, 2007; Weyandt et al., 2014). Furthermore, numerous studies have reported 
on the extensive side effects and potential for adverse outcomes related to ADHD 
medication, including insomnia, appetite loss and anorexia, emotional lability, 
abdominal cramps, nausea and vomiting, dizziness, and nervousness, as well as 
changes in blood pressure and heart rate (Heal & Pierce, 2006; Weyandt et al., 2014). 
It is encouraging to note, however, that findings from a recent study hold promise for a 
brief expectancy challenge intervention to weaken positive cognitive enhancement 
expectancies (Looby, Young, & Earlywine, 2013).  
Unfortunately, college students and adults are engaging in non-medical 
prescription stimulant use and misuse at alarmingly high rates, with lifetime 
prevalence rates ranging from between 5 and 55% among college students and 7 and 
29% among adults outside of the college setting (Weyandt et al., 2013a; Weyandt et 
al., 2014). Therefore, researchers (e.g., Weyandt et al., 2013a) have called for more 
studies examining the cognitive effects of prescription stimulants among adults 
without ADHD. College students with ADHD, however, should not be overlooked 
because these students may be more susceptible to stimulant misuse and diversion 
than students without ADHD (Weyandt et al., 2014). Therefore, research examining 
the neurocognitive effects of prescription stimulants among students with ADHD is 
warranted. 
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CHAPTER 2: Cognitive Constructs and Measures 
 Cognition refers to the functional behavior of information-handling (Lezak, 
Howieson, Bigler & Tranel, 2012); however, prescription stimulants for 
neuroenhancement of cognition may refer to a variety of underlying constructs of 
cognition.  Major classes of cognitive function have been described by Lezak and 
colleagues (2012) to include receptive functions, learning and memory, thinking, and 
expressive functions, all of which may be separated according to verbal and nonverbal 
functions. There are numerous neurocognitive instruments designed to test these major 
areas of cognition. Tests of abilities of focused behavior, learning and memory, and 
executive function are among some of the most common assessments of cognition 
(Lezak et al., 2012) that have been used to measure ADHD medication for 
neurocognitive enhancement. The following section provides a description of these 
constructs, as well as common tests designed to assess them. It is important to note, 
however, that these constructs overlap, as do the instruments designed to measure 
them. Even within each instrument, specific measures may represent varying cognitive 
constructs. For example, a Continuous Performance Task (CPT) may provide a 
measure of both commission errors and omission errors – the former measure may 
primarily capture the construct of sustained attention, while the latter measure may 
primarily capture inhibitory control. Therefore, the following review, which includes 
the most commonly reported cognitive constructs, instruments, and measures in the 
literature concerning ADHD medication and cognition, should be interpreted as an 
overall guide for understanding measurement of cognition.  
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Abilities of Focused Behavior 
Abilities of focused behavior involve vigilance (sustained attention and 
inhibitory control), processing speed, and working memory, all of which rely on speed 
of processing within a time-limited capacity and regulate the activity of cognitive 
functions (Lezak et al., 2012). Although these behaviors work in concert, specific 
measures have been developed to target attention, processing speed, and working 
memory separately (Lezak et al., 2012).  
Vigilance and Inhibitory Control  
Vigilance, which involves sustained or focused attention (Lezak et al., 2012), 
is an essential component for human performance (Finomore, Matthews, Shaw & 
Warm, 2009). Tests of vigilance often involve the detection of a predetermined target 
among the presentation of sequential stimuli occurring over a period of time and 
sometimes require participants to ignore competing stimuli (Lezak et al., 2012). This 
latter requirement has also been used as a measure of inhibitory control or impulsivity 
by requiring participants to inhibit a response often related to a distractor target.  
Inhibitory control has been defined as the ability to “override dominant, or 
habitual, automatic responses for the sake of implementing more adaptive, goal-
directed behaviors” (Ilieva et al., 2015, p. 3). A similar, but related construct is 
selective attention, which refers to the ability to attend to a prioritized stimulus while 
simultaneously ignoring competing input and information that is irrelevant (Buehner, 
Mangels, Krumm & Ziegler, 2005; Repantis et al., 2010).  Three different components 
of inhibition have been proposed by Friedman and Miyake (2004) that include 
prepotent response inhibition, resistance to distraction, and resistance to proactive 
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interference. In a recent meta-analysis examining the performance within Go/No-go 
tasks, Wright and colleagues (2014) identified two commonly measured components 
of inhibitory control: cancellation, i.e., stopping a response that is already underway 
and withholding, i.e., stopping a prepared but uninitiated response. Withholding can 
be measured with go/no-go tasks, including continuous performance tasks using a 
go/no-go framework (Wright et al., 2014).   
Instruments commonly used to assess vigilance and/or inhibitory control 
include anticaccades tasks, Digit Vigilance, Flankers task, general Go/No-Go tasks, 
Rapid Visual Information Processing (RVIP), Stroop tasks, and the Stop-Signal Task 
(Ilieva et al., 2013; Lezak et al., 2012; Llorente et al., 2001; Silber, Croft, Papafotiou, 
& Stough, 2006; Turner, Blackwell, Dowson, McLean, & Sahakian, 2005; Wright et 
al., 2014). Outcome measures within these tasks may either capture vigilance or 
inhibitory control. For example, measures of error of omission may best capture 
sustained attention while measures of errors of commission may be best used to assess 
inhibitory control (Lezak et al., 2012).  
Antisaccades. Antisaccade tasks, which are usually paired with prosaccade or 
predictive saccade tasks, require participants to fixate on a central target that moves in 
opposite directions of the fixation point. While predictive saccades require participants 
to follow the same direction of the target moving in a predictable manner, antisaccade 
tasks require participants to generate a saccade in the opposite direction of the 
pseudorandomised moving target, i.e., inhibiting their response to look at the target 
(Allman et al., 2010). Predictive saccade tasks are commonly used as estimates of 
motor planning and temporal processing and antisaccade tasks are used as measures of 
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response inhibition (Allman et al., 2012). Error rates for antisaccade tasks have been 
found to be elevated among some children with ADHD (Rommelse et al., 2008). 
Digit Vigilance. A measure of sustained attention, Digit Vigilance is a subtest 
of the Cognitive Drug Research (CDR) battery, which is a computerized 
neuropsychological battery developed for the use with drug development research 
(Gualtieri, 2004; Silber et al., 2006). The task requires respondents to press a key each 
time they view a target digit. Outcome measures for Digit Vigilance include accuracy, 
reaction time, and commission errors (Silber et al., 2006). 
 Flanker. Flanker tasks present participants with images of congruent and 
incongruent target items, requiring participants to identify the direction of the target 
item as quickly as possible. The original standard Eriksen Flankers task required 
participants to respond to a central letter of a congruent or incongruent string of letters 
in which participants were instructed to make directional responses associated with 
specific letters (de Bruijn et al., 2004; 2005; Servan-Schreiber et al., 1998). More 
recent versions have used images of five horizontally aligned arrows in place of 
letters, requiring participants to identify the direction of the central arrow as quickly as 
possible (Ilieva et al., 2013). Congruent trials present arrows that are all pointing in the 
same direction and incongruent trials present arrows pointing in different directions, 
where the central arrow is pointed in the opposing direction to the peripheral arrows 
(Ilieva et al., 2013). Outcomes of Flanker tasks are usually measured with response 
error and Response Time (RT). Further, a specific measure of inhibition cost has been 
calculated by dividing the median RT of incongruent trials by the median RT of 
congruent trials (Ilieva et al., 2013). 
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 Go/No-Go. Go/No-go tasks require participants to respond as quickly and 
accurately as possible to a series of signals that reinforces a response tendency to these 
signals (go-signals). Within a portion of subtest trials, participants must inhibit this 
response tendency in response to a different signal (no-go signal) (Wright et al., 2014). 
There are numerous versions of go/no-go tasks, varying according to type of stimuli 
(visual, auditory, etc.) (Wright et al., 2014).  Three different versions of Go/No-go 
tasks are described below, including the Continuous Performance Test (CPT), the 
Sustained Attention to Response Test (SART), and Test of Variables of Attention 
(TOVA). 
CPT instruments are designed to measure sustained attention or vigilance and 
behavioral inhibition or impulsivity and have been shown to be sensitive for the 
measurement of drug treatment effects (Connors, 2000; DuPaul et al., 2012; Spreen & 
Strauss, 1998). The CPT was initially developed by Rosvold, but the most common 
version currently used is Connnor’s CPT (Lezak et al., 2012; Spreen & Strauss, 1998). 
The computerized version of Connor’s CPT requires the user to press a specified key 
every time they see a letter other than X appear on the screen (DuPaul et al., 2012; 
Lezak et al., 2012; Spreen & Strauss, 1998). Other versions of the CPT follow a 
similar format to Connor’s CPT, varying by visual or auditory modality, all of which 
yield similar data for evaluation (omissions, commissions, interstimulus interval, 
measures of sensitivity – d’, and response criterion – β) (Spreen & Strauss, 1998). 
The SART is also a type of continuous performance task. It requires 
respondents to press keys when presented with frequent non-target digits and to 
withhold from pressing keys when presented with the less frequent target digits 
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(Robertson, Manly, Andrade, Baddeley, & Yiend, 1997; Sofuoglu, Waters, Mooney, 
& Kosten, 2008). Error scores on the SART may indicate impairments in sustained 
attention considering they are associated with a “drift” from controlled processing into 
automatic responding (Sofuoglu et al., 2008). Some of the primary outcome measures 
from the SART may include commission errors, omission errors, and reaction time 
(Sofuoglu et al., 2008). 
Finally, the TOVA is a visual CPT that requires participants to discriminate 
between a predetermined target among nontargets (Agay, Yechiam, Carmel, & 
Levkovitz, 2014). The first half of the test is similar to other CPTs, requiring attention 
sustained over time and primarily measuring omission errors (i.e., inattention). The 
second half of the test, however, is similar to a fast paced Go/No-Go task and requires 
participants to respond quickly without making errors of commission (i.e., inhibiting 
responses) (Llorente et al., 2001). 
RVIP. A subtest within the CANTAB (Cambridge Cognition, 2015), one of 
the most well known computerized neurocognitive batteries (Gualtieri, 2004), the 
RVIP task requires respondents to respond to infrequent three-digit sequences among 
serially presented digits (Turner et al., 2005). Between 2 to 9 digits are presented at a 
rate of 100 digits per minute for 10 minutes in a pseudo-random order (Cambridge 
Cognition, 2015; Whiting et al., 2008). Digits are shown in a white box in the center 
of a computer screen. Outcome measures may include target sensitivity (A’) and 
response bias (B’), as well as mean latency (Turner et al., 2005). 
Stroop Tasks. Cognitive research indicates that it takes more time for people 
to state the names of color blocks than it does to read color words, and it takes even 
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more time for people to state the names of color words embedded in opposing 
(incongruent) color blocks (Lezak et al., 2012). The latter finding has been attributed 
to problems with response conflict, inhibitory control and selective attention, making 
it an effective measure of focused attention and executive function (Lezak et al., 
2012). Therefore, Stroop tasks require participants to read aloud from a list of words 
presented in three varying formats: a list of words (colors) presented in black ink, a list 
of colored bars or blocks, and a list of words (colors) presented in an incongruent 
color (Lezak et al., 2012; Taylor & Russo, 2000). The number of trials, items, and 
colors included in the task vary among research studies and outcome measures may 
include time, error, and/or the number of items read in a specified duration of time 
(Lezak et al., 2012). 
 Stop-Signal. The Stop-signal task typically provides a measure of inhibitory 
control related to cancellation, or the stopping of a response that is already underway 
(Wright et al., 2014). Participants are trained to respond to a Go-trial and to inhibit 
their responses in the No-Go trials (Nandam, Hester, & Bellgrove, 2014). Stop-signal 
tasks vary according to stimuli and tasks. For example, Nandam et al. (2014) used a 
Stroop Task to test inhibitory control with the stop-signal format and Aron, Dowson, 
Sahakian, & Robbins (2003) used pointing arrows similar to a Flankers task that the 
researchers termed a “tracking” stop-signal task. Outcome measures used to measure 
inhibitory control may include RT for no-signal trials, discrimination errors, the 50% 
inhibition threshold (calculated by subtracting the stop-signal delay from the Mean 
RT), and the intraindividual coefficient of variation (ICV), a measure of response 
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variability calculated by dividing the standard deviation of the Go RT by the Mean RT 
(Aron et al., 2003; Nandam et al., 2011). 
Processing Speed 
Processing speed typically refers to the amount of time required to make an 
accurate judgment of a stimulus (Cella & Wykes, 2013; Owsley, 2013) and is usually 
measured by simple tests of response time (Lezak et al., 2012). More complex tasks of 
attention, such as symbol substitution tests, involve visual scanning, motor 
persistence, sustained attention, response speed, and visuomotor coordination (Lezak 
et al., 2012) and are also commonly conceptualized as tests of processing speed. Some 
of the tasks used for the assessment of visual processing speed may include the 
detecting of a target’s presence, target discrimination, target recognition, and locating 
a target according to its spatial location (Owsley, 2013). Common measures of 
processing speed include the Digit Symbol Substitution Test (DSST), Simple Reaction 
Tests (SRT), Choice Reaction Tests (CRT), and the Trail-Making Test (trail A; TMT-
A) (Litchenberger & Kaufman, 2009; Repantis et al., 2010; Sánchez-Cubillo et al., 
2009).  
Simple Reaction Tests and Choice Reaction Tests. SRTs require participants 
to respond to one sensory stimulus, while CRTs require participants to respond to 
multiple sensory stimuli (Repantis et al., 2010). The Stimulus Evaluation Response 
Selection (SERS) task, which involves a stimulus and response pattern, encompasses 
an SRT and CRT. For the SERS easy task, which is analogous to an SRT, the 
respondent must press the same key each time an X appears without any distractors on 
the screen. For the hard task, similar to a CRT, the respondent must select a key 
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related to the location of the X, which appears embedded in four stars (Halliday, 
Callaway, Naylor, Gratzinger, & Prael, 1986; Naylor, Halliday & Callaway, 1985). 
DSST. Completed with paper and pencil, the DSST measures attention, motor 
performance, response speed and visuomotor coordination (Silber et al., 2006). The 
task provides a list of nine individually paired digits and symbols that participants use 
as a key to substitute numbers with symbols as efficiently as possible (Litchenberger 
& Kaufman, 2009). Silber et al., 2006). On the Wechsler Adult Intelligence Scale – 
Fourth Edition (WAIS-IV), the DSST score is combined with the Symbol Search task 
score to generate a standard score of processing speed that measures skills in speed of 
mental problem-solving, attention, and hand-eye coordination. 
TMT-A. The Trail Making Test has been used to assess scanning and 
visuomotor tracking, divided attention and cognitive flexibility and is often used to 
measure executive function because of the importance of mental flexibility when 
alternating between numbers and letter sets (Lezak et al., 2012). It is considered to be 
one of the most widely used neuropsychological assessment instruments (Sánchez-
Cubillo et al., 2009). It is completed with paper and pencil and includes two 
components, trail A (TMT-A) and trail B (TMT-B) (Silber et al., 2006), the latter of 
which will be described in more detail under the category of working memory. TMT-
A, which is completed first, requires participants to draw a continuous line that 
connects 24-circled digits in ascending order (Silber et al., 2006). Performance is 
measured by task completion time (Silber et al., 2006). Although commonly 
associated with divided attention, recent findings indicate that Test-A is most closely 
related to processing speed (Sánchez-Cubillo et al., 2009).  
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Working Memory 
Although working memory may be considered a function of attention, memory 
and/or executive function, and there is considerable debate about how best to define it, 
working memory is generally considered to be responsible for brief or temporary 
storage of information that allows for active maintenance and manipulation for 
complex cognitive operations (Lezak et al., 2012; McCabe, Roediger, McDaniel, 
Balota, & Hambrick, 2010). Working memory is highly associated with the general 
factor of intelligence (g) possibly because of the importance for short-term storage 
within both constructs (Colom, Abad, Quiroga, Shih, & Flores-Mendoza, 2008); 
however, the two constructs are clearly distinct from one another as evidenced by a 
meta-analysis examining correlations of working memory and g (Ackerman, Beier, & 
Boyle, 2005). While there is an abundance of measures available to assess WM, some 
of the most readily used measures include Digit Span (DS), Spatial Working Memory 
(SWM), Spatial Span (SS), Sternberg Memory Task, and the n-back (Cambridge 
Cognition, 2015; Lezak et al., 2012; Litchenberger & Kaufman, 2009; Turner et al., 
2005). The Trail-Making Test-B may also be considered a test of WM given recent 
findings indicate it is most closely related to WM (Sánchez-Cubillo et al., 2009). 
DS. Wechler’s DS includes the repetition of a sequence of numbers forwards 
and backwards in the same order they are presented (Litchenberger & Kaufman, 
2009). While cognitive assessments combine the two scores for an overall measure of 
working memory, the two subtests are theoretically distinct (Lezak et al., 2012; 
Litchenberger & Kaufman, 2009). DS backwards is most closely aligned with working 
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memory, while DS forwards is an assessment of overall attentional capacity (Lezak et 
al., 2012). 
n-back. Used frequently for research involving functional magnetic resonance 
imaging (fMRI), the n-back requires respondents to determine if a target is the same as 
one presented “n” steps prior to the target (Lezak et al., 2012). For example, using a 2-
back condition, a correct response to the sequence of numbers 4-3-9-7-2-3-2 would be 
“yes” following the second 2. 
SS. The SS is an assessment of working memory capacity described as a 
visuospatial analogue to Wechsler’s DS. The test involves a visual display of white 
squares that change in color and the respondent must remember the order of color 
changes with numbers of squares increasing from two to nine. Outcome measures 
include span length, errors, number of attempts and latency (Cambridge Cognition, 
2015; Turner et al., 2005). 
Sternberg Memory Task. For the Sternberg Memory Task, participants are 
required to remember a random sequence of digits that are presented sequentially and 
then presented with a target digit. Participants must determine if the target digit 
matches one of the digits presented previously in the sequence of numbers quickly as 
possible (Neubauer, Riemann, Mayer, & Angleitner, 1997). 
SWM. A measure of working memory, as well as strategy, the SWM requires 
participants to search for tokens within boxes visually displayed on a computer screen 
(Cambridge Cognition, 2015). Levels of difficulty range from 6-box to 8-box tasks 
(Turner et al., 2005). The test yields data for within-search errors (selecting boxes that 
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were previously found to be empty) and between-search errors (selecting boxes where 
a token was already retrieved). 
TMT-B. The second part of the TMT, TMT-B, is similar to the task of TMT-
A, but requires participants to draw a continuous line connecting numbers and letters 
in ascending order while alternating between number and letter (e.g., 1-A-2-B-2-C, 
etc.) (Silber et al., 2006). A comprehensive review of the construct validity of the 
TMT suggests that TMT-B is primarily a measure of working memory, but also 
measures task-switching ability (Sánchez-Cubillo et al., 2009). Performance on the 
TMT is measured by task completion time. 
Learning and Memory 
 Memory, learning and “intentional access to memory stores,” are critical 
components within all cognitive functions. Even mild impairments of memory can 
have profound effects of human functioning (Lezak et al., 2012). Memory refers to the 
ability to retain and access information and it can be divided into three stages: 1) the 
selection and processing of information; 2) immediate storage of memory involving 
temporary holding of information and requiring rehearsal for longer-term retention; 
and 3) long-term storage of memory achieved through consolidation of information, 
i.e., learning. Learning generally refers to the organization and consolidation of 
information, in some cases requiring effort and attention, i.e., declarative memory, but 
in other cases occurring incidentally, i.e., non-declarative memory (Lezak et al., 
2012). 
Declarative Learning and Memory 
Declarative learning and memory refers to the abilities to explicitly learn and 
remember information, objects, and events (Kumari et al. 1997; Lezak et al., 2012). 
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Memory retrieval may involve recall, which refers to remembering of information, or 
recognition, which relies on a stimulus to trigger remembering of information (Lezak 
et al., 2012). Both episodic memory - memories that are “localizable in time and 
space” - and semantic memory - memories that do not rely on time or space (e.g., the 
alphabet) have been studied (Lezak et al., 2012, p. 31); however episodic memory is 
most commonly tested in research studies assessing stimulant effects on cognition 
(Ilieva et al., 2015). Episodic memory is largely contingent on working memory 
efficiency (McCabe et al., 2010). 
Tests of episodic memory may be verbal (recall and recognition of stories, 
word lists, phrases, or passages) or visual (tests of drawing or design reproduction) 
(Lezak et al., 2012). Tests may require memorization of lists, spatial location, images, 
or paired associations. In addition to visual and verbal tests requiring recall or 
recognition, common standardized memory tests include the Auditory Verbal 
Learning Test (AVLT), California Verbal Learning Test (CVLT), Paired Associates 
Learning (PAL) Test, and Rey Verbal Auditory Learning Task (RVALT) (Cambridge 
Cognition, 2015; DuPaul et al., 2012; Klaassen, Riedel, Deutz, & Van Praag, 2002; 
Lezak et al., 2012; Linssen, Sambeth, Vuurman, & Riedel,  2014a; Makris, Rush, 
Frederich, Taylor, & Kelly, 2007; Spreen & Strauss, 1998). 
Tests of Recall or Recognition. Research assessing learning or memory has 
used a variety of tests of recall or recognition that may be verbal or visual. Verbal 
recall and recognition tasks may require respondents to remember information from 
stories, word lists, phases, or passages (Lezak et al., 2012). Visual recall and 
recognition tasks include memory of pictures or objects. 
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AVLT. The AVLT involves the learning of a 15-word list (Lezak et al., 2012). 
An adapted version of the AVLT, the Visual Verbal Learning Test (VLT) that 
includes 30 words has also been used in the literature (Klaassen et al., 2002; Linssen et 
al.,  2014a). Outcome measures include immediate free recall of words, as well as 
delayed verbal free recall and recognition tests given 30 minutes and 24 hours after 
learning (Linssen et al., 2014a). 
CVLT. The CVLT is an assessment of strategies and processes related to 
verbal learning and memory (DuPaul et al., 2012; Spreen & Strauss, 1998) that 
assesses a respondent’s use of semantic associations for learning (Lezak et al., 2012). 
It measures immediate and delayed word list recall and recognition (DuPaul et al., 
2012) and involves two word lists, the second of which is designed to be an 
interference with the learning of the first (Spreen & Strauss, 1998). Some of the data 
provided by the CVLT include: total recall and recognition, semantic and serial 
learning strategies, serial position effects, learning rate, perseverations and intrusions 
in recall, and false positives, i.e., commissions (Spreen & Strauss, 1998). 
PAL. Assessing visual episodic memory and new learning, the PAL is a 
subtest of the Cambridge Neuropsychological Test Automated Battery (CANTAB) 
battery that yields outcome measures related to error, number of trials required to 
locate patterns, memory scores, and stages completed (Cambridge Cognition, 2015). 
The PAL tests visuospatial associations utilizing cues to learn associations (Turner et 
al., 2003). For example, Kinsbourne, De Quiros, & Tocci Rufo (2001) used a version 
of the PAL in which a computer randomly generated pairings of stimulus in response, 
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requiring the respondent to memorize a digit associated with a consonant. Outcome 
measures may include accuracy, error, and total number of trials. 
RVALT. The RVALT assesses immediate memory, new learning, 
susceptibility to interference, and recognition memory. It includes 15 nouns that are 
read aloud followed by a free recall test. An interference of 15 words is presented and 
then delayed recall of the original lists is measured. Finally, recognition is measured 
through the presentation of a story including the original list of words (Spreen & 
Strauss, 1998). 
Non-declarative Learning and Memory 
Non-declarative learning and memory involves an unconscious remembering 
of knowledge typically subdivided into procedural memory or learning and priming or 
perceptual learning (Kumari et al., 1997; Lezak et al., 2012). Procedural learning and 
memory refers to rule-based learning in which performance improves with practice 
(Kumari et al., 1997). Priming or perceptual learning and memory involve recall based 
on cues related to prior learning or associations (Lezak et al., 2012). Simple tasks of 
probabilistic learning, as well as the Repeated Acquisition of Response Sequences 
Task (RA), have been used in the literature to measure non-declarative memory 
(Makris et al., 2007).  
RA. Although primarily used to test cognitive behavior with animal models 
(Cohn & Paule, 1993), the RA Task has been used in human studies as well. It 
requires participants to learn new response sequences within individual sessions in 
order to measure an overall rate of learning (Cohn & Paule, 1993; Makris et al., 2007) 
For example, in their investigation of the behavioral and subjective effects of d-AMP 
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and modafinil, Makris and colleagues used the RA Task involving the learning of a 
10-response order on four keys. 
Probabilistic Learning. Probabilistic and reversal learning involves 
associative learning based on punishing and rewarding feedback in which participants 
must modify learned associations throughout the task (Clarke, Dalley, Crofts, & 
Robbins, 2004; van der Schaaf, Fallon, Huurne, Buitelaar, & Cools, 2013). 
Executive Function 
 Executive function refers to capacities that allow for independent, purposive, 
self-directed, and self-serving behavior (Lezak et al., 2012; Weyandt & Willis, 1995) 
even “in the face of irrelevant competing inputs or more habitual but inappropriate 
response patterns” (Farah et al., 2004, p. 422). Among other functions, executive 
function may include control functions that inhibit prepotent responses, 
cognitive/mental shifting, cognitive flexibility, regulation and monitoring of 
performance, goal maintenance, planning, and working memory (McCabe et al., 
2010). Lezak et al. (2012) conceptualized these functions to comprise the constructs of 
volition (i.e., capacity for intentional behavior), planning and decision-making, 
purposive action, self-regulation and effective performance. It is important to note that 
there is a substantial amount of overlap between executive function abilities and other 
cognitive constructs (Farah et al., 2004; Repantis et al., 2010) and there is an ongoing 
debate about how best to conceptualize executive function, i.e. as a unitary construct 
or as separate, but synergetic, constructs (McCabe et al., 2010; Weyandt, 2006). The 
following sections describe some of the most commonly explored executive function 
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constructs among studies related to prescription stimulants: planning and decision-
making and self-regulation. 
Planning and Decision-Making 
Among other capacities, planning and decision-making require looking ahead, 
objective assessments, perceiving alternatives, weighing choices, and utilizing 
conceptual frameworks (Lezak et al., 2012). Memory, impulse control, and sustained 
attention are all necessary components of planning and decision making behavior. 
Tests of planning and decision-making may include gambling tasks and tower tests 
(Lezak et al., 2012). 
 Gambling Tasks. Although a number of iterations of gambling tasks are 
available, the most common task is the Iowa Gambling Task (IGT). The IGT is played 
with cards on a computer in which the participant selects varying decks and cards with 
the purpose of minimizing losses and winning as much money as possible (Lezak et 
al., 2012). 
 Tower Tests. The Tower of London Spatial Planning Task (NTOL) is the most 
commonly used version of the tower tasks, which require participants to rearrange 
rings or balls of varying colors to arrive at the solution using the least number of 
moves and in the most direct way (Lezak et al., 2012). 
Self-regulation 
Self-regulation assessments may either measure productivity or flexibility and 
the capacity to shift (Lezak et al., 2012); however, tasks of self-regulation have most 
commonly focused on flexibility and set-shifting, as opposed to productivity, among 
studies examining ADHD medication effects on self-regulation. Assessments of 
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flexibility have also been used to identify levels of creativity (Lezak et al., 2012) and 
some measures of verbal fluency assess the ability to think flexibly, switch response 
sets, self-regulate and self-monitor (Lezak et al., 2012). In particular, verbal fluency 
tests measure how well individuals organize information (Lezak et al., 2012). 
Therefore, tasks of self-regulation may include tasks assessing productivity, 
flexibility, the capacity to shift, creativity, and verbal fluency (i.e. organization). One 
important distinction to note relates to the difference between tasks of flexibility and 
tasks of non-declarative learning and memory. Although some tasks of flexibility 
utilize associative learning similar to tasks measuring non-declarative memory, tasks 
measuring flexibility require respondents to shift their thinking by changing the rules 
during the task (i.e., reversal or probabilistic learning that is not constant). 
In addition to general tasks designed to assess set-shifting or switch-costs, the 
Wisconsin Card Sorting Test (WCST) and the Intra-Extra Dimensional Set-shift Task 
(IDED) are common tests of cognitive flexibility (Lezak et al., 2012; Wild & Musser, 
2014). Both probabilistic and reversal learning paradigms have also been used as 
measures of cognitive flexibility. Measures assessing creativity might include the 
Alternative Uses Task, the Group Embedded Figures Task, the Drawing Task from the 
Abbreviated Torrance Test for Adults, and the Remote Associations Task. Finally, 
common verbal fluency measures include the Controlled Oral Word Association Test 
(COWAT) and the Verbal Fluency Test (Elliott et al., 1997; Farah, Haimm, 
Sankoorikal, & Chatterjee, 2009; Lezak et al., 2012). 
Cognitive Flexibility Tasks. The IDED has been described as an analog to the 
WCST on the computer (Wild & Musser, 2014). It assesses set formation and 
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maintenance, shifting, and attentional flexibility (Wild & Musser, 2014). Participants 
view two color-filled shapes and must learn through trial and error based on computer 
driven feedback which response is correct (Cambridge Cognition, 2015). The test 
becomes increasingly difficult as it progresses through nine stages, transitioning from 
intra-dimensional to extra-dimensional rules (Wild & Musser, 2014).The WCST is 
used to assess abstract concepts and set-shifting (Spreen & Strauss, 1998) by requiring 
participants to deduce a pattern by matching cards of varying symbols and shapes 
based on the examiner’s cues (Lezak et al., 2012). 
As described previously, probabilistic and reversal learning are a kind of 
associative learning based on punishing and rewarding feedback that require 
modifications to learned associations throughout the task (Clarke et al., 2004; Schaaf, 
Fallon, ter Huurne, Buitelaar, & Cools, 2013). These tasks may provide a measure of 
cognitive flexibility when they require a shift in thinking in response to an unexpected 
outcome, e.g., shift analysis as examined by van der Schaaf et al. (2013). 
Creativity Tasks. Used to measure divergent thinking, the Alternative Uses 
Task requires participants to listen to a list of objects and describe as many alternative 
uses for the objects within a specified period of time as possible (Farah et al., 2009). 
Stimuli is presented verbally and responses also given verbally (Farah et al., 2009).  
The Drawing Task is a standardized subtest from the Abbreviated Torrance 
Test for Adults used to measure divergent thinking (Farah et al., 2009). Participants 
are presented with an incomplete figure and instructed to make a picture, as well as 
providing the picture with a title (Farah et al., 2009). Norm-referenced scoring is 
based on fluency, originality, elaboration, and flexibility and some of the criterion-
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referenced creativity indicators are scored based on openness, unusual visualization, 
and movement (Farah et al., 2009). 
Finally, two tasks used to measure convergent creative thinking have included 
the Group Embedded Figures Task and the Remote Associations Task. The former 
instrument is a nonverbal task that has been used to test convergent creative thinking 
(Farah et al. 2009). Participants must reorganize the elements of a geometric design in 
order to reveal embedded figures (Farah et al., 2009). The Remote Associations Task 
requires participants to supple one word associated with three words (Farah et al., 
2009). 
Verbal Fluency Tasks. Two instruments used to measure verbal fluency 
include the COWAT and the Verbal Fluency Test. The COWAT requires participants 
to list as many words as possible that begin with a certain letter (Lezak et al., 2012). In 
addition to verbal fluency, it has been suggested to measure task persistence and 
divided attention (Taylor & Russo, 2000). Benton’s Verbal Fluency Test is another 
instrument used to measure verbal fluency. This test is similar to the COWAT and 
requires participants to generate as many words as possible that start with a specific 
letter falling under a semantic category such as “animals” (Elliott et al., 1997). 
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CHAPTER 3: Research Justification and Predictions 
Prescription Stimulants for Neurocognitive Enhancement of Cognition in Adults 
The positive effects of prescription stimulants on cognitive functioning among 
children and adolescents with ADHD have been explored (Coghill et al., 2013), but to 
date no systematic meta-analysis has been conducted concerning adults with and 
without ADHD. Although Ilieva et al. (2015) reported on the cognitive effects of MPH 
and AMP for inhibitory control, working memory, and episodic memory, questions 
remain about the cognitive effects of other ADHD medications (pro-stimulants and 
non-stimulants) and how prescription stimulant medication may influence other 
cognitive processes such as sustained attention, processing speed, planning and 
decision-making, and creativity. Indeed, Ilieva et al. suggested a number of areas for 
future researchers to address, including how ADHD medication may influence 
sustained attention and processing speed and whether particular groups of healthy 
adults, such as those with low cognitive performance prior to medication, may benefit 
more or less than other populations.  
Given the rise of stimulant misuse across college populations with and without 
ADHD, it is important to understand if prescription stimulants proffer cognitive 
effects, i.e., neurocognitive enhancement, or if they impair other areas of cognitive 
functioning. Therefore, in an attempt to elucidate whether prescription stimulants 
affect cognition, the proposed study will explore the following questions: 1) Are 
prescription stimulant medications effective for enhancing cognition among adults 
with and without ADHD? 2) What types and doses of prescription stimulants and what 
timing of ingestion of medications yield the greatest and smallest effects on cognition? 
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3) Does baseline functioning of cognition impact the effect of prescription stimulants 
on cognition? 4) Do prescription stimulants enhance or impair different sub-
components of cognition (e.g., vigilance tasks, memory tasks, and executive function 
tasks)? 5) Do the effects of prescription stimulants vary for adults with and without 
ADHD?  
Based on a previous research (e.g., Advokat, 2010; Smith & Farah, 2011), the 
following hypotheses will be examined for adults with and without ADHD:  
1) Medications for the treatment of ADHD (prescription stimulant, prostimulant 
and nonstimulant medications) will demonstrate general positive effects on 
tasks of focused behavior, learning and memory, and executive function 
among adults with and without ADHD.  
2) The relationship between prescription stimulant, prostimulant, and 
nonstimulant ADHD medications and cognition will vary according to dose, 
with higher doses yielding greater effects than lower doses among adults with 
and without ADHD. 
3) The relationship between prescription stimulant, prostimulant, and 
nonstimulant ADHD medication and cognition will vary according to timing of 
dose, with activation of stimulant during learning processes yielding greater 
effects than activation at other times among adults with and without ADHD. 
4) The relationship between prescription stimulant, prostimulant, and 
nonstimulant ADHD medication and cognition will be consistent across 
medication activation types (short-acting, medium-acting, or long-acting 
medications) among adults with and without ADHD.  
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5) Prescription stimulant, prostimulant, and nonstimulant medication ADHD 
effects on cognition will negatively correlate with baseline cognitive 
functioning of adults with and without ADHD.  
6) The relationship between prescription stimulant, prostimulant, and 
nonstimulant ADHD medications and cognition will vary according to ADHD 
status, with greater effects among adults with ADHD compared to adults 
without ADHD. 
 
  
 36
 
CHAPTER 4: Methodology 
Literature Searches 
A systematic search and retrieval process was conducted according to Lipsey 
and Wilson’s (2001) guide for meta-analysis, the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) 27-item checklist (Liberati et al., 
2009; Moher, Liberati, Tetzlaff, & Altman, 2009), and Okoli and Schabram’s (2010) 
eight-step guide to systematic literature reviews. The study attempted to identify and 
retrieve all empirical studies and datasets that examined cognitive effects of 
prescription stimulants and prostimulants conducted at any time. The search and 
retrieval process was conducted between the months of June and October 2014 and 
included a comprehensive search of the following bibliographic databases: PsycINFO, 
MEDLINE, ScienceDirect, and Dissertations and Theses (PROQUEST). A 
combination of the following keyterms were used: Prescription stimulant, 
dextroamphetamine, Adderall, methylphenidate, Ritalin, Concerta, lisdexamfetamine, 
Vyvanse, atomoxetine or Strattera, and cognitive, cognition, learning, memory, or 
executive function.  Note that for the searches conducted within Dissertations and 
Theses, terms were searched within the category of “anywhere except full text” (ALL) 
and for PsycINFO terms were searched without the selection of a field; however, for 
MEDLINE and ScienceDirect terms were searched within “keyterms.” In addition to 
searches within bibliographic databases, studies were searched within the following 
review articles: Advokat, (2010), Linssen et al. (2014b), Smith & Farah, (2011), 
Repantis et al., (2010). Titles, abstracts, and full articles were examined to assess if 
studies met eligibility criteria, described in the following section.  
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The present study’s search and retrieval process was similar to two recent 
systematic reviews that addressed the effects of ADHD medication on neurocognitive 
enhancement. However, the present study differed from previous publications in a 
number of meaningful ways. First, while the present study included adults with and 
without ADHD, Linssen et al. (2014b) and Ilieva et al. (2015) included studies using 
samples of healthy adults only. Furthermore, the present study included studies that 
administered stimulants, prostimulants and nonstimulants, as opposed to MPH only 
like Linssen et al. and AMP and MPH only like Ilieva et al. A final major difference 
between studies relates to the cognitive outcomes included for analysis. While Ilieva et 
al. selected studies based on specific tests of cognition, limiting key terms to 
predetermined tests, Linssen et al. selected studies based on a previous review 
(Nuechterlein et al., 2004) of the effects of MPH for cognitive enhancement that 
categorized neuropsychological tests into six domains (speed of processing, 
attention/vigilance, working memory, verbal learning and memory, visual learning and 
memory and reasoning). The present study, however, attempted to include a variety of 
tests to measure multiple domains of cognition that were not predetermined, i.e., the 
present study did not specify particular domains of cognition prior to data collection. 
Instead, the present study attempted to retrieve as many studies as possible that 
explored the cognitive effects of ADHD medication and then coded results according 
to cognitive literature and theory described in Chapter 2. This method was chosen in 
order to include the maximum number of studies available, reduce self-selection bias, 
and capture the variability in study findings. The present study was the first meta-
analysis to provide insight about ADHD medication’s effects in populations that 
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include adults with and without ADHD and to explore particular areas of cognition 
(planning and decision-making, self-regulation, processing speed).  This study also 
addressed issues concerning previous reviews that have relied on studies that were 
underpowered and varied in design, requiring statistical techniques to account for 
study design variability.  
Selection of Studies 
Although meta-analysis is a powerful method that can help elucidate the true 
effect of a treatment or intervention (Kraemer, Gardner, Brooks, & Yesavage, 1998), 
results are limited by the quality of available published studies. Many criticisms of 
meta-analysis stem from the decision to either maintain open inclusion criteria 
(leading to a variety of studies that may not be comparable) or to adopt rigid inclusion 
criteria (resulting in less meaningful findings because of the exclusion of potentially 
meaningful studies) (Kraemer et al., 1998). Therefore, the present study attempted to 
include as many quality studies as possible without excluding potentially meaningful 
studies. Methods of analysis and eligibility criteria were documented in a protocol 
prior to data collection and analysis as recommended by PRISMA (Liberati et al., 
2009; Moher et al., 2009). Studies were selected for review based on the following 
criteria: 
1) The study was published in English. 
2) The study used a placebo-controlled design. 
3) The sample included human subjects only, at least 18 years of age; if the study 
included special groups, only data involving healthy controls or individuals 
with ADHD were included. 
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4) The sample size was greater than one; single case studies were excluded. 
5) The study investigated the effects of d-AMP, MPH, LDX, or ATX; if the study 
investigated additional drugs, only data involving the stimulants listed 
previously and placebo were included. 
6) The study addressed variables related to effects of prescription stimulants on 
cognition most closely aligned with neurocognitive enhancement. Specific 
dependent variables included behavioral measures of focused behavior, 
memory, learning and executive function. Dependent measures were not 
limited beyond these broad constructs; however, assessments of cognitive 
function that were not behavioral (i.e., self report) and those that simulated 
behavior (e.g., simulated driving) were excluded.  
An amendment to the protocol was made after the search and retrieval process had 
begun. Protocol modifications are not uncommon nor inappropriate for systematic 
reviews; however, researchers are encouraged to describe and justify any protocol 
modifications, taking into account the potential for increased selective reporting bias 
(Liberati et al., 2009). The protocol was modified during data collection to specify 
additional criteria for inclusion as outlined below: 
7) The procedure did not limit sleep for participants; studies investigating sleep 
deprivation or studies that deprived participants of sleep were excluded. There 
is a large body of literature (e.g., Baranski & Pigeau, 1997; Kilgore et al., 
2008; Kilgore, Grugle, & Balkin, 2012) investigating the effects of prescription 
stimulant medication on sleep deprivation. Because the present study was 
focused on cognition within healthy adults samples and adults with ADHD and 
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sleep did not relate to the present study’s hypotheses, studies investigating 
sleep deprivation were excluded to reduce any additional confounds across 
findings. Based on this framework for decision-making, it is unlikely this 
protocol amendment resulted in an increase in bias.  
8) Studies that used drug discrimination learning procedures, i.e., teaching 
participants to discriminate between drugs or doses of drugs, were not included 
in the present study in order to minimize confounds associated with these 
learning tasks.  
9) Studies that used a single-blind design, where participants were unaware of the 
type of drug administered but researchers were aware, were included.  
10) Studies that included participants who reported regular drug use (e.g., MDMA 
as reported in Kuypers & Ramaekers, 2005) or were conducted among prison 
populations (Ginsberg, Hirvikoski, Grann, & Lindefors, 2012) were excluded. 
Although the eligibility criteria determined prior to data collection specified 
that only populations reported as healthy and/or with ADHD diagnoses would 
be included, examination of the literature search revealed the need to specify 
these requirements further. An increase in bias was not suspected as a result of 
this amendment considering the focus of the study was on the effects of ADHD 
medication within the context of neuroenhancement, which would exclude 
other types of drug users and prison populations. 
11) Studies that focused on latent inhibition, which refers to the slowing of 
learning about consequences of a stimulus resulting from the stimulus having 
been inconsequential in the past (Kumari, 1997), were excluded. This process 
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is distinctly separate from the focus of neuroenhancement and its exclusion 
reflects the overall study’s focus. 
Data Extraction and Coding 
Once all studies were identified and retrieved, data were extracted and coded 
according to a standardized coding manual (see Appendix A). A comprehensive 
coding sheet included the following variables: study descriptors (name of study, 
country of researcher, year of publication), descriptive statistics (sample size, reported 
ES statistics, effect direction and raw data to recalculate ES), sample descriptors 
(participant demographics of mean age, special groups, ethnicity and sex), participant 
descriptors (cognitive abilities prior to medication), participant diagnostic 
characteristics (ADHD status), variables related to methods and procedures (form of 
data analysis, type of outcome score used [change score or post treatment score], study 
design [parallel or crossover study], and use of counterbalancing, minimum days of 
washout between treatments), stimulant medication descriptors (stimulant medication 
type, stimulant dose, stimulant dose type [fixed dose or titration to best dose], and time 
of dose relative to assessment and/or learning), and dependent constructs and 
measures related to cognition.  
Dependent constructs and measures were further coded based on methods used 
by previous research and on the theoretical constructs of cognition described in the 
preceding chapter. Therefore, the exact dependent constructs used in this study were 
identified after all other data were extracted and coded. Accordingly, studies addressed 
at least one of 10 narrow constructs of cognition, grouped according to three broad 
categories of cognition: (1) Abilities of Focused Behavior, including the narrow 
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constructs of (a) Vigilance, (b) Inhibitory Control, (c) Processing Speed, and (d) 
Working Memory; (2) Learning and Memory, including (a) Declarative Memory – 
Immediate (measured within 20 minutes of learning), (b) Declarative Memory – 
Delayed (measured after 20 minutes, but within the same day as learning), (c) 
Declarative Memory – Long-term (measured after more than a day from learning), and 
(d) Non-declarative Learning; or (3) Executive Function, including (a) Planning and 
Decision Making and (b) Self-regulation.  
In order to estimate a single ES that most accurately captured each cognitive 
construct, specific measures considered to be representative of the construct were 
selected from each instrument. Table 1 displays a list of the selected measures 
organized by construct and instrument. Although these measures varied according to 
individual constructs, in general, measures of error and accuracy were selected first, 
and measures of Reaction Time (RT) were excluded unless they were the only 
extractable data for a given study. Exceptions to this convention were for the 
constructs of processing speed and planning and decision-making, in which RT was 
considered an important component for measurement of these constructs and was 
therefore included as a primary measure.  
Selected measures of vigilance included accuracy, errors of omission, and 
attentiveness (d’). An attempt was made to include accuracy and attentiveness in 
addition to errors of omission, considering some studies have reported a ceiling effect 
for omission errors (e.g., Boonstra et al., 2005). One study (Agay et al., 2014) 
calculated a measure of sustained attention with a weighted averaging of response 
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time, d’ (accuracy over time, mostly impacted by errors of commission), and response 
time variability, and was also coded as an assessment of vigilance.  
Based on previous meta-analyses concerning inhibitory control (Ilieva et al., 
2015; Smith, Mattick, Jamadar, & Iredale, 2014), errors of commission on tests of 
attention were selected as measures of inhibitory control. (Note that measures of 
attention related to omission errors were used to measure vigilance; therefore, in some 
cases individual measures within the same instrument were considered to be 
representative of differing constructs). In general, commission errors, i.e., false alarms, 
reflect difficulties with restraint and inhibition (Lezak et al., 2012). For instruments 
designed to measure inhibitory control specifically, conventions were based on 
measures selected by previous researchers (Ilieva et al., 2015; Smith et al., 2014; 
Westerhausen, Kompus, & Hugdahl, 2011). For Stop-Signal tasks the probability of 
inhibiting a response and the Stop-Signal Reaction Time, calculated by subtracting the 
mean Stop delay from the mean Go RT, were favored (Ilieva et al., 2015; Smith et al., 
2014). Similarly, effect sizes from measures of the Stroop task included Interference, 
defined as the performance (errors or RT) in a neutral condition subtracted from the 
performance in the incongruent condition, which has been considered an inverse 
gauge of inhibition (MacLeod, 1991; Westerhausen et al., 2011). When Stroop task 
results were reported for individual measures of error or RT only, incongruent 
errors/RT were selected to measure susceptibility to interference (Ideström & 
Schalling, 1970). Measures from the Flanker included the difference or ratio between 
congruent and incongruent accuracy (Ilieva et al., 2015) and when error was reported 
for incongruent individually, measures of incongruence were selected. Measures 
 44
 
selected from the Go/No Go task included accuracy and errors of commissions (Ilieva 
et al., 2015; Smith et al., 2014). Finally, for the antisaccade task, error saccades to the 
target were selected (Ilieva et al., 2015).  
Most studies (k = 5) that reported measures of processing speed from the 
provided a standard or accuracy score; one study (Wardle et al., 2013) provided the 
area under the curve (AUC). Therefore, both standard scores and AUC were selected 
as measures of processing speed from the DSST. Measures of simple and choice 
reaction tests included response time, accuracy rate, and errors. Primary measures of 
working memory included accuracy, sensitivity, and error measures; RT was selected 
in the cases where none of these measures were provided (see Table 1). 
In order to measure declarative learning and memory, error and accuracy 
scores were selected from studies. Outcomes may have included recall (free and cued), 
recognition, sensitivity, and confabulations, among others. Specific measures of non-
declarative memory, however, included accuracy/error measures, as well as learning 
rate measures indicative of the amount of time required to learn an association.  
For planning and decision-making, measures of accuracy or error, number of 
steps or attempts required to reach accuracy, time required for making a decision, and 
estimates of probability related to quality of choices were selected. To measure self-
regulation, standard scores reported for measures of creativity and verbal fluency were 
selected. For cognitive flexibility, preferred measures from the WCST included 
categories achieved (number of correct sorts indicating an understanding of the idea), 
perseverative errors (where higher errors reflect difficulty in understanding the 
concept and may indicate difficulties with conceptual flexibility), trials to complete 
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first category (indicating conceptualization readiness to shift), as well as overall 
accuracy and error measures (Lezak et al., 2012; Spreen & Strauss, 1998). Measures 
from IDED and other instruments measuring cognitive flexibility were similar, 
including discrimination, reversal and shift errors/accuracy. One study included a 
switch-cost paradigm. For this study, the switch-cost measure, calculated by 
subtracting the average response time on repetition trials from switch trials, was used 
(Samanez-Larkin et al., 2013). 
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Table 1 
Measures by Construct and Task 
Instrument Accuracy Error RT Other 
Vigilance 
Continuous Performance Task 
(CPT) 
 
Accuracy 
Detectability/ 
attentiveness  
Omission   
Digit Vigilance Test  Accuracy    
Oddball Task  Omission   
Rapid Visual Information 
Processing (RVIP) 
Detectability/target 
sensitivity Omission    
Sustained Attention to Response 
Test (SART)  Omission   
Test of Variables of Attention 
(TOVA) Accuracy over time  
Omission 
 
  
Mackworth Clock Test     
Miscellaneous Tasks of Attention Sensitivity 
Errors 
Biasa   
Inhibitory Control 
Antisaccades   Antisaccade error   
Change Task (extension of Stop-   MRT (Stop-  
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Instrument Accuracy Error RT Other 
Signal Task) Signal, Change 
Response) 
Continuous Performance Task 
(CPT) 
 Commission   
Digit Vigilance Test  Commission   
Flanker 
Difference/ratio between 
congruent and 
incongruent accuracy 
Difference/ratio 
between congruent 
and incongruent 
error 
Incongruent errora 
  
Go/No-Go No-Go accuracy No-Go error Commission   
Oddball Task  Commission   
Rapid Visual Information 
Processing (RVIP)  Commission   
Sustained Attention to Response 
Test (SART)  Commission   
Stop-Signal Task 
Probability of inhibiting 
response  
Stop Signal RT 
(mean go RT 
minus mean stop 
delay)a 
 
Stroop Task   Error interference RT interferencea  
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Instrument Accuracy Error RT Other 
Incongruent errorsa 
Test of Variables of Attention 
(TOVA)  Commission   
Working Memory 
Digit Span (DS) - Wechsler, Guild Standard score 
Longest span* 
 
   
Dot-Letter Task  Accuracy 
 
 RTa  
n-back  Accuracy 
 
Omission 
Commission 
 
RTa  
Number Recognition Object-
relocation Standard score  Latency
a 
 
Spatial Delay Response  Accuracy    
Spatial Location  Accuracy  RTa  
Spatial Working Memory (SWM) Accuracy 
Strategy score 
Positive fit 
Between 
Within 
Total 
Absolute 
  
Spatial Span (SS) Span length Errors   
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Instrument Accuracy Error RT Other 
Sternberg’s Memory Test  Recall of Consonants Error Rate   
Trail Making Test-B (TMT-B)   RT  
Visual Working Memory Task Accuracy    
Processing Speed 
DSST Standard score    
Simple/Choice Reaction Time 
Tests: 
-Contingent Negative 
Variation (CNV) Stop Light 
Task 
-CNV Lines Task 
-Stimulus Evaluation 
Response Selection (SERS)  
-Simple Motor Response  
-Motor Reaction Task  
-Simple Reaction Time Test  
-Visual Search Task 
 
Errors 
Omission 
Commission 
RT 
Distraction time  
Spatial Orienting Task  Errors RT  
Trail Making Test-A (TMT-A)   RT  
Declarative Learning & Memory (Immediate, Delayed, & Long-term) 
California Verbal Learning Test 
(CVLT) Level of Recall    
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Instrument Accuracy Error RT Other 
Guild Memory Test Recall 
Paired Associates score 
Designs 
   
Paired Associates Learning Test 
(PAL) 
Accuracy 
 
Errors  Total trialsa 
Pattern Recognition Memory Task Accuracy    
Recall of Words, Pictures, Stories, 
Objects Recognition of Words, 
Pictures, Stories, Objects  
Recall 
Recognition 
Sensitivity (d’) 
 
Commission 
Intrusions 
Confabulations 
Response bias (C) 
  
Rey Verbal Auditory Learning 
Task (RVALT) 
Accuracy 
Trials 1-5 Score 
Trial 1 Scorea 
Sensitivity 
 
Errors  Number of Trialsa 
Non-Declarative Learning & Memory 
Probabilistic Learning  
Accuracy 
Mean errors to 
criterion 
Perseverative errors 
 
Feedback 
sensitivity 
Repeated Acquisition of Response 
Sequences Task (RA) 
 
Correct response rate Incorrect response 
rate   
Learning Tasks Learning rate    
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Instrument Accuracy Error RT Other 
Reversal Learning Tasks  Reward accuracy 
Punishment accuracy Errors   
Planning & Decision Making 
Iowa Gambling Task (IGT) 
 
Probability of accuracy 
Advantageous choices 
Disadvantageous 
choices 
Deliberation 
timea 
Latency of RTa 
Mean attempt 
of moves 
Tower of London Spatial 
Planning Task (NTOL) Accuracy  
Latency* 
RTa 
Mean attempt 
of moves 
Self Regulation 
Controlled Oral Word Association 
Test (COWAT) 
 
Accuracy 
Standard score    
Drawing Task from the 
Abbreviated Torrance Test for 
Adults  
Standard score    
Group Embedded Figures Task  Accuracy    
Intra-Extra Dimensional Set-shift 
Task  (IDED) 
Accuracy 
Total 
ED 
Perseverative 
Discrimination 
Reversal 
  
Probabilistic Learning  Accuracy Mean errors to 
criterion   
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Instrument Accuracy Error RT Other 
Perseverative errors 
Remote Association Task  Accuracy    
Switch Cost and Switch Setting 
Tasks    Switch cost  
Verbal Fluency Test  Fluency    
Wisconsin Card Sorting Test 
(WCST) Accuracy Trials to Complete First 
Category 
Perseverative 
Errors 
Failures/errors 
 
Conceptual 
Level 
Number of 
Categories 
Notes. * indicates a measure that was selected secondary to other measures; ED = Extra Dimensional; RT = 
Response Time. 
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To test the study hypotheses, specific moderating variables were coded based 
on the following rationale: 
1) Medication Dose (low or high): Because the study included a variety of 
medications (AMP, MPH, ATX, and LDX), dose level was coded separately as 
high or low for each drug. Specifically, a doses coded as “high” included the 
following: ≥ 20-mg (AMP), ≥ 40-mg (MPH), ≥ 50-mg (LDX), and ≥ 70-mg 
(ATX). “Low” doses were those that fell below this convention. When studies 
reported dose in units of mg/kg, doses were multiplied by the global average 
adult weight of 62-kg (Walpole et al., 2012) and then coded accordingly. 
2) Timing of Dose Activation (during, prior, or after learning): Timing of dose 
activation was coded as occurring during learning processes, prior to learning 
process, or after learning processes according to the medication type used in 
each study. Studies utilizing pharmacokinetic data have indicated that plasma 
levels peak after oral ingestion of AMP between 2-3 hours (Angrist et al.,1987; 
Wachtel, ElSohly, Ross, Ambre & de Wit, 2002), MPH between 1-2 hours 
(Kimko, Cross, & Abernethy, 1999; Volkow et al. 1998), LDX between 2-4 
hours (Wigal et al., 2010) and ATX between 1-2 hours (Sauer, Ring, & 
Witcher, 2005). Therefore, doses administered within these time windows for 
each medication were coded as occurring “during learning,” doses 
administered prior were coded as occurring “prior to learning,” and doses 
administered following were coded as occurring “after learning.” 
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3) Medication Activation Types (short-acting or medium/long-acting treatment): 
Medications were coded as either short-acting treatments or medium or long-
acting according to the following criteria: Short-acting stimulants included 
amphetamine/dextroamphetamine (Adderall), dextroamphetamine sulfate 
(Dexedrine, Dextrostat), dexmethylphenidate (Focalin), or MPH (Methylin, 
Ritalin); medium or long-acting stimulants, prostimulants, and non-stimulants 
included methylphenidate sustained release (Metadate CD, Metadate ER, 
Methylin ER, Ritalin LA, or Ritalin SR), amphetamine/dextroamphetamine 
(Adderall XR), methylphenidate (Concerta), methylphenidate (Daytrana), d-
amphetamine sulfate (Dexedrine Spansules), dexmethylphenidate (Focalin 
XR), atomoxetine (Strattera), and lisdexamfetamine dimesylate (Vyvanse) 
(Cascade, Kalali, & Weisler, 2008). When studies reported medications as 
MPH or AMP, without specifying anything further, medications were coded as 
short-acting. 
4) Baseline Cognitive Functioning: When available, effect size data were 
recorded separately for participants with low cognitive baseline scores and 
those with high cognitive baseline scores prior to medication administration. 
Additionally, when studies reported assessments of overall cognitive 
functioning prior to medication administration the particular assessment and 
scores were recorded. Specific measures included the Wechsler Adult 
Intelligence Scale (WAIS), the National Adult Reading Test (NART), the 
Wide Range Achievement Test, the Wechsler Abbreviated Scale of 
Intelligence (WASI) and the Peabody Picture Vocabulary Test. Because the 
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majority of studies that included cognitive assessments prior to drug 
administration reported verbal abilities, if multiple measures were available, 
measures of verbal abilities were selected first. Scores were transformed to a 
percentile equivalent based on standard scores. 
5) ADHD Status (yes or no): Studies were also coded based on recruited sample 
populations; samples including participants with ADHD were coded as “yes” 
and samples including participants without ADHD were coded as “no.” Only 
participants with ADHD were included in the present study in studies that 
reported findings across samples with and without ADHD. 
Additional coded variables that were included to assess the influence of study design 
variability on stimulant effects were:  
6) Study design (crossover or parallel): Studies were coded as using either a 
crossover or within-subjects design or a parallel or between-subjects design.  
7) Participant Group Assignment (yes or no): For parallel studies, randomization 
into treatment vs. placebo was coded; for crossover studies, randomization into 
varying orders of sessions was coded (e.g., placebo then treatment vs. 
treatment then placebo). 
8) Measurement Order (yes or no): Counterbalancing of treatment was coded. 
9) Randomization (yes or no): Studies were coded according to randomization of 
participants into treatment and placebo groups. 
10) General Sample Characteristics (adults, university students, or elderly adults): 
Samples were coded to include adults, university students, and/or elderly 
populations. 
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11) Sample Recruitment Characteristics (community, clinic, university): Studies 
were coded as recruiting participants via local communities, clinics (hospitals 
or inpatient/outpatient settings), and/or university campuses. 
12) Age of Sample: Mean age, standard deviation of age, and age range were 
coded. 
13) Gender Distribution: Percent female was coded as an estimate of gender 
distribution. 
14) Years of Education: Studies’ participants’ mean years of education was 
recorded. 
15) Number of Sessions: Studies were coded according to number of sessions 
included in study design. 
16) Minimum Wash-out Days: For crossover studies only, the minimum number of 
wash-out days between drug treatment(s) and placebo were recorded. 
17) Number of Doses: The number of relevant doses reported was coded for each 
study. 
18) Medication Dose Type (fixed or titrated): Studies were coded as either 
administering medication with a fixed dose or a titrated dose; studies 
administering titrated doses of medications were also coded according to 
average number of days participants maintained final medication doses. 
19) Learning/Practice Effects (yes or no): For all cognitive outcome variables with 
the exception of non-declarative memory, studies that provided a learning or 
practice session prior to drug or placebo treatment were coded.  
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20) Inclusion of Other Drugs (yes or no): Some studies investigated the effects of 
drugs not relevant to the present study and were coded accordingly.  
21) Inclusion of Non-behavioral Measures (yes or no): Studies that conducted 
cognitive assessments in conjunction with neurological (e.g., fMRI, Event 
Related Potentials [ERP]) or physiological (e.g., electroencephalogram [EEG], 
electrocardiogram [EKG]) assessments were coded in order to account for any 
influence of non-behavioral measures. Studies that utilized biological 
assessments (e.g., blood samples, saliva samples, blood pressure) were not 
coded in this category. 
22) Medication Types (stimulant, prostimulant, or nonstimulant medications): 
Medications were coded as either stimulant (AMP and MPH), prostimulant 
(LDX), or nonstimulant (ATX) medications. The following criteria was used 
when studies investigated the effects of a combination of these medications: 
Effect sizes were combined for studies investigating the effects of both AMP 
and MPH; for studies investigating ATX, as well as MPH or AMP, only data 
related to MPH or AMP were selected given the importance of assessing 
prescription stimulant effects that have been reported to be more commonly 
misused for academic enhancement (e.g., Bossaer et al., 2013; Garnier-Dykstra 
et al., 2012; Verdi et al., 2014; Weyandt et al., 2013a); additionally, only data 
related to LDX were selected when studies reported results for both LDX and 
another stimulant or nonstimulant ADHD medication because of the fewer 
number of studies that investigated LDX effects.  
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23) Significant and Non-significant Findings (yes or no): Studies that reported both 
significant and non-significant results for all measures were coded and studies 
that reported only significant (or only non-significant) findings were coded. 
Statistical and Other Software 
 Microsoft Word, Microsoft Excel, Google Sheets, Biostat’s Comprehensive 
Meta-Analysis, and SPSS 17.0 were employed to conduct all data analyses. A 
comprehensive coding manual was created in Microsoft Word. Microsoft Excel was 
used for literature search tracking and Google Sheets was used for data extraction, 
storage, and computation of study ES. Google Sheets allows for more than one 
researcher to enter and access data at a time. Finally, statistical analysis for the meta-
analysis was run using SPSS and Biostat’s Comprehensive Meta-Analysis 
(Borenstein, Hedges, Higgins, & Rothstein, 2015). 
Statistical Analyses 
Meta-analyses, which pool weighted estimates of effects into a common metric 
across studies, taking into account study variability and yielding more power than 
individual studies (Aloe, 2014; Lipsey & Wilson, 2001), were conducted on the 
retrieved studies. In total, 14 individual meta-analyses were conducted across three 
levels ranging in scope from broad to narrow. Analyses were conducted across three 
levels to capture results from as many studies as possible without sacrificing 
individual differences. Findings from the analyses conducted on the broadest level of 
concepts may help account for the high degree of overlap inherent to individual 
cognitive constructs and cognitive instruments. For example, tests of learning and 
memory also require working memory and processing speed skills and tests of 
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cognitive flexibility require skills related to vigilance.  Findings from the analyses 
conducted on the narrowest level of concepts, however, may help elucidate any 
important differences that may otherwise have been lost when averaged within broad 
constructs.  
At the broadest level, all cognitive constructs were averaged to comprise 
cognition in general; this level involved only one meta-analysis that included all of the 
identified studies. The second set of analyses included the relatively broad constructs 
of abilities of focused behavior, learning and memory, and executive function. Mean 
effect sizes were calculated by averaging across multiple tests that were categorized 
according to one of the three broad constructs, resulting in 3 meta-analyses at this 
level. A final set of analyses, involving the narrowest level of constructs, included 10 
individual meta-analyses, one for each dependent variable of cognition: constructs 
related to abilities of focused behavior included sustained attention, inhibitory control, 
processing speed, and working memory; constructs considered under the category of 
learning and memory were declarative memory - immediate, declarative memory - 
delayed, declarative memory – long-term, and non-declarative learning; and constructs 
associated with executive function were planning and decision-making and self-
regulation. Tasks were coded according to these constructs based on previous research 
and cognitive theory presented in Chapter 2 (see Table 1 for measure selection).  
Primary analyses included effect size calculation for maximum change in 
cognition of treatment compared to control. Additional analyses included visual 
inspection of outliers, homogeneity tests of ES distribution, analyses of publication 
bias, and exploration of potential moderating variables. 
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Assessment of Effect Size 
Effect size was calculated from a variety of statistics. Whenever possible, 
effect size was calculated using descriptive data, i.e., means and standard deviations. 
When descriptive statistics were not reported, statistics of F (in cases of df = 1) and t, 
reported from inferential statistics were used. If both sample size and exact p values 
were reported, but F or t statistics were not, estimates of F and t statistics were 
computed interpolating from the t-distribution table of inverse distribution functions 
provided by Lipsey and Wilson (see Appendix B, Table 13, in Lipsey & Wilson, 
2001). The order of degrees of approximation was based on recommendations by 
Lipsey and Wilson (2001), as well as the finding that compared to effect sizes based 
on inferential statistics, descriptive statistics lead to reduced bias in repeated measures 
designs (Ilieva et al., 2015; Dunlap, Cortina, Vaslow, & Burke, 1996). For missing 
raw data necessary for effect size computation, a request for more information was 
made to researchers; otherwise, studies with missing data for effect size computation 
were excluded. 
Hedge’s g was selected as the measure of effect size for the present study. 
Hedge’s g was chosen because (a) the majority of studies reporting an effect size 
examining the effects of prescription stimulants on cognition reported standardized 
mean differences, (b) Hedge’s g can be calculated when studies report insufficient 
descriptive statistics, and (c) when calculated among samples of at least 20, the 
magnitude of positive bias from Hedge’s g as an estimator of the population parameter 
is small (Kline, 2004). Hedge’s g (for standardized mean difference) and Proportion 
Difference were calculated and converted to standardized mean difference (Hedge’s g) 
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for comparing across studies. Hedge’s g is typically calculated by taking d, which is 
the difference of group means divided by the pooled within group standard deviation 
(Borenstein et al., 2009; Hedges, 1981; Lipsey & Wilson, 2001), then multiplying by 
the coefficient J, a correction factor to account for small sample bias defined as:
 
  1   	
         (1) 
(Borenstein et al., 2009). The formulas for calculating Hedge’s g vary according to 
study design and available data. In general, however, the formula for Hedge’s g is:  
              (2) 
(Borenstein et al., 2009; Lipsey & Wilson, 2001).  
For studies using a between-subjects or parallel design, which compares a 
treatment and a control group, Hedge’s g, pooled within group standard deviation (Sp) 
and standard error of g (SEg) were calculated with the formulas below: 
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(Borenstein et al., 2009; Lipsey & Wilson, 2001). When descriptive statistics were not 
available, but t statistics, F statistics and/or p values were reported, Hedge’s g was 
calculated for a between-subjects or parallel design by using the following formulas:  
      '"         (6) 
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(Lipsey & Wilson, 2001). Note that if only p values were reported, the t statistic was 
interpolated from the t-distribution table of inverse distribution functions provided by 
Lipsey and Wilson (see Appendix B, Table 13, in Lipsey & Wilson, 2001). 
Within-subjects or crossover designs require a different set of formulas for 
calculating Hedge’s g than between-subjects or parallel designs. While between-
subjects studies’ natural unit of deviation is the standard deviation within groups, the 
standard deviation of the difference score (SDDIFF) is the statistic of interest for 
estimating the natural unit of deviation for within-subjects studies (Borenstein et al., 
2009). In particular, SDDIFF uncovers the relationship between variables as opposed to 
the variables themselves (Elliott et al., 1997). Because most studies did not report the 
standard deviation of the difference score, an estimate was calculated by using the 
following formula, where r refers to the population correlation of scores in treatment 
level drug with those in treatment level placebo, i.e., correlation of repeated measures: 
 )*+((   , )*-./# &  )01#  23)*-./)01     (8) 
 
(Maxwell & Delaney, 2004). Because none of the studies included in the present 
analysis provided a measure of r, statistics of available test-retest reliability were used 
as an estimate of the correlation of repeated measures. In the cases where test-retest 
reliability was not available for a given test, reliability estimates reported for similar 
measures were used. Exact test-retest reliability coefficients used as an estimate of the 
correlation between repeated measures are displayed according to construct and 
measure in Appendix B.  
Depending on the descriptive statistics provided by the studies, a number of 
formulas were available to calculate Hedge’s g for within-subjects or crossover 
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studies. Formulas used to calculate Hedge’s g and standard error of g for within-
subjects or crossover designs using descriptive statistics are below: 
4    
 ,#
5 *677        (9) 
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(Borenstein et al., 2009). Formulas used to calculate Hedge’s g for within-subjects 
studies that only provided inferential statistics, i.e., t statistics, F statistics (where df = 
1), and/or p values were: 
4      ' ;21  3 <       (11) 
 
4     ( ;21  3 <       (12) 
 
(Dunlap, Cortina, Vaslow, & Burke, 1996), where equation 12 was calculated based 
on the equation F = t2.  
One study reported results as a dichotomized variable (percent of 
improvement); therefore the following formula was used to convert proportion of 
differences to Hedge’s g: 
     2  =3>?@ABC,D5E%    2  =3>?@AB,F01 G   
 (13) 
(Lipsey & Wilson, 2001). 
 Finally, many studies reported the standard error of the mean (SE), which was 
converted to standard deviation based on the formula: 
  $√A         (14) 
(Lipsey & Wilson, 2001; Meyers, Well, & Lorch, 2010). 
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Weighting of Studies 
 After all effect sizes were extracted and converted to Hedge’s g, they were 
weighted by their inverse variance weight (w) in order to weight studies according to 
sample size. Inverse variance weight was calculated by taking the reciprocal of the 
standard error squared, reported in equations 5 and 10 for between and within-subjects 
designs respectively: 
w   JK!           (15) 
Confidence Intervals 
 A 95% Confidence Interval (CI) was computed for each effect size in order to 
provide a range of effect size estimates that the effect size is likely to fall 95% of the 
time. For Hedge’s g, a 95% CI was estimated by first calculating g and the standard 
error, shown in the previous equations and then using the following formulas for a 
lower limit (LL) and an upper limit (UL) of the CI: 
LL%       1.96  $%       (16) 
PL%     &  1.96  $%       (17) 
(Borenstein et al., 2009). CI estimates are reported numerically and graphed using a 
forest plot for each effect size. 
Interpretation of Effect Sizes 
Cohen (1992) proposed estimates to assess the magnitude of the mean effect 
(Cohen’s d). Within Cohen’s proposed conventions, magnitudes of effects may be 
considered small (0.20), medium (0.50) or large (0.80). The present study used these 
conventions as a general guide for interpreting effect size; however, estimates were 
also considered in the context of studies investigating ADHD medication efficacy, 
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which have reported significant standardized mean differences ranging between d = 
0.4 and d = 1.5 for prescription stimulant and prostimulant medication (Faraone et al., 
2006; Faraone & Glatt, 2010; Weyandt et al., 2014). These effects have varied by 
medication type, with one meta-analysis reporting a standardized mean difference of 
long-acting stimulants and prostimulants as d = 0.73, short-acting stimulants as d = 
0.96, and nonstimulants as d = 0.39 (Faraone & Glatt, 2010). While these effect sizes 
relate to the reduction of ADHD symptomology, magnitudes of effects related to 
enhanced cognition could be expected to follow a similar, but likely smaller, 
convention.  
Homogeneity of Variance 
Homogeneity of variance is important to consider prior to combining effect 
sizes across studies as it represents an estimate of excess or true variance. 
Homogeneity of the effect size distribution was tested visually, with forest plots, and 
statistically, with the use of the Q statistic and I2 (95% CI) index. The Q statistic is a 
standardized measure that approximates to a chi-square distribution with k – 1 degrees 
of freedom, where k is the number of studies (Hedges & Olkin, 1984; Huedo-Medina, 
Sánchez-Meca, Marín-Martínez, & Botella, 2006) and a statistically significant Q is 
indicative of a heterogeneous distribution, signaling the potential to test for 
moderators (Lipsey & Wilson, 2001), where: 
Q   ∑ STT   U  #VT W         (18) 
(Borenstein et al., 2009; Lipsey & Wilson, 2001); for this formula, ST is equal to the 
study weight ( J!), T refers to the study ES, M is the summary effect, and k represents 
the number of studies (ES) (Borenstein et al., 2009; Lipsey & Wilson, 2001).  
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Model of Analysis 
A random effects model, which assumes that measured effect sizes are subject 
to sampling error and random effects variance (Lipsey & Wilson, 2001), was chosen a 
priori given the heterogeneity of the design of studies and cognitive measures as 
recommended by Field and Gillett (2010) and Hunter and Schmidt (2000) (however 
results from both a random and fixed effects model are reported). Biostat’s 
Comprehensive Meta-analysis was used to provide a random effects mean effect size, 
computed by weighting each effect size by the inverse of its variance (wi), and 
confidence intervals, computed by multiplying the standard error by a critical z-value 
(Hedges & Olkin, 1984). Therefore, each study was weighted by the inverse of its 
variance calculated for a random effects model, which not only includes the within-
study variance, but also an estimate of between-study variance (Borenstein et al., 
2009). 
Statistical Tests of Moderators 
An important consideration regarding meta-analysis is its susceptibility to 
overlook important influences, such as the social context of the study, the quality of 
the study, and theoretical influences/implications (Lispey & Wilson, 2001). For 
example, in their meta-analysis assessing stimulant effects on ADHD 
symptomatology, Faraone & Glatt (2010) suggested systematic variability across 
methodology between classes of drugs may have produced misleading results. 
Therefore, the present study sought not only to measure the enhancing neurocognitive 
effects of prescription stimulant medications, but also to investigate variables that may 
moderate these effects by comparing the variance between two groups. Statistical tests 
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of moderators were conducted for variables identified a priori as described previously 
(dose, timing of dose, type of drug, baseline functioning, ADHD status), as well as any 
of the additional variables yielding a significant Q statistic. Because the moderating 
variables of interest were both categorical (type of drug, ADHD status) and continuous 
(dose, timing of dose, baseline functioning), analog to analysis of variance (ANOVA) 
and weighted regression analysis (meta-regression) were run for tests of moderators.  
A mixed effects model, which uses a random effects model for the 
combination of studies within subgroups and a fixed effects model across each 
subgroup (Borenstein et al., 2009), was used to test categorical moderators (i.e., 
subgroup analysis).  Subgroup analyses were conducted with the analog to ANOVA, 
which is similar to a standard ANOVA given both the pooled group variance (Q4) and 
the between group variance (Q) were used with the formulas:   
Q4    ∑ STT   UX   #VT W         (19) 
and 
Q    ∑ SXUX#    Y∑ Z[[\
!
∑ Z[
VT W        (20) 
where SX is equal to the sum of weights for each subgroup, UX refers to the weighted 
mean effect size for each subgroup, ST is equal to the study weight ( J!), T refers to 
the study effect size, M is the summary effect, k represents the number of studies 
(effect size) and j refers to the number of groups (Borenstein et al., 2009; Lipsey & 
Wilson, 2001).  
 To test for the continuous moderators, a mixed effects model (method of 
moments) for weighted regression analysis or meta-regression was used. Similar to 
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regression or multiple regression, meta-regression assesses level of study as a 
covariate and uses effect sizes as dependent variables, as opposed to level of subject 
and individual scores in regressions (Borenstein et al., 2009). A Q test, similar to that 
of the Q test for the analog to ANOVA, was run to assess multiple predictor variables 
simultaneously. The Q statistic was separated into the variability accounted for by the 
regression (Q-) and the error or residual variance (Q]), the comparable statistics to Q4 
and Qin the analog to ANOVA, respectively (Borenstein et al., 2009; Lipsey & 
Wilson, 2001).  
To assess an analog to proportion of variance, true variance explained was 
calculated by: 
 ^#  1  _ a`bcdefgbch!
i`jife!
k       (21) 
where R2 represents the variance of true effect sizes across studies (Borenstein et al., 
2009). 
Assumption of Independence 
 Meta-analysis relies on the assumption that each measure of effect is 
representative of independent studies. Yet, most studies investigating prescription 
stimulant effects reported findings from multiple outcomes, yielding a potential for 
multiple effect size estimates. Therefore, a protocol to handle studies with more than 
one effect size was used, including the following guidelines: 
(1) When more than one cognitive construct was reported within a single study, 
data were calculated to estimate effect sizes for each construct separately and 
used in separate meta-analyses of each narrow construct (e.g., sustained 
attention, inhibitory control, working memory, etc.). Mean effect sizes from 
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these narrow constructs were then averaged together to calculate a mean effect 
size for each of the three broader constructs. Specifically, for abilities of 
focused behaviors, a mean effect size was calculated by averaging sustained 
attention, inhibitory control, working memory, and processing speed; the mean 
effect size for learning and memory was calculated by averaging declarative 
memory (immediate, delayed, and long-term) and non-declarative memory; 
and planning and decision-making and self-regulation were averaged together 
to calculate the mean effect size for executive function. Similarly, mean effect 
sizes from these three broader constructs were then averaged together to 
calculate a mean effect size for cognition in general. 
(2) When data were available to calculate an effect size generated from multiple 
measures per construct in a single study, only the most relevant measures were 
averaged to calculate a single effect size. Relevant measures were determined 
separately for each construct and were reported previously (see Table 1). 
(3) When data were available to calculate more than one effect size because a 
single study investigated the cognitive effects of multiple drug doses, effect 
sizes across doses were averaged and estimates of doses were averaged (e.g., a 
study investigating the cognitive effects of 10mg and 20 mg of MPH was 
averaged to 15mg of MPH). 
(4) When data were available to calculate more than one effect size because a 
single study investigated more than one type of stimulant medication (e.g., d-
AMP and MPH), effect sizes were averaged for both drug types. If data were 
available to calculate more than one effect size due to the inclusion of a 
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stimulant and non-stimulant medication, however, only data related to the 
stimulant medication were selected. 
(5) When data were available to calculate more than one effect size within a single 
study exploring stimulant effects on both adults with and without ADHD, only 
effect sizes from adults with ADHD were included given fewer studies 
investigated populations of adults with ADHD. 
(6) Effect sizes from studies that investigated effects across varying time intervals 
of drug administration were averaged (e.g., a study measuring WM at 60 and 
120 minutes post drug administration was averaged to 90 minutes). Exceptions 
to this convention were studies that included data across multiple time-points 
for declarative learning and memory, where outcome variables were calculated 
separately for immediate (less than 20 minutes after learning), delayed (a 
minimum of 20 minutes, but occurring the same day as learning), and long-
term (a minimum of 1 day). For the broader construct of learning and memory, 
however, these effect sizes, as well as any calculated from non-declarative 
learning and memory, were averaged together to calculate a mean effect size. 
(7) Effect sizes from studies that investigated effects across multiple sessions were 
averaged. 
Outliers 
 In order to verify accurate data entry and to account for potential effects of 
context within studies, a careful examination of any study level effect size outliers was 
conducted. In the case where outliers were identified because of large sample sizes, 
parallel analyses that included and excluded these outliers were conducted. To 
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maintain as much data as possible, only extreme outliers (falling more than 3 standard 
deviations away from the mean) that were identified as irrelevant or out of context 
were removed from the final analysis. 
Missing Data 
Missing data can refer to missing studies, where studies cannot be identified 
(further discussed in the section on publication bias), missing effect sizes, where data 
are unavailable to calculate an effect sizes within a study, and missing moderators. 
While efforts were made to request descriptive and/or inferential data for every 
eligible study that was missing the necessary data to calculate measures of effects, 
studies where data were not available for effect size calculations were excluded from 
the final analysis.  
Most studies reported descriptive data across variables that resulted in both 
positive and negative effect sizes. Therefore, when data were missing and was 
reported simply as significant or “non-significant,” without a t or F statistic or 
descriptive data, no effect size was recorded. For studies that reported enough data to 
calculate the effect size for significant outcomes only, but did not report the minimal 
data to compute an effect size for other outcomes of the same construct (reported as 
“non-significant”), a dummy variable with the effect size set to zero was used to 
account for positive bias. For example, Finke et al. (2010) provided the means and 
standard deviations, as well as the t statistic, for significant differences between MPH 
and PBO found within adults with low baseline scores, but did not reported any 
descriptive statistic data for the “non-significant” differences between drug groups 
within the high performing group. To estimate an effect size for comparing across 
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studies (that did not separate findings by baseline functioning), the effect size was 
calculated by averaging the significant findings with an effect size of zero. On the 
other hand, Fillmore, Kelly, and Martin (2004) reported both significant and “non-
significant” p-values from simple effects tests for a measure of processing speed, but 
did not report enough statistics to calculate any effect size for drug effects on 
inhibitory control. In this case, an effect size including all outcome measures was 
calculated for processing speed, but no effect size was calculated for inhibitory 
control.  
Regarding missing moderator data, case analysis for studies that did report 
moderator data were employed. A decision to omit data, as opposed to imputing data, 
was made given the variability across studies. For ANOVA analog, results were 
calculated with the inclusion of missing categories, as well as with the exclusion of 
these categories. 
Publication Bias 
 Publication bias, which generally refers to the increased likelihood of studies 
with significant findings being published compared to studies without significant 
findings, may stem from missing data within included studies (e.g., when data were 
extracted from studies that only report significant findings as described previously) or 
from missing data that cannot be extracted from studies because they were never 
published due to non-significant findings. The latter phenomenon is referred to as the 
“file drawer” problem, which can significantly distort and misrepresent the size of 
effects found through meta-analysis (Bradley & Gupta, 1997). The present study 
utilized a variety of methods aimed at reducing the level of publication bias during the 
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literature search and retrieval process and during the stage of analysis. First, focused 
efforts were made during the search and retrieval process to access unpublished data 
(i.e., dissertations), as well as missing articles through interlibrary loan and by way of 
contacting researchers directly. In a similar vein, researchers were contacted with 
requests for missing data in the cases where retrieved articles did not provide 
sufficient data to calculate an estimate of effect size. During the analysis stage, six 
different methods were utilized to assess level and presence of publication bias: 
Egger’s regression index, the funnel plot, Duval and Tweedie’s trim and fill, 
Rosenthal’s fail-safe N, Orwin’s adapted version of Rosenthal’s fail-safe N, and an 
assessment of publication bias as a moderating variable.  
In order to assess the presence of sampling bias on the mean effects, both 
visual inspection of a funnel plot and a statistical evaluation of Egger’s test of funnel 
plot asymmetry with regression intercept (Egger, Smith, Schneider, & Minder, 1997; 
Lipsey & Wilson, 2001). Funnel plots are a visual display of effect sizes by their 
standard errors where studies with smaller error variances are clustered near the top of 
the plot and studies with larger error variances are dispersed near the bottom of the 
plot, falling to the right and left of the mean. Visual inspection reveals the presence of 
bias when higher numbers of studies are shown to the bottom and right of the mean, 
which indicates studies relying on small sample sizes and generating large effect sizes.  
It is important to note, however, that this method of visual inspection can be 
difficult to interpret and may not always proffer an accurate representation of bias - for 
example, the heterogeneity of the studies may also influence the dispersion of studies 
(Egger et al., 1997). Therefore, Egger’s test of funnel plot asymmetry with regression 
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intercept, which provides a quantitative estimate of the bias represented in the funnel 
plot (Borenstein et al., 2009), was also used to assess the presence publication bias. 
For this test, the standardized effect (i.e., the effect size divided by standard error) is 
regressed on the inverse of the standard error, an estimate of precision. Studies with 
higher estimates of standard error yield a precision estimate that is closer to zero and 
thus tend to represent studies relying on small sample sizes. Conversely, studies with 
lower estimates of standard error yield a precision estimate moving away from zero, 
indicating studies with more robust sample sizes. The absence of bias is represented 
by a regression line that approaches the intercept of the origin and the presence of bias 
is depicted by a regression line that deviates from this pattern. 
Duval and Tweedie’s trim and fill analysis was utilized to identify how 
eliminating the bias would impact the measure of effect (Borenstein, 2009). 
Specifically, this analysis identifies specific studies to be trimmed, leading to a 
symmetrical funnel plot. Following the general guidelines of four or more studies 
indicating a high risk of publication bias (Borenstein et al., 2009; Sutton, 2009), 
imputations were conducted only for analyses that revealed four or more. Once 
identified, studies were removed from contributing to the overall mean effect. In order 
to calculate variance, however, the identified studies were then returned to the analysis 
by imputing mirror images on the opposite side of the funnel plot. 
In order to assess the magnitude of the effects of publication bias, Rosenthal’s 
fail-safe N and Orwin’s adapted version of Rosenthal’s fail-safe N were used. 
Rosenthal’s method, intended to account for the file-drawer effect, computes the 
number of missing studies with nil effects that would need to be added to the analyses 
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in order to yield a non-significant effect (i.e., p > .05) (Borenstein, 2009) and can be 
calculated by:  
 l-   ;∑ mg <!mn!  A       (22) 
(Rosenberg, 2005). For this equation, n signifies the number of studies, Z(pi) 
represents the Z-scores for significance values, and Zα is the one-tailed Z-score 
connected to the predetermined alpha-level. This method has been criticized for a 
number of reasons, namely that it relies on statistical significance as opposed to 
clinical significance and that it assumes the missing studies’ mean effect size to be 
non-significant (Borenstein, 2009). Therefore, Orwin’s method was also employed, 
which determines the number of studies with predetermined effect sizes needed to 
reduce the mean effect size to a predetermined level, in this case .10, which would 
represent very small effects (Lipsey & Wilson, 2001). Orwin’s N was calculated using 
the following equation: 
 l1   Jo
 Jop Jop
 Job ,       (23) 
where n represented the number of studies, ĒO represented the mean of the studies 
computed in the meta-analysis, Ēn reflected the mean of the added NO studies, and Ēm 
was the predetermined effect size (Rosenberg, 2005). Finally, the present study also 
included an assessment of publication bias within published studies by including a 
variable of publication bias as a potential moderating variable as described previously 
(i.e., studies reporting only significant findings were identified and coded).  
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CHAPTER 5: RESULTS 
Search Results 
The search process is summarized in Figure 1. A total of 7,608 titles were initially 
identified via the bibliographic databases PsycINFO (2,445), MEDLINE (3,683), 
ScienceDirect (670), and Dissertations and Theses (809) based on the keyterms listed 
previously. Forty-one studies were identified from review articles examining the 
effects of ADHD medication on cognition. Based on a manual review of titles, 715 
abstracts were selected for review for eligibility based on inclusion criteria. Of the 
reviewed abstracts, a total of 236 titles were identified as potentially meeting criteria 
and these publications were retrieved or requested. After manual review of full text, 
another 105 titles were eliminated based on eligibility criteria. A total of 131 titles 
were maintained, meeting all inclusion criteria. After a thorough examination of 
available effect size statistics, 52 manuscript titles and 3 dissertation titles were 
identified as eligible for inclusion, but missing data. Of these titles, researchers of 39 
publications were contacted with requests for missing data; contact information was 
unavailable for the remaining 13 researchers. Researchers of 11 studies supplied the 
required effect size statistics and were maintained in the study. The remaining 44 titles 
(including 50 studies) that met inclusion criteria, but did not have sufficient data to 
calculate effect sizes, are described in Appendix C.  
A final 87 titles, including 91 studies (four titles reported for two separate 
studies) reporting data to calculate at least one effect size were included in this study. 
Included studies resulted in a total of 2,778 participants for this study. Data were 
extracted from original manuscripts and raw data sent from researchers. Final studies 
  
 
 
included in the study were published between 
final 91 studies included 
Figure 1 
Search and Retrieval Process Results
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1958 and 2014. Characteristics of the 
in analyses can be seen in Tables 2 and 3.  
 
 
  
 
 
78
 
Table 2 
Characteristics of Studies Included for ADHD Medication Effects on Neurocognitive Enhancement of Cognition 
Study Instrument(s) (Construct) 
ADHD  
Status N Recruitment 
Ethnicity 
(Percent) 
Mean  
Age 
(Range) 
Percent 
Female 
Design (days 
between 
treatment) 
Adminis-
tration 
Type 
Medi-
cation 
(Type) 
Average 
Dose 
 (Level) 
Dose 
Time 
(Acti-
vation) 
Agay, Yechiam, 
Carmel, & Levkovitz 
(2010) 
DS (WM) 
TOVA (V, IC) 
IGT (PD) 
RPM (CF) 
Yes 26 Clinic; Community NR 32.25 57.69 Parallel Fixed 
MPH 
(SA) 
15-mg 
(Low) 40 (Prior) 
Agay, Yechiam, 
Carmel, & Levkovitz 
(2014) 
DS (WM) 
WM Task (WM) 
TOVA (V) 
IGT (PD) 
Yes 20 Community NR 20.9 (20-40) NR 
Crossover 
(NR) Fixed 
MPH 
(SA) 
0.28-
mg/kg 
(Low) 
60 
(During) 
Allman et al. (2010) Antisaccade (IC) No 24 NR NR NR  (18-34) 29.17 Crossover (2) Fixed 
AMP 
(SA) 
0.3-mg/kg 
(Low) 
180 
(During) 
Allman, Ettinger, 
Joober, & O'Driscoll 
(2012) 
Antisaccade (IC) No 29 NR Caucasian (100%) 26.2 0 Crossover (6) Fixed 
MPH 
(SA) 
20-mg 
(Low) 
90 
(During) 
Aron, Dowson, 
Sahakian, & Robbins 
(2003) 
Stop-Signal Task 
(IC) Yes 13 Clinic NR 
26.2 (18-
41) 23.08 Crossover (3) Fixed 
MPH 
(SA) 
30-mg 
(Low) 
75 
(During) 
Ballard, Gallo, & de 
Wit (2013) 
Recall of Pictures 
(DM-L) No 25 
University; 
Community NR 
NR  
(18-35) 48.00 
Crossover 
(NR) Fixed 
AMP 
(SA) 
15-mg 
(Low) 
2880 
(After) 
Ballard, Gallo, & de 
Wit (2014) 
Recall of Pictures 
(DM-L) 
Recognition of 
Words (DM-L) 
No 31 Community NR 22.6 (18-35) 51.61 
Crossover 
(NR) Fixed 
AMP 
(SA) 
15-mg 
(Low) 
86.25 
(Prior) 
Barch & Carter 
(2005) 
Stroop (IC) 
DLT(WM) No 22 Community NR 36.6 45.45 Crossover (2) Fixed 
AMP 
(SA) 
0.25-
mg/kg 
(Low) 
150 
(During) 
Barkley, Murphy, 
O'Connell, & Connor 
(2005) 
CPT (V, IC) Yes 56 Clinic 
White 
(83%); 
African 
American 
(3.7%); 
Hispanic 
(5.6%); 
Native 
American 
(5.6%); 
Other 
(1.9%) 
31.3 (18-
65) 25.93 Crossover (7) Fixed 
MPH 
(SA) 
15-mg 
(Low) 
75 
(During) 
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Study Instrument(s) (Construct) 
ADHD  
Status N Recruitment 
Ethnicity 
(Percent) 
Mean  
Age 
(Range) 
Percent 
Female 
Design (days 
between 
treatment) 
Adminis-
tration 
Type 
Medi-
cation 
(Type) 
Average 
Dose 
 (Level) 
Dose 
Time 
(Acti-
vation) 
Ben-Itzhak, Giladi, 
Gruendlinger, 
Hausdorff (2008) 
Go/No-Go (IC) 
Recognition of 
Object Orientation 
(DM-I) 
No 26 Community NR 73.18 (65-90) 65.38 Crossover (7) Fixed MPH 
20-mg 
(Low) 
120 
(during) 
Boonstra, Kooij, 
Oosterlaan, Sergeant, 
& Buitelaar (2005) 
CPT (V, IC) 
Stop Signal (IC) Yes 43 Clinic NR 38.4 51.16 Crossover (7) Titrated 
MPH 
(SA) 
.75-mg/kg 
(High) 
75 
(During) 
Breitenstein et al. 
(2004) AWL (NDL) No 40 University NR 
25.12 (20-
33) 0 Parallel Fixed 
AMP 
(SA) 
0.25-
mg/kg 
(Low) 
120 
(During) 
Brignell, Rosenthal, 
& Curran (2007) 
 
Recognition of 
Story (DM-I) 
Recall of Object 
(DM-I) 
Recall of Story 
(DM-D) 
No 48 NR NR 22.8 (18-35) 52.08 Parallel Fixed 
MPH 
(SA) 
40-mg 
(High) 
120 
(During) 
Bron et al. (2014) CPT (V, IC) TOVA (V, IC) Yes 22 Clinic NR 
30.5 (18-
55) 22.73 Crossover (7) Titrated 
MPH 
(LA) 
54-mg 
(High) NR 
Brumaghim, 
Klorman, Strauss, 
Lewine, & Goldstein 
(1987)a 
SMT (WM) No 19 University NR
 
19.37 0 Crossover (NR) Fixed 
MPH 
(SA) 
21.84-mg 
(Low) 
70 
(During) 
Brumaghim, 
Klorman, 
Brumaghim, 
Klorman, Strauss, 
Lewine, & Goldstein 
(1987)b 
SMT (WM) No 14 University NR 20 57.14 Crossover (NR) Fixed 
MPH 
(SA) 
21.84-mg 
(Low) 
70 
(During) 
Burns, House, 
Fensch, & Miller 
(1967) 
Learning Task 
(NDL) No 30 NR NR NR NR Parallel Fixed 
AMP 
(SA) 
15-mg 
(Low) 
150 
(During) 
Campbell-
Meiklejohn et al. 
(2012) 
n-back (WM) No 38 Community NR 23 100 Parallel Fixed MPH (SA) 
20-mg 
(Low) 
62 
(During) 
Chamberlain et al. 
(2007) 
Stop Signal (IC) 
SWM (WM) 
RVIP (V, IC) 
IDED (SR) 
Yes 20 Clinic NR NR 0.30 Crossover (5) Fixed ATX (LA) 
60-mg 
(Low) 
120 
(During) 
Chamberlain et al. 
(2009) Stop Signal (IC) No 19 Community NR 
28.95 (19-
46) 0 Crossover (5) Fixed 
ATX 
(LA) 
40-mg 
(Low) 
90 
(During) 
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Study Instrument(s) (Construct) 
ADHD  
Status N Recruitment 
Ethnicity 
(Percent) 
Mean  
Age 
(Range) 
Percent 
Female 
Design (days 
between 
treatment) 
Adminis-
tration 
Type 
Medi-
cation 
(Type) 
Average 
Dose 
 (Level) 
Dose 
Time 
(Acti-
vation) 
Chevassus et al. 
(2013) 
Stroop (IC) 
Recall of Pictures 
(DM-I) 
DS (WM) 
DSST (PS) 
SRT (PS) 
CRT (PS) 
No 12 NR NR 26  (21-35) 0 
Crossover 
(17) Fixed 
MPH 
(SA) 
20-mg 
(Low) 
150 
(After) 
Clark, Geffen, 
Geffen (1986a) 
Task of Attention 
(IC) No 12 NR NR 
NR  
(18-30) 0 
Crossover 
(NR) Fixed MPH 
0.65-
mg/kg 
(High) 
60 
(during) 
Clatworthy et al. 
(2009) 
SWM (WM) 
Reversal Learning 
(SR) 
No 10 Community NR NR  (22-32) 0 Crossover (3) Fixed 
MPH 
(SA) 
60-mg 
(High) 
60 
(During) 
Coons et al. (1981)a CPT (V, IC) No 13 Clinical NR 23.84 0 Crossover (6.9 (mean)) Fixed MPH 
20-mg 
(Low) 
105 
(During) 
Coons et al. (1981)b CPT (V, IC) No 23 University NR 19.68 0 Crossover (7.61 (mean)) Fixed MPH 
20-mg 
(Low) 
87.5 
(During) 
Costa et al. (2013) Go/No-Go (V, IC)  Stop-Signal (IC) No 50 6 NR 
23.65 (18-
30) 0 Crossover (7) Fixed MPH 
40-mg 
(High) 
60 
(during) 
de Bruijn, Hulstijn, 
Verkes, Ruigt, & 
Sabbe (2004) 
 
Flanker (IC) No 12 NR NR 22.58 (19-39) 41.67 
Crossover 
(NR) Fixed 
AMP 
(SA) 15-mg 
210 
(After) 
de Wit, Enggasser, & 
Richards (2002) 
DS (WM) 
 
No 26 6 
63.89% 
Caucasian; 
2.78% 
African-
American; 
16.67% 
Asian; 
16.67% 
Hispanic 
24  
(18-44) 0.5 Crossover (3) Fixed AMP 
15-mg 
(Low) NR 
Duke & Keeler 
(1968) 
TMT-A (PS) 
TMT-B (WM) No 8 University NR NR 0 
Crossover 
(NR) Fixed 
AMP 
(SA) 
30-mg 
(High) NR 
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Study Instrument(s) (Construct) 
ADHD  
Status N Recruitment 
Ethnicity 
(Percent) 
Mean  
Age 
(Range) 
Percent 
Female 
Design (days 
between 
treatment) 
Adminis-
tration 
Type 
Medi-
cation 
(Type) 
Average 
Dose 
 (Level) 
Dose 
Time 
(Acti-
vation) 
DuPaul et al. (2012) 
CVLT (DM-I, DM-
D) 
CPT (V, IC) 
Yes 24 University 
African 
American 
(4.17%); 
White 
(91.67%); 
Asian/Pacif
ic Islander 
(4.17%) 
20.17 (18-
23) 37.5 Crossover (0) Fixed 
LDX 
(LA) 
50-mg 
(High) 
180 
(During) 
Elliott et al. (1997) 
SWM (WM) 
RVIP (V) 
NTOL (PD) 
IDED (SR) 
VF (SR) 
No 28 Community NR 21.25 0 Crossover (7) Fixed MPH (SA) 
30-mg 
(Low) 
90 
(During) 
Farah, Haimm, 
Sankoorikal, Smith, 
& Chatterjee (2009) 
RAT (SR) 
GEF (SR) 
AUT (SR) 
Drawing of TTA 
(SR) 
No 16 NR NR 21.25 (21-30) 75.00 Crossover (7) Fixed 
AMP 
(SA) 
10-mg 
(Low) 30 (Prior) 
Faraone et al. (2005) Stroop (IC) Yes 536 Clinic NR NR NR Parallel Titrated ATX (LA) 
90-mg 
(High) NR 
Fillmore, Kelly, & 
Martin (2005) RIP (WM) No 22 NR NR 
21.5 (18-
30) 54.54 Crossover (2) Fixed 
AMP 
(SA) 
11.25-
mg/70-kg 
(Low) 
90 (Prior) 
Finke et al., 2010 Whole-report task (PS, DM-I) No 18 Community NR 
NR  
(20-35) 50 Crossover (7) Fixed MPH 
40-mg 
(High) 
180 
(after) 
Fleming, Bigelow, 
Weinberger, & 
Goldberg (1995) 
RVALT (DM-I) 
PAL Task (DM-I) 
SDR (WM) 
CPT (V, IC) 
COWAT (SR) 
WCST (SR) 
No 17 
Community; 
Institution 
websites 
NR 27.5 47.06 Crossover (7) Fixed AMP (SA) 
0.25-
mg/kg 
(Low) 
60 (Prior) 
Gilbert, Donnelly, 
Zimmer, & Kubis 
(1973) 
DS (WM) 
GMT (DM-I) No 78 Community NR 
NR  
(60-NR) NR Parallel Titrated 
MPH 
(SA) 
20-mg 
(Low) NR 
Graf et al. (2011) Go/No-Go (IC) No 12 NR NR 27.1 0 Crossover (6) Fixed ATX (LA) 
80-mg 
(High) 
120 
(During) 
Halliday, Callaway, 
Naylor, Gratzinger, 
& Prael (1986)a 
SERS (PS) No 16 Community NR NR  (30-60s) 100 Crossover (7) Fixed 
MPH 
(SA) 
10-mg 
(Low) 45 (Prior) 
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Study Instrument(s) (Construct) 
ADHD  
Status N Recruitment 
Ethnicity 
(Percent) 
Mean  
Age 
(Range) 
Percent 
Female 
Design (days 
between 
treatment) 
Adminis-
tration 
Type 
Medi-
cation 
(Type) 
Average 
Dose 
 (Level) 
Dose 
Time 
(Acti-
vation) 
Halliday, Callaway, 
Naylor, Gratzinger, 
& Prael (1986)b 
SERS (PS) No 24 Community NR 26  (21-69) 0 Crossover (7) Fixed 
MPH; 
AMP 
(SA) 
10-mg 
(Low) 45 (Prior) 
Hester et al. (2012) 
Nandam, Hester, & 
Bellgrove (2014) 
Go/No-Go (IC) No 27 University NR 22  (18-35) 0 Crossover (7) Fixed 
MPH 
(SA) 
30-mg 
(Low) 
120 
(During) 
Hink, Fenton, 
Pfefferbaum, 
Tinklenberg, & 
Kopell (1978) 
AAT (V, IC) No 16 NR NR NR  (20-28) 0 Crossover (2) Fixed MPH 
10-mg 
(Low) 
60 
(during) 
Ideström & Schalling 
(1970) 
Stroop (IC) 
DSST (PS) 
RTT (PS) 
No 22 Military NR NR  (19-22) 0 
Crossover 
(NR) Fixed 
AMP 
(SA) 
10-mg/70-
kg (Low) 60 (Prior) 
Ilieva , Boland , & 
Farah (2013) 
Go/No-Go (IC) 
Flanker (IC) 
Recognition of 
Faces (DM-D) 
Recognition of 
Words (DM-D) 
DS (WM) 
n-back (WM) 
RAT (SR) 
GEF (SR) 
No 46 University; Community 
Caucasian 
(100%) 
24  
(21-30) 66.67 Crossover (7) Fixed 
AMP 
(SA) 
20-mg 
(High) 75 (Prior) 
Izquierdo et al. 
(2008) 
Retention of facts 
(DM-L) No 20 NR NR 
NR  
(35-74) 45.00 Parallel Fixed 
MPH 
(SA) 
10-mg 
(Low) 
5760 
(After) 
Kinsbourne, De 
Quiros, & Tocci 
Rufo (2001) 
PAL (DM-I) Yes 17 Clinic NR 34 58.82 Crossover (NR) Fixed 
MPH 
(SA) 
11.67-mg 
(Low) 
120 
(During) 
Kollins et al. (2015) n-back (WM) CPT (V, IC) No 16 NR NR 
24.6 (18-
45) 37.50 Crossover (2) Fixed 
MPH 
(SA) 
25-mg 
(Low) 
150 
(After) 
Kornetsky (1958) 
SMR (PS) 
CVA (PS) 
SLT (NDL) 
No 8 NR NR NR  (18-22) 37.50 
Crossover 
(NR) Fixed 
AMP 
(SA) 
8.5-mg 
(Low) 
150 
(During) 
Kratz et al. (2009) Go/No-Go (V, IC) No 14 NR NR NR 
 (20-40) 42.86 Crossover (7) Fixed MPH 
20-mg 
(low) 
95 
(during) 
Levin, Conners, 
Silva, Canu, & 
March (2001) 
CPT (V, IC) Yes 20 NR NR 37.75 (19-56) 35.00 Parallel Fixed 
MPH 
(MA) 
20-mg 
(Low) NR 
Linssen et al. (2011) SRT (PS) No 19 2 NR 23.4 (19-37) 0 Crossover (2) Fixed MPH 
20-mg 
(Low) 
155 
(after) 
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Study Instrument(s) (Construct) 
ADHD  
Status N Recruitment 
Ethnicity 
(Percent) 
Mean  
Age 
(Range) 
Percent 
Female 
Design (days 
between 
treatment) 
Adminis-
tration 
Type 
Medi-
cation 
(Type) 
Average 
Dose 
 (Level) 
Dose 
Time 
(Acti-
vation) 
Linssen, Vuurman, 
Sambeth, & Riedel 
(2012) 
Stop-Signal (IC) 
SWM (WM) 
NTOL (PD) 
IDED (SR) 
No 19 Community NR 23.4 (19-37) 0 Crossover (2) Fixed 
MPH 
(SA) 
23.33-mg 
(Low) 
90 
(During) 
Linssen, Sambeth, 
Vuurman, & Riedel 
(2014) 
RVALT (DM-I, 
DM-D, DM-L) 
PAL (DM-I) 
SWM (WM) 
SMT (WM) 
No 30 Community NR 20.7 (18-28) 33.33 Crossover (2) Fixed 
MPH 
(SA) 
40-mg 
(High) 
120 
(During) 
Makris, Rush, 
Frederich, Taylor, & 
Kelly (2007) 
SNRT (WM) 
DSST (PS) 
RA (NDL) 
No 11 University; Community 
African 
American 
(8.33%); 
Caucasian 
(36.36%); 
Hispanic 
(25%); 
Pacific 
Islander 
(8.33%); 
Asian/Nativ
e American 
(8.33%); 
Asian/Cauc
asian 
(8.33%) 
26.3 (21-
35) 54.54 Crossover (2) Fixed 
AMP 
(SA) 
0.08-
mg/kg 
(Low) 
155 
(During) 
Marquand et al. 
(2011) 
Spatial Location 
(WM) No 15 
University; 
Community NR 
NR  
(20-39) 0 
Crossover 
(NR) Fixed 
MPH  
(SA) 
30-mg 
(Low) 
135 
(After) 
Mattay et al. (1996)  WCST (SR) No 8 NR NR 
25  
(22-32) 50 Crossover (7) Fixed 
AMP 
(SA) 
0.25-
mg/kg 
(Low) 
120 
(During) 
Mattay et al. (2000) n-back (WM) No 10 NR NR 30 20 Crossover (7) Fixed AMP (SA) 
0.25-
mg/kg 
(Low) 
120 
(During) 
Mehta et al. (2000) SWM (WM) No 10 NR NR 34.8 0 Crossover (14) Fixed 
MPH 
(SA) 
40-mg 
(High) 
90 
(During) 
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Study Instrument(s) (Construct) 
ADHD  
Status N Recruitment 
Ethnicity 
(Percent) 
Mean  
Age 
(Range) 
Percent 
Female 
Design (days 
between 
treatment) 
Adminis-
tration 
Type 
Medi-
cation 
(Type) 
Average 
Dose 
 (Level) 
Dose 
Time 
(Acti-
vation) 
Moeller et al. (2014) Stroop (IC) No 15 Community 
African 
American 
(66.67%); 
Caucasian 
(20.00%); 
Other 
(13.33%) 
38.9 6.67 Crossover (7) Fixed MPH (SA) 
20-mg 
(Low) 
90 
(During) 
Muller et al. (2005) Motor Reaction 
Task (PS) No 12 Community NR 
69.8 (61-
80) 66.67 Crossover (7) Fixed 
MPH 
(SA) 
20-mg 
(Low) 
90 
(During) 
Nandam et al. (2011) Stop-Signal (IC) No 24 University NR NR  (18-35) 0 Crossover (7) Fixed 
MPH 
(SA) 
30-mg 
(Low) 
165 
(After) 
Naylor, Halliday, & 
Callaway (1985) SERS (PS) No 8 University NR 
NR  
(30-39) 100 Crossover (7) Fixed MPH 
11.67-mg 
(Low) 
45 
(Before) 
Oken, Kishiyama, & 
Salinsky (1995) 
DS (WM) 
SOT (PS) 
VST (PS) 
No 23 NR NR 25  (21-39) 52.17 
Crossover 
(NR) Fixed 
MPH 
(SA) 
0.20mg-
/kg (Low) 
60 
(During) 
Pauls et al. (2012) Stop-Signal (IC) No 16 2 NR 23.6 (19-30) 0 Crossover (5) Fixed MPH 
40-mg 
(High) 
90 
(during) 
Ramasubbu, Singh, 
Zhu, & Dunn (2012) n-back (WM) No 13 University NR 28 61.54 Crossover (1) Fixed 
MPH 
(SA) 
20-mg 
(Low) 
60 
(During) 
Rapoport, 
Buchsbaum, & 
Weingartner (1980) 
CPT (V) No 31 University NR 22.35 (18-30) 0 Crossover (2) Fixed 
AMP 
(SA) 
0.38-
mg/kg 
(High) 
47.5 
(Prior) 
Rogers et al. (1999) IDED (SR) No 32 NR NR 20.5 0 Parallel Fixed MPH (SA) 
40-mg 
(High) NR 
Samanez-Larkin et 
al. (2013) 
DSST (PS) 
SCT (SR) No 40 NR NR 
22.4 (18-
31) 47.5 Crossover (1) Fixed 
AMP 
(SA) 
0.43-
mg/kg 
(High) 
90 (Prior) 
Schlösser et al. 
(2009) 
Probabilistic 
Learning (NDL) No 12 NR NR 26.8 0 Crossover (0) Fixed MPH 
40-mg 
(High) 
90 
(during) 
Servan-Schreiber, 
Carter, Bruno, & 
Cohen (1998) 
Flanker (IC) No 10 2 NR NR 
 (24-39) 50 Crossover (3) Fixed AMP 
0.25-
mg/kg 
(Low) 
120 
(during) 
Silber, Croft, 
Papafotiou, & Stough 
(2006) 
DS (WM) 
TMT-B (WM) 
DSST (PS) 
TMT-A (PS) 
DVT (V, IC) 
No 20 Community NR 25.4 (21-32) 50.00 Crossover (7) Fixed 
AMP 
(SA) 
0.42-
mg/kg 
(High) 
180 
(During) 
Sofuoglu, Waters, 
Mooney, & Kosten 
(2008) 
SART (V, IC) No 12 Community NR 27.7 41.67 Crossover (3) Fixed AMP (SA) 
20-mg 
(High) 
120 
(During) 
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Study Instrument(s) (Construct) 
ADHD  
Status N Recruitment 
Ethnicity 
(Percent) 
Mean  
Age 
(Range) 
Percent 
Female 
Design (days 
between 
treatment) 
Adminis-
tration 
Type 
Medi-
cation 
(Type) 
Average 
Dose 
 (Level) 
Dose 
Time 
(Acti-
vation) 
Spencer et al., 1998 Stroop (IC) Yes 21 Clinic NR 34 
 (20-59) 52.38 Crossover (7) Titrated 
ATX 
(LA) 
76-mg 
(Low) NR 
Strauss et al. (1984) CPT (V) No 22 University NR 19.23 0 Crossover (7) Fixed MPH (SA) 
20-mg 
(Low) 
75 
(During) 
Studer, Wangler, 
Diruf, Kratz, Moll, & 
Heinrich (2010) 
Visual WM Task 
(WM) No 11 NR NR 29.7 54.54 Crossover (7) Fixed 
MPH 
(SA) 
40-mg 
(High) 
120 
(During) 
Taylor & Russo 
(2000) 
Stroop (IC) 
DS (WM) 
VF (SR) 
Yes 22 Community NR 40.8 (18-59) 40.91 Crossover (4) Titrated 
AMP 
(SA) 
25-mg 
(Low) 
180 
(After) 
Taylor & Russo 
(2001) 
Stroop (IC) 
VF (SR) Yes 17 Clinic NR 
41.2 (21-
57) 58.82 Crossover (4) Titrated 
AMP 
(SA) 
2.50-20-
mg (Low) 
240 
(During) 
Theunissen, Elvira, 
van de Bergh, & 
Ramaekers (2009) 
MCT (V, IC) 
Stop-Signal (IC) No 16 Community NR 
21.8 (19-
29) 31.25 
Crossover 
(NR) Fixed MPH 
20-mg 
(Low) 
120 
(During) 
Turner, Robbins, 
Clark, Aron, 
Dowson, & Sahakian 
(2003) 
 
PAL (DM-I) 
DS (WM) 
SWM (WM) 
SSP (WM) 
RVIP (V, IC) 
NTOL (PD) 
IGT (PD) 
IDED (SR) 
No 60 Community NR 61.55 0 Parallel Fixed MPH (SA) 
30-mg 
(Low) 
90 
(During) 
Turner, Blackwell, 
Dowson, McLean, & 
Sahakian (2005). 
Pattern Recognition 
Memory Task 
(DM-I, DM-D) 
n-back (WM) 
SWM (WM) 
RVIP (V, IC) 
Yes 18 Clinic NR 28.44 (35-
74) NR Crossover (7) Fixed 
MPH 
(SA) 
30-mg 
(Low) 
75 
(During) 
Unrug, Coenen, & 
van Luijtelaar (1997) 
Recall of 
Vocabulary (DM-I, 
DM-D) 
No 12 University NR 24  (19-27) 50.00 
Crossover 
(10) Fixed 
MPH 
(SA) 
20-mg 
(Low) 
60 
(During) 
van der Schaaf, 
Fallon, Ter Huurne, 
Buitelaar, & Cools 
(2013) 
DS (WM) 
Reversal Learning 
(NDL) 
Reversal Learning - 
shift (SR) 
No 19 University NR 20.9 (19-24.4) 52.63 Crossover (7) Fixed 
MPH 
(SA) 
20-mg 
(Low) 
165 
(After) 
Verster et al. (2010) Recall of Words (DM-I, D) Yes 18 NR NR 38.3 38.89 Crossover (6) Titrated 
MPH 
(SA) 
14.7-mg 
(Low) 
180 
(After) 
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Study Instrument(s) (Construct) 
ADHD  
Status N Recruitment 
Ethnicity 
(Percent) 
Mean  
Age 
(Range) 
Percent 
Female 
Design (days 
between 
treatment) 
Adminis-
tration 
Type 
Medi-
cation 
(Type) 
Average 
Dose 
 (Level) 
Dose 
Time 
(Acti-
vation) 
Ward, Kelly, Foltin, 
& Fischman (1997) 
Number 
Recognition (PS) 
DSST (PS) 
No 6 NR Caucasian (66.66%) 
29.7 (27-
35) 0 Parallel Fixed 
AMP 
(SA) 
7.5-
mg/70kg 
(Low) 
205 
(During) 
Wardle, Hart, 
Palmer, & de Wit 
(2013) 
n-back (WM) 
DSST (PS) 
WCST (SR) 
No 192 Community 
Caucasian 
(96%); 
Hispanic 
(4%) 
23.3 (18-
35) 49.50 Crossover (2) Fixed 
AMP 
(SA) 
11.66-mg 
(Low) 
102 
(Prior) 
Weitzner (1965) 
PAL (DM-I) 
Digit-Letter Coding 
Tests (PS) 
No 96 University NR NR NR Parallel Fixed AMP 
14-
mg/70kg 
(Low) 
120 
(During) 
Whiting, Chenery, 
Chalk, Darnell, & 
Copland (2008) 
Recall of Names 
(DM-L) 
Recognition of 
Names (DM-L) 
RVIP (V, IC) 
No 37 NR NR 23.21 (18-34) 70.27 Parallel Fixed 
AMP 
(SA) 
10-mg 
(Low) 
125 
(During) 
Zeeuws & Soetens 
(2007) 
Recall of Words 
(DM-I, DM-D, 
DM-L) 
No 36 University NR NR  (18-25) 0 Crossover (7) Fixed 
AMP 
(SA) 
10-mg 
(Low) 60 (Prior) 
Zeeuws, Deroost, & 
Soetens (2010a) 
Recall of Words 
(DM-I, DM-D; 
DM-L) 
No 17 University NR 21.56 (18-30) 0 Crossover (7) Fixed 
AMP 
(SA) 
10-mg 
(Low) 75 (Prior) 
Zeeuws, Deroost, & 
Soetens (2010b)a 
Recall of Words 
(DM-I, DM-D, 
DM-L) 
No 24 University NR 21.1 (18-25) 0 Crossover (7) Fixed 
AMP 
(SA) 
10-mg 
(Low) 60 (Prior) 
Zeeuws, Deroost, & 
Soetens (2010b)b 
Recall of Words 
(DM-I, DM-D, 
DM-L) 
No 16 University NR 21.4 (18-25) 0 Crossover (7) Fixed 
AMP 
(SA) 
10-mg 
(Low) 60 (Prior) 
Notes. AAT = Auditory Attention Task; AMP = Amphetamine; ATX = Atomoxetine; AUT = Alternative Uses Test; AWL = Associative Word Learning; COWAT = 
Controlled Oral Word Association Test; CPT = Continuous Performance Task; CRT = Choice Reaction Time; CVA = Choice Visual Attention; CVLT = California 
Verbal Learning Test; DLT = Dot-Letter Task; DM-I = Declarative Memory – Immediate; DM-D = Declarative Memory – Delayed; DM – L = Declarative Memory – 
Long-term; DS = Digit Span; DSST = Digit Symbol Substitution Task; DVT = Digit Vigilance Task; GEF = Group Embedded Figures; GMT = Guild Memory Test; IC 
= Inhibitory Control; IDED = Intra-Extra Dimensional Set-Shift Task; IGT = Iowa Gambling Task; LA = Long-Acting; LDX = Lisdexamfetamine Dymesylate; MPH = 
Methylphenidate; NDL = Non-Declarative Learning; NR = Not Reported; PAL = Paired Associates Task; PD = Planning and Decision-Making; PS = Processing Speed; 
RA = Repeated Acquisition of Response Sequences Task; RAT = Remote Associations Task; RIP = Rapid Information Processing Task; RTT = Reaction Time Test; 
RVALT = Rey Verbal Auditory Learning Task; RVIP = Rapid Visual Information Processing; SA = Short-Acting; SART = Sustained Attention to Response Test; SDR 
= Spatial Delay Response; SCT = Switch Cost Task; SERS = Stimulus Evaluation Response Selection; SLT = Simple Learning Task; SMR = Simple Motor Response; 
SMT = Sternberg Memory Task; SNRT = Sternberg Number Recognition Task; SOT = Spatial Orientation Task; SRT = Simple Reaction Test; SSP = Spatial Span Task; 
SWM = Spatial Working Memory; SR = Self-Regulation; TOVA = Test of Visual Attention; TMT = Trail-Making Task; NTOL = Tower of London Spatial Planning 
Task; TTA = Torrance Test for Adults; V = Vigilance; VF = Verbal Fluency; VST = Visual Search Task; WCST = Wisconsin Card Sorting Test; WM = Working 
Memory. 
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Table 3 
General Characteristics of the Studies 
  k (91) Percent Mean SD 
ADHD Status     
 Yes 16 17.58   
 No 75 82.24   
Sample Characteristics     
 Adults (Miscellaneous) 75 82.42   
 College/University Students 12 13.19   
 Elderly Adults 4 4.40   
Recruitment Characteristics     
 University 31 34.06   
 Community 28 30.77   
 Clinic 13 14.28   
 Military 1 1.10   
 Not Reported 26 28.57   
Mean Age 71 78.02 28.09 10.32 
% Female 87 95.60 30.26 28.16 
Years of Education 12 13.19 14.47 1.11 
Baseline Cognitive Functioning 15 16.48 79.80 10.89 
Country of Researcher     
 Australia 4 4.40   
 Europe 39 42.86   
 Israel 4 4.40   
 North America 44 48.35   
 South America 1 1.10   
Sample Size (n) 30.53 58.28   
Study Design     
 Parallel (Between-Subjects) 14 15.38   
 Crossover (Within-Subjects) 77 84.62   
 
Average number of days 
between sessions 63 69.23 5.48 
 
Learning or Practice Session     
 Yes 31 34.06   
 No Report 49 53.85   
 
NAa (Studies only testing 
learning and memory) 11 12.09  
 
Medication Type     
 Stimulant 85 93.41   
 AMP 34 37.36   
 MPH 52 57.14   
 Prostimulant LDX 1 1.10   
 Nonstimulant ATX 5 5.49   
Medication Dose Levelb     
 Low 69 75.82   
 High 22 24.18   
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Table 3 
General Characteristics of the Studies 
  k (91) Percent Mean SD 
Medication Dose Type     
 Fixed 83 91.21   
 Titrated 8 8.79   
Medication Type     
 Short-Acting 83 
 
91.21   
 Medium or Long-Acting 8 8.79   
Timing of Dose Activation     
 Prior to Learning 17 18.68   
 During Learning 54 59.34   
 After Learning 11 12.09   
 NR 9 9.89   
Inclusion of Other Drugs     
 Yes 25 27.47   
 No 66 72.53   
Cognitive Construct     
 Abilities of Focused Behavior 74 81.32   
 Vigilance 24 26.37   
 Inhibitory Control 43 47.25   
 Working Memory 32 35.16   
 Processing Speed 18 19.78   
 Learning & Memory 29 31.87   
 Declarative - Immediate 18 19.78   
 Declarative - Delayed 11 12.09   
 Declarative– Long-term 9 9.89   
 Non-declarative  6 6.59   
 Executive Function 17 18.68   
 
Planning and Decision 
Making 5 5.50  
 
 Self Regulation 15 16.48   
Inclusion of Non-behavioral Measures 
(e.g., fMRI, PET)    
 
 Yes 28 30.77   
 No 63 69.23   
Reported Significant and Non-significant 
Findings    
 
 Yes 85 93.41   
 No 6 6.589   
Notes: astudies examining learning and memory and no other constructs were not included in 
these results. bfor studies reporting dose in mg/kg average dose was estimated by multiplying 
by average adult weight worldwide of 62kg (Walpole et al., 2012) and for studies reporting 
multiple doses or ranges of doses, the average was used. High doses were considered to be≥ 
20mg (AMP), ≥ 40mg (MPH), ≥ 50mg (LDX), and ≥ 70mg (ATX). 
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The remainder of the results is organized based on three levels of analyses, ranging in 
scope from broad to narrow. First, at the broadest level, findings from the analysis 
including all cognitive constructs are presented. Second, findings from the analyses 
including the relatively broad constructs of abilities of focused behavior, learning and 
memory, and inhibitory control are presented. Finally, findings from analyses 
conducted across the narrowest level of cognitive constructs are presented last.  
Neurocognitive Enhancement  
Neurocognitive Enhancement of Cognition 
Because cognitive constructs overlap considerably, the first analysis involved 
averaging the effect sizes from each of the three cognitive areas (abilities of focused 
behavior, learning and memory, and executive function). This analysis included data 
extracted from all 91 studies that investigated the neurocognitive effects of ADHD 
medication on cognition, including abilities of focused behavior (k = 74), learning and 
memory (k = 29), and executive function (k = 17). Effect sizes resulted from a total of 
2,778 participants (see Appendix D for the individual measures). Table 4 displays the 
descriptive data and effect size estimates (Hedge’s g) from each of the 91 studies. 
Effect sizes ranged from g = -1.226 to g = 3.937. Under the random effects model the 
mean effect size was g =0.147 and significantly different than zero (SE = 0.027, 95% 
CI [0.095, 0.199], p < .001). The fixed effects model resulted in a large reduction of 
the mean effect size (g = -0.005, SE = 0.009, 95% CI [-0.023, 0.014], p = .621). The 
homogeneity of variance analysis yielded a Q statistic that was significant (Q [90] = 
300.435, p < .001).  
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Table 4  
ADHD Medication Neurocognitive Effects on Cognition 
 
  
Study name ADHD Comparison Outcome Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
Agay et al. (2010) Yes MPH vs. PBO AFB & EF 0.200 0.339 0.115 -0.465 0.864 0.589 0.556
Agay et al. (2014) Yes MPH vs. PBO AFB & EF 0.016 0.185 0.034 -0.346 0.378 0.086 0.931
Allman et al. (2010) No AMP vs. PBO AFB 0.329 0.079 0.006 0.175 0.483 4.194 0.000
Allman et al. (2012) No MPH vs. PBO AFB -0.058 0.070 0.005 -0.196 0.080 -0.829 0.407
Aron et al. (2003) Yes MPH vs. PBO AFB 0.534 0.304 0.092 -0.062 1.130 1.757 0.079
Ballard et al. (2013) No AMP vs. PBO LM 0.277 0.134 0.018 0.015 0.539 2.073 0.038
Ballard et al. (2014) No AMP vs. PBO LM -0.087 0.012 0.000 -0.110 -0.064 -7.442 0.000
Barch & Carter (2005) No AMP vs. PBO AFB 0.155 0.140 0.020 -0.119 0.429 1.107 0.268
Barkley et al. (2005) Yes MPH vs. PBO AFB 0.103 0.147 0.022 -0.185 0.390 0.700 0.484
Ben-Itzhak et al. (2008) No MPH vs. PBO AFB & LM 0.185 0.116 0.013 -0.043 0.412 1.590 0.112
Boonstra et al. (2005) Yes MPH vs. PBO AFB 0.014 0.139 0.019 -0.260 0.287 0.097 0.922
Breitenstein et al. (2004) No AMP vs. PBO LM 0.515 0.307 0.095 -0.088 1.118 1.675 0.094
Brignell et al. (2007) No MPH vs. PBO LM 0.251 0.347 0.120 -0.429 0.931 0.724 0.469
Bron et al. (2014) Yes MPH vs. PBO AFB 0.247 0.186 0.035 -0.118 0.611 1.327 0.184
Brumaghim et al. (1987)a No MPH vs. PBO AFB 0.248 0.080 0.006 0.091 0.405 3.103 0.002
Brumaghim et al. (1987)b No MPH vs. PBO AFB 0.240 0.090 0.008 0.064 0.416 2.673 0.008
Burns et al. (1967) No AMP vs. PBO LM -1.226 0.555 0.308 -2.313 -0.139 -2.211 0.027
Campbell-Meiklejohn et al. (2012) No MPH vs. PBO AFB 0.211 0.312 0.097 -0.400 0.821 0.676 0.499
Chamberlain et al. (2007) Yes ATX vs. PBO AFB & EF 0.162 0.181 0.033 -0.192 0.515 0.896 0.370
Chamberlain et al. (2009) No ATX vs. PBO AFB 0.354 0.303 0.092 -0.240 0.948 1.169 0.242
Chevassus et al. (2013) No MPH vs. PBO AFB & LM 0.045 0.158 0.025 -0.265 0.355 0.285 0.776
Clark et al. (1986) No MPH vs. PBO AFB 0.523 0.380 0.145 -0.222 1.268 1.376 0.169
Clatworthy et al. (2009) No MPH vs. PBO AFB & EF 0.022 0.204 0.042 -0.378 0.421 0.106 0.915
Coons et al. (1981)a No MPH vs. PBO AFB -0.020 0.270 0.073 -0.549 0.509 -0.074 0.941
Coons et al. (1981)b No MPH vs. PBO AFB 0.138 0.245 0.060 -0.341 0.618 0.566 0.571
Costa et al. (2013) No MPH vs. PBO AFB 0.010 0.134 0.018 -0.252 0.272 0.074 0.941
de Bruijn et al. (2004) No AMP vs. PBO AFB 0.150 0.210 0.044 -0.263 0.562 0.711 0.477
de Wit et al. (2002) No AMP vs. PBO AFB 0.189 0.104 0.011 -0.016 0.393 1.809 0.070
Duke & Keeler (1968) No AMP vs. PBO AFB -0.545 0.320 0.102 -1.173 0.082 -1.704 0.088
DuPaul et al. (2012) Yes LDX vs. PBO AFB & LM 0.097 0.154 0.024 -0.204 0.398 0.630 0.529
Elliott et al. (1997) No MPH vs. PBO AFB & EF 0.055 0.171 0.029 -0.280 0.390 0.323 0.747
Farah et al. (2009) No AMP vs. PBO EF 0.084 0.106 0.011 -0.124 0.292 0.792 0.428
Faraone et al. (2005) Yes ATX vs. PBO AFB 0.138 0.097 0.009 -0.052 0.327 1.426 0.154
Fillmore et al. (2005) No AMP vs. PBO AFB 0.231 0.205 0.042 -0.171 0.633 1.128 0.259
Finke et al., 2010 No MPH vs. PBO AFB & LM 0.357 0.188 0.035 -0.010 0.725 1.904 0.057
Fleming et al. (1995) No AMP vs. PBO AFB, LM, & EF 0.107 0.145 0.021 -0.178 0.391 0.734 0.463
Gilbert et al. (1973) No MPH vs. PBO AFB & LM -0.158 0.133 0.018 -0.419 0.103 -1.187 0.235
Graf et al. (2011) No ATX vs. PBO AFB -0.402 0.148 0.022 -0.692 -0.112 -2.721 0.007
Halliday et al. (1986)a No MPH vs. PBO AFB 0.053 0.129 0.017 -0.201 0.306 0.407 0.684
Halliday et al. (1986)b No AMP, MPH vs. PBO AFB 0.161 0.203 0.041 -0.237 0.559 0.792 0.428
Hester et al. (2012); Nandam et al. (2014) No MPH vs. PBO AFB 0.168 0.167 0.028 -0.159 0.495 1.007 0.314
Hink et al. (1978) No MPH vs. PBO AFB 0.238 0.294 0.087 -0.339 0.815 0.809 0.419
Idestrom & Schalling (1970) No AMP vs. PBO AFB -0.052 0.114 0.013 -0.275 0.171 -0.456 0.648
Ilieva et al. (2013) No AMP vs. PBO AFB, LM, & EF 0.059 0.093 0.009 -0.124 0.242 0.628 0.530
Izquierdo et al. (2008) No MPH vs. PBO LM 3.937 1.128 1.272 1.726 6.148 3.491 0.000
Kinsbourne et al.(2001) Yes MPH vs. PBO LM 0.243 0.207 0.043 -0.164 0.650 1.172 0.241
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Meta Analysis
Meta Analysis
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Table 4 continued 
 
Notes. AFB = Abilities of Focused Behavior; AMP = Amphetamine; ATX = Atomoxetine; EF = Executive Function; LDX 
= Lisdexamfetamine Dymesylate; LM = Learning and Memory; MPH = Methylphenidate; PBO = Placebo.  
Study name ADHD Comparison Outcome Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
Kollins et al. (2015) No MPH vs. PBO AFB 0.001 0.154 0.024 -0.302 0.303 0.003 0.997
Kornetsky (1958) No AMP vs. PBO AFB & LM -0.109 0.131 0.017 -0.366 0.149 -0.828 0.407
Kratz et al. (2009) No MPH vs. PBO AFB 0.329 0.138 0.019 0.058 0.600 2.383 0.017
Levin et al. (2001) Yes MPH vs. PBO AFB -0.117 0.457 0.209 -1.012 0.778 -0.256 0.798
Linssen et al. (2011) No MPH vs. PBO AFB 0.387 0.109 0.012 0.174 0.600 3.564 0.000
Linssen et al. (2012) No MPH vs. PBO AFB & EF 0.091 0.221 0.049 -0.342 0.523 0.411 0.681
Linssen et al. (2014) No MPH vs. PBO AFB & LM 0.038 0.149 0.022 -0.254 0.330 0.255 0.799
Makris et al.(2007) No AMP vs. PBO AFB & LM 0.325 0.147 0.022 0.037 0.612 2.214 0.027
Marquand et al. (2011) No ATX vs. PBO AFB -0.025 0.196 0.038 -0.409 0.359 -0.127 0.899
Mattay et al. (1996) No AMP vs. PBO EF 0.082 0.206 0.043 -0.322 0.487 0.399 0.690
Mattay et al. (2000) No AMP vs. PBO AFB -0.138 0.237 0.056 -0.602 0.327 -0.580 0.562
Mehta et al. (2000) No MPH vs. PBO AFB 0.326 0.218 0.048 -0.101 0.754 1.497 0.134
Moeller et al. (2014) No MPH vs. PBO AFB 0.377 0.144 0.021 0.095 0.659 2.621 0.009
Muller et al. (2005) No MPH vs. PBO AFB 0.039 0.124 0.015 -0.204 0.283 0.318 0.751
Nandam et al. (2011) No ATX vs. PBO AFB 0.639 0.226 0.051 0.196 1.082 2.825 0.005
Naylor et al. (1985) No MPH vs. PBO AFB 0.264 0.132 0.017 0.005 0.524 2.000 0.046
Oken et al. (1995) No MPH vs. PBO AFB 0.031 0.117 0.014 -0.200 0.261 0.260 0.795
Pauls et al. (2012) No MPH vs. PBO AFB 0.183 0.322 0.104 -0.448 0.814 0.569 0.570
Ramasubbu et al. (2012) No MPH vs. PBO AFB 0.426 0.252 0.063 -0.068 0.920 1.692 0.091
Rapoport et al. (1980) No AMP vs. PBO AFB 0.020 0.219 0.048 -0.409 0.449 0.091 0.927
Rogers et al. (1999) No MPH vs. PBO EF 0.016 0.341 0.116 -0.652 0.684 0.047 0.963
Samanez-Larkin et al. (2013) No AMP vs. PBO AFB & EF 0.530 0.120 0.014 0.295 0.764 4.430 0.000
Schlösser et al. (2009) No MPH vs. PBO LM 0.100 0.149 0.022 -0.191 0.392 0.676 0.499
Servan-Schreiber et al. (1998) No AMP vs. PBO AFB 0.637 0.247 0.061 0.154 1.121 2.585 0.010
Silber et al. (2006) No AMP vs. PBO AFB 0.025 0.158 0.025 -0.284 0.335 0.161 0.872
Sofuoglu et al. (2008) No AMP vs. PBO AFB -0.197 0.185 0.034 -0.559 0.166 -1.065 0.287
Spencer et al., 1998 Yes ATX vs. PBO AFB 0.320 0.124 0.015 0.076 0.564 2.568 0.010
Strauss et al. (1984) No MPH vs. PBO AFB 0.526 0.233 0.054 0.070 0.983 2.259 0.024
Studer et al. (2010) No MPH vs. PBO AFB -0.140 0.207 0.043 -0.547 0.266 -0.678 0.498
Taylor & Russo (2000) Yes AMP vs. PBO AFB & EF 0.350 0.138 0.019 0.080 0.621 2.540 0.011
Taylor & Russo (2001) Yes AMP vs. PBO AFB & EF 0.141 0.134 0.018 -0.123 0.404 1.047 0.295
Theunissen et al. (2009) No MPH vs. PBO AFB -0.143 0.240 0.057 -0.612 0.327 -0.597 0.551
Turner et al. (2003) No MPH vs. PBO AFB, LM, & EF 0.076 0.310 0.096 -0.531 0.683 0.245 0.807
Turner et al. (2005) Yes MPH vs. PBO AFB & LM 0.039 0.147 0.022 -0.249 0.328 0.267 0.790
Unrug et al. (1997) No MPH vs. PBO LM 0.330 0.177 0.031 -0.017 0.676 1.865 0.062
van der Schaaf et al. (2013) No MPH vs. PBO AFB & EF 0.135 0.150 0.023 -0.159 0.429 0.900 0.368
Verster et al. (2010) Yes MPH vs. PBO LM 0.106 0.152 0.023 -0.193 0.404 0.695 0.487
Ward et al. (1997) No AMP vs. PBO AFB 0.332 0.545 0.297 -0.737 1.401 0.609 0.542
Wardle et al. (2013) No AMP vs. PBO AFB & EF 0.112 0.066 0.004 -0.017 0.240 1.707 0.088
Weitzner (1965) No AMP vs. PBO AFB & LM 0.219 0.338 0.114 -0.444 0.882 0.648 0.517
Whiting et al. (2008) No AMP vs. PBO AFB & LM 0.640 0.329 0.108 -0.005 1.284 1.945 0.052
Zeeuws & Soetens (2007) No AMP vs. PBO LM 0.154 0.110 0.012 -0.062 0.369 1.398 0.162
Zeeuws et al. (2010a) No AMP vs. PBO LM 1.117 0.201 0.041 0.723 1.512 5.549 0.000
Zeeuws et al. (2010b)a No AMP vs. PBO LM 0.089 0.174 0.030 -0.252 0.430 0.513 0.608
Zeeuws et al. (2010b)b No AMP vs. PBO LM 0.010 0.159 0.025 -0.302 0.322 0.063 0.950
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Meta Analysis
Meta Analysis
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Outlier Examination 
Studies with effect sizes falling outside 3 standard deviations (SD = 0.257) of 
the mean (g < -0.626 or g > 0.920) were examined as potential outliers. Three studies 
were identified under this criterion: Burns et al. (1967), g = -1.226, 95% CI[-2.313, -
0.139], Izquierdo et al. (2008), g = 3.397, 95% CI[1.272, 1.726], and Zeeuws et al. 
(2010a), g = 1.117, 95% CI[0.723, 1.512]. Table 5 displays the mean effect sizes with 
inclusion of all studies, with the removal of each study individually, with the removal  
the two studies potentially skewing the mean effect size in a positive direction, and 
with the removal of all studies.  
Table 5 
Outlier Summary of ADHD Medication and Cognition 
Analysis k Model g 95% CI p Q (df) 
LCL UCL 
All studies 91 Fixed -0.005 -0.023 0.014 .621 
300.435** 
(90) 
Random 0.147 0.095 0.199 <.001  
Burns et al. (1967) 
removed 90 
Fixed -0.004 -0.023 0.014 .647 295.582** (89) 
Random 0.150 0.098 0.202 <.001  
Izquierdo et al. 
(2008) removed 90 
Fixed -0.005 -0.023 0.014 .600 288.221
**
 
(89) 
Random 0.145 0.094 0.196 <.001  
Zeeuws et al. 
(2010a) removed 90 
Fixed -0.007 -0.026 0.011 .450 269.313
**
 
(89) 
Random 0.137 0.087 0.187 <.001  
All studies with 
extreme positive 
effects removed 
89 Fixed -0.007 -0.026 0.011 .433 
257.084** 
(88) 
Random 0.135 0.086 0.184 <.001  
All studies 
removed 89 
Fixed -0.007 -0.026 0.011 .455 252.254
** 
(87) 
Random 0.138 0.089 0.187 <.001  
Notes. * p < .01; ** p < .001. 
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The first study that was examined as a potential outlier was conducted by 
Burns and colleagues in 1967. The researchers examined the effects of AMP and 
magnesium pemoline on learning rate in male college students. In order to stabilize 
variance, an arcsine transformation was performed on outcome data. Results from this 
study indicated that college students administered AMP demonstrated a significantly 
slower rate of learning compared to those administered placebo. When this study was 
removed from the analysis, the mean effect was g = 0.150, resulting in only a slight 
increase from the original mean effect size of g = 0.147. 
Izquierdo and colleagues (2008) examined the effects of MPH on a learning 
task involving the memorization of explicit factual information about the 1954 World 
Soccer Cup. Assessment occurred 2 and 7 days after drug administration and learning. 
Examination of the individual effect sizes revealed that the 7-day delay resulted in an 
extremely large effect size (g = 1.843) and the 2-day delay was much smaller (g = 
0.412), tempering the study’s mean effect size. Similar discrepancies were found in 
Zeeuw et al.’s (2010a) study that examined the effects of d-AMP on memory, where 
the mean effect size for long-term delayed word recall was very large (g = 1.707), but 
the mean effect sizes for immediate (g = 0.935) and delayed (g = 0.710) delayed 
memory were smaller. Removing Izquierdo et al.’s (2008) study from the main 
analysis resulted in only a slight reduction in the mean effect size to g = 0.145. The 
removal of Zeeuws et al.’s (2010a) study also resulted in a reduced mean effect size (g 
= 0.137). When both studies were removed there was a reduction in the mean effect 
size to g = 0.135 from g = 0.147.  
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A decision to maintain these studies was made given their minimal effects on 
the mean effect size and relevance to the present study’s investigation. Furthermore, 
previous research has indicated that prescription stimulant medication may result in 
the greatest benefits for recall and recognition of information assessed days after drug 
administration and learning (Advokat et al., 2010; Ilieva et al., 2015; Smith & Farah, 
2011). Therefore, the large effect sizes from the studies with extreme positive values 
may be meaningful to the present study’s investigation.  
Publication Bias Analysis 
Analysis of publication bias indicated minimal risk with a Rosenthal’s N of 
1,480 to lead to a p-value at or above an alpha of .05 and Orwin’s N of 42 to reduce 
the measure of effect to g = 0.10. Trim and fill analysis suggested the imputation of 38 
studies resulting in a reduction in the mean effect size to g = -0.023, 95% CI [-0.075, 
0.030] (see Figure 2 where the filled circles represent imputed values) and Egger’s 
regression was significant (B = 1.451, SE = 0.193, t(89) = 7.534, 95% CI [1.069, 
1.834], p < .001). Findings suggest that this analysis was subject to a high degree of 
publication bias. 
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Figure 2 
Funnel Plot with Observed Studies for Cognition 
 
Because the trim and fill procedure relies on model assumptions as 
explanations for missing studies and because it is easily influenced by a small number 
of deviant studies (Borenstein et al., 2009), a post-hoc analysis was conducted to 
better understand the influence of study precision on the skewed findings. Specifically, 
a cumulative meta-analysis in which studies were added in order of largest to smallest 
sample sizes, used as an estimate of precision, was conducted. For this analysis, if the 
point estimates (standardized mean differences) remain stable for the larger studies, 
but shift for the smaller studies, a deeper understanding of the variability of effect 
sizes is gleaned (Borenstein et al., 2009). 
 Results from the cumulative meta-analysis are displayed in Table 6 and 
suggest that the effect sizes remained relatively stable for larger studies and smaller 
studies. The removal of studies with standard errors greater than SE = 0.300 resulted 
in a slight reduction to g = 0.142 in the overall mean effect size. When studies with 
standard errors greater than SE = 0.200 were removed, the effects were also minimal, 
resulting in a reduction in the mean effect size to g = 0.121. Even at this conservative 
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level, Trim and fill analysis suggested the imputation of 25 studies resulting in a 
reduction in the mean effect size to g = -0.046, 95% CI [-0.100, 0.009] and Egger’s 
regression remained significant (B = 1.733, SE = 0.258, t(52) = 6.725, 95% CI [1.216, 
2.250], p < .001). These findings confirm the previous finding that suggested a high 
degree of bias. 
Table 6 
Cumulative Meta-Analysis of ADHD Medication and Cognition 
Analysis k Model g 95% CI p Q (df) 
LCL UCL 
All studies 91 Fixed -0.005 -0.023 0.014 .621 
300.435** 
(90) 
Random 0.147 0.095 0.199 <.001  
Studies with SE ≥ 
0.300 removed 74 
Fixed -0.007 -0.026 0.011 .437 264.596
**
 
(72) 
Random 0.142 0.089 0.195 <.001  
Studies with SE ≥ 
0.200 removed 54 
Fixed -0.016 -0.035 0.003 .090 200.410
**
 
(89) 
Random 0.121 0.066 0.177 <.001  
Notes. * p < .01; ** p < .001. 
Moderator Analysis 
 The potential for the presence of moderating effects was indicated by the 
significant Q statistic (indicating between study variance). Effect sizes and moderator 
analyses identified a priori are displayed in Table 7. Meta-regression and analog to 
ANOVA did not reveal any significant continuous variables (age, gender distribution, 
years of education, baseline cognitive functioning, number of sessions, number of 
days on medication) or categorical variables (ADHD status, sample characteristics, 
study design, randomization, counterbalancing, training/practice effects, medication 
administration, medication dose, medication, medication activation type, timing of 
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dose activation, number of doses, inclusion of other drugs, inclusion of non-behavioral 
measures) as moderators.  
Although not statistically significant, ANOVA analog revealed trend level (p < 
.10) differences between the different recruitment types of studies Q(6) = 11.945, p = 
.063. Follow-up two-group ANOVA analog analyses revealed significantly larger 
effect sizes among studies that conducted recruitment within communities (g = 0.268) 
compared to studies recruiting participants within university settings (g = 0.082), Q(1) 
= 7.908, p = .005. as well as trend level differences compared to studies that did not 
report recruitment settings (g = 0.118), Q(1) = 3.736, p = .053. Larger effect sizes 
from studies that conducted recruitment within communities compared to studies 
recruiting participants within clinical settings (g = 0.154) approached significance, 
Q(1) = 2.739, p = .098.  Comparisons including military recruitment settings, and 
recruitment settings that combined university and community or clinic and community 
were not conducted given the small number of studies for each category. Homogeneity 
analysis within recruitment type revealed significant results for recruitment conducted 
within university settings, Q(22) = 51.862, p < .001, and within community settings, 
Q(21) = 41.646, p = 0.005; these analyses were not significant for the remainder of 
recruitment settings (clinic, military, university and community, clinic and 
community), but a significant Q statistic was found for studies that did not report 
recruitment settings, Q(25) = 69.121, p < .001.  
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Table 7 
Effect Sizes and Moderator Analyses for Cognition 
Variable k g SE 95% CI p 
LCL UCL 
Mean Effect Size   
 
    
Fixed 91 -0.005 0.009 -0.023 0.014 .621 
Random 91 0.147 0.027 0.095 0.199 <.001a 
Homogeneity Q [90] = 300.435, p < .001a    
ADHD Status     
 
 
Yes 16 0.159 0.039 0.082 0.236 .776 
No 75 0.145 0.030 0.086 0.204  
Sample 
Characteristics       
Misc. Adults 75 0.151 0.029 0.094 0.209 .337 
University 
Students 12 0.181 0.065 0.054 0.309  
Elderly Adults 4 0.036 0.081 -0.122 0.194  
Recruitment 
Characteristics       
University 23 0.082 0.042 -0.000 0.163 .063 
Community 22 0.268 0.051 0.167 0.369  
Clinic 11 0.154 0.046 0.064 0.244  
Military 1 -0.052 0.114 -0.275 0.171  
Clinic & 
Community 2 -0.027 0.194 -0.408 0.354  
University & 
Community 6 0.140 0.052 0.038 0.243  
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Table 7 
Effect Sizes and Moderator Analyses for Cognition 
Variable k g SE 95% CI p 
LCL UCL 
NR 26 0.118 0.058 0.005 0.232  
Study Design       
Crossover 77 0.148 0.027 0.094 0.202 .948 
Parallel 14 0.156 0.114 -0.067 0.378  
Learning/Practice 
Practice or Training 
Effects  
      
Yes 31 0.142 0.041 0.061 0.222 .112 
No 49 0.114 0.032 0.052 0.176  
NA (Studies 
only testing 
learning and 
memory) 
11 0.318 0.092 0.137 0.499  
Randomized       
Yes 60 0.172 0.020 0.133 0.211 .168 
No Report 31 0.097 0.050 -0.002 0.196  
Counterbalanced       
Yes 39 0.139 0.038 0.064 0.215 .781 
No Report 52 0.153 0.032 0.091 0.216  
Medication 
Administration   
 
   
Fixed 83 0.148 0.028 0.092 0.204 .922 
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Table 7 
Effect Sizes and Moderator Analyses for Cognition 
Variable k g SE 95% CI p 
LCL UCL 
Titrated 8 0.142 0.058 0.027 0.256  
Medication Dose       
Low 69 0.170 0.031 0.109 0.231 .112 
High 22 0.076 0.051 -0.024 0.175  
Medication       
AMP 33 0.155 0.048 0.062 0.248 .990 
MPH 51 0.143 0.027 0.090 0.197  
LDX 1 0.097 0.154 -0.204 0.398  
ATX 5 00.094 0.134 -0.168 0.357  
AMP & MPH 1 0.161 0.203 -0.237 0.559  
Medication 
Activation Type       
Short-acting 83 0.152 0.028 0.097 0.206 .619 
Medium or 
Long-acting 8 0.104 0.092 -0.076 0.284  
Timing of Dose 
Activation       
Prior 17 0.157 0.060 0.039 0.274 .751 
During 54 0.131 0.029 0.075 0.186  
After 11 0.220 0.080 0.064 0.377  
NR 9 0.131 0.073 -0.012 0.275  
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Table 7 
Effect Sizes and Moderator Analyses for Cognition 
Variable k g SE 95% CI p 
LCL UCL 
Inclusion of Other 
Drugs       
Yes 25 0.084 0.050 -0.015 0.183 .156 
No 66 0.168 0.031 0.107 0.229  
Inclusion of Non-
behavioral Measures       
Yes 28 0.148 0.040 0.069 0.227 .994 
No 63 0.149 0.032 0.086 0.211  
Significant and Non-
significant Findings       
Yes 85 0.144 0.028 0.090 0.198 .577 
No 6 0.184 0.067 0.052 0.317  
 
Variable k QR B SE B 95% CI p LCL UCL 
Study Year 91 2.06 0.003 0.002 -0.001 0.007 .151 
Demographics        
Mean Age 69 0.02 -0.000 0.003 -0.006 0.005 .890 
% Female 85 0.08 0.000 0.001 -0.002 0.002 .772 
Years of 
Education 12 0.37 -0.030 0.049 -0.126 0.066 .542 
Baseline Cognitive 
Functioning 15 0.10 0.001 0.004 -0.007 0.010 .758 
Number of Sessions 91 0.02 -0.002 0.015 -0.031 0.026 .876 
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Variable k QR B SE B 95% CI p LCL UCL 
Number of Doses 91 0.01 -0.005 0.040 -0.081 0.072 .905 
Days on 
Medication 91 0.08 -0.001 0.003 -0.006 0.005 .780 
Days Between 
Sessions 91 0.02 -0.002 0.015 -0.031 0.026 .876 
Note. a indicates significance of mean effect size. 
Missing Data 
 A total of 50 studies were excluded from the analysis involving the effects of 
ADHD medication on neurocognitive enhancement of cognition (see Appendix C). 
Studies were excluded because of missing data critical for calculating effect sizes, 
such as univariate statistics, means, standard deviations, and/or the standard deviation 
of the difference scores. Fourteen of the studies (28.00%) reported mixed results that 
included both positive, negative and non-significant findings, 1 (2.00%) study reported 
significant impairments, 14 studies (28.00%) reported non-significant findings, and 18 
(36.00%) studies reported significant positive effects related to ADHD medication and 
cognition.  A final 3 studies (6.00%) did not report findings related to cognitive effects 
(because the focus was on non-behavioral assessments) or were unavailable to review. 
The variability of significant, non-significant, and mixed findings across missing 
studies supports the findings from the present analysis 
Neurocognitive Enhancement by Broad Constructs 
 
Neurocognitive Enhancement of Abilities of Focused Behavior 
Abilities of focused behavior included vigilance (k = 24), inhibitory control (k 
= 43), working memory (k = 32), and processing speed (k = 18). Seventy-four studies 
included abilities of focused behavior as a cognitive outcome variable, including a 
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total of 2,376 participants. Fourteen of these studies investigated medication effects on 
abilities of focused behavior among adults with ADHD and 60 investigated effects 
among adults without ADHD. Furthermore, these studies examined the effects of 
AMP (k = 23), MPH (k = 44), LDX (k = 1), ATX (k = 5), or AMP and MPH (k = 1). 
Table 8 displays the descriptive statistics, as well as the mean effect sizes, from each 
of the 74 studies addressing abilities of focused behavior. A random effects model 
analysis resulted in a statistically significant mean effect size of g =0.140 (SE  = 0.024, 
95% CI [0.094, 0.186], p < .001), with effect sizes ranging between g =  -0.664 to g = 
0.639. The fixed effects model yielded similar results (g =0.148, SE = 0.017, 95% CI 
[0.115, 0.181], p < .001) and the heterogeneity of variance indicated significant 
between study variance, Q (73) = 120.770, p <.001. 
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Table 8 
ADHD Medication Neurocognitive Effects on Abilities of Focused Behavior Study and Mean Results 
 
Study name ADHD Comparison Outcome Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
Agay et al. (2010) Yes MPH vs. PBO V, IC & WM 0.330 0.342 0.117 -0.340 1.000 0.966 0.334
Agay et al. (2014) Yes MPH vs. PBO V 0.046 0.157 0.025 -0.262 0.354 0.294 0.769
Allman et al. (2010) No AMP vs. PBO IC 0.329 0.079 0.006 0.175 0.483 4.194 0.000
Allman et al. (2012) No MPH vs. PBO IC -0.058 0.070 0.005 -0.196 0.080 -0.829 0.407
Aron et al. (2003) Yes MPH vs. PBO IC 0.534 0.304 0.092 -0.062 1.130 1.757 0.079
Barch & Carter (2005) No AMP vs. PBO IC & WM 0.155 0.140 0.020 -0.119 0.429 1.107 0.268
Barkley et al. (2005) Yes MPH vs. PBO V & IC 0.103 0.147 0.022 -0.185 0.390 0.700 0.484
Ben-Itzhak et al. (2008) No MPH vs. PBO IC 0.309 0.107 0.011 0.099 0.518 2.888 0.004
Boonstra et al. (2005) Yes MPH vs. PBO V & IC 0.014 0.139 0.019 -0.260 0.287 0.097 0.922
Bron et al. (2014) Yes MPH vs. PBO V & IC 0.247 0.186 0.035 -0.118 0.611 1.327 0.184
Brumaghim et al. (1987)a No MPH vs. PBO WM 0.248 0.080 0.006 0.091 0.405 3.103 0.002
Brumaghim et al. (1987)b No MPH vs. PBO WM 0.240 0.090 0.008 0.064 0.416 2.673 0.008
Campbell-Meiklejohn et al. (2012) No MPH vs. PBO WM 0.211 0.312 0.097 -0.400 0.821 0.676 0.499
Chamberlain et al. (2007) Yes ATX vs. PBO V, IC & WM 0.175 0.200 0.040 -0.218 0.567 0.873 0.383
Chamberlain et al. (2009) No ATX vs. PBO IC 0.354 0.303 0.092 -0.240 0.948 1.169 0.242
Chevassus et al. (2013) No MPH vs. PBO IC, WM & PS 0.096 0.145 0.021 -0.188 0.381 0.663 0.507
Clark et al. (1986) No MPH vs. PBO IC 0.523 0.380 0.145 -0.222 1.268 1.376 0.169
Clatworthy et al. (2009) No MPH vs. PBO WM 0.069 0.212 0.045 -0.346 0.484 0.328 0.743
Coons et al. (1981)a No MPH vs. PBO V & IC -0.020 0.270 0.073 -0.549 0.509 -0.074 0.941
Coons et al. (1981)b No MPH vs. PBO V & IC 0.138 0.245 0.060 -0.341 0.618 0.566 0.571
Costa et al. (2013) No MPH vs. PBO V & IC 0.010 0.134 0.018 -0.252 0.272 0.074 0.941
de Bruijn et al. (2004) No AMP vs. PBO IC 0.150 0.210 0.044 -0.263 0.562 0.711 0.477
de Wit et al. (2002) No AMP vs. PBO WM 0.189 0.104 0.011 -0.016 0.393 1.809 0.070
Duke & Keeler (1968) No AMP vs. PBO WM & PS -0.545 0.320 0.102 -1.173 0.082 -1.704 0.088
DuPaul et al. (2012) Yes LDX vs. PBO V & IC 0.305 0.191 0.036 -0.069 0.679 1.597 0.110
Elliott et al. (1997) No MPH vs. PBO V 0.092 0.185 0.034 -0.271 0.455 0.497 0.619
Faraone et al. (2005) Yes ATX vs. PBO IC 0.138 0.097 0.009 -0.052 0.327 1.426 0.154
Fillmore et al. (2005) No AMP vs. PBO WM 0.231 0.205 0.042 -0.171 0.633 1.128 0.259
Finke et al., 2010 No MPH vs. PBO PS 0.607 0.183 0.033 0.248 0.966 3.316 0.001
Fleming et al. (1995) No AMP vs. PBO V, IC & WM 0.141 0.189 0.036 -0.230 0.511 0.745 0.456
Gilbert et al. (1973) No MPH vs. PBO WM -0.099 0.136 0.019 -0.366 0.168 -0.730 0.465
Graf et al. (2011) No ATX vs. PBO IC -0.402 0.148 0.022 -0.692 -0.112 -2.721 0.007
Halliday et al. (1986)a No MPH vs. PBO PS 0.053 0.129 0.017 -0.201 0.306 0.407 0.684
Halliday et al. (1986)b No AMP, MPH vs. PBO PS 0.161 0.203 0.041 -0.237 0.559 0.792 0.428
Hester et al. (2012); Nandam et al. (2014) No MPH vs. PBO IC 0.168 0.167 0.028 -0.159 0.495 1.007 0.314
Hink et al. (1978) No MPH vs. PBO V & IC 0.238 0.294 0.087 -0.339 0.815 0.809 0.419
Idestrom & Schalling (1970) No AMP vs. PBO IC & PS -0.052 0.114 0.013 -0.275 0.171 -0.456 0.648
Ilieva et al. (2013) No AMP vs. PBO IC & WM 0.028 0.108 0.012 -0.183 0.239 0.261 0.794
Kollins et al. (2015) No MPH vs. PBO V, IC & WM 0.001 0.154 0.024 -0.302 0.303 0.003 0.997
Kornetsky (1958) No AMP vs. PBO PS -0.117 0.137 0.019 -0.386 0.151 -0.855 0.392
Kratz et al. (2009) No MPH vs. PBO V & IC 0.329 0.138 0.019 0.058 0.600 2.383 0.017
Levin et al. (2001) Yes MPH vs. PBO V & IC -0.117 0.457 0.209 -1.012 0.778 -0.256 0.798
Linssen et al. (2011) No MPH vs. PBO PS 0.387 0.109 0.012 0.174 0.600 3.564 0.000
Linssen et al. (2012) No MPH vs. PBO IC & WM 0.079 0.252 0.064 -0.416 0.573 0.313 0.754
Linssen et al. (2014) No MPH vs. PBO WM -0.034 0.135 0.018 -0.299 0.232 -0.250 0.803
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Meta Analysis
Meta Analysis
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Table 8 (continued) 
 
Notes. AMP = Amphetamine; ATX = Atomoxetine; IC = Inhibitory Control; LDX = Lisdexamfetamine Dymesylate; MPH 
= Methylphenidate; PBO = Placebo; PS = Processing Speed; V = Vigilance; WM = Working Memory. 
 
Study name ADHD Comparison Outcome Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
Makris et al.(2007) No AMP vs. PBO WM & PS 0.119 0.085 0.007 -0.047 0.285 1.402 0.161
Marquand et al. (2011) No ATX vs. PBO WM -0.025 0.196 0.038 -0.409 0.359 -0.127 0.899
Mattay et al. (2000) No AMP vs. PBO WM -0.138 0.237 0.056 -0.602 0.327 -0.580 0.562
Mehta et al. (2000) No MPH vs. PBO WM 0.326 0.218 0.048 -0.101 0.754 1.497 0.134
Moeller et al. (2014) No MPH vs. PBO IC 0.377 0.144 0.021 0.095 0.659 2.621 0.009
Muller et al. (2005) No MPH vs. PBO PS 0.039 0.124 0.015 -0.204 0.283 0.318 0.751
Nandam et al. (2011) No ATX vs. PBO IC 0.639 0.226 0.051 0.196 1.082 2.825 0.005
Naylor et al. (1985) No MPH vs. PBO PS 0.264 0.132 0.017 0.005 0.524 2.000 0.046
Oken et al. (1995) No MPH vs. PBO WM & PS 0.031 0.117 0.014 -0.200 0.261 0.260 0.795
Pauls et al. (2012) No MPH vs. PBO IC 0.183 0.322 0.104 -0.448 0.814 0.569 0.570
Ramasubbu et al. (2012) No MPH vs. PBO WM 0.426 0.252 0.063 -0.068 0.920 1.692 0.091
Rapoport et al. (1980) No AMP vs. PBO V & IC 0.020 0.219 0.048 -0.409 0.449 0.091 0.927
Samanez-Larkin et al. (2013) No AMP vs. PBO PS 0.262 0.085 0.007 0.095 0.430 3.066 0.002
Servan-Schreiber et al. (1998) No AMP vs. PBO IC 0.637 0.247 0.061 0.154 1.121 2.585 0.010
Silber et al. (2006) No AMP vs. PBO V, IC, WM & PS 0.025 0.158 0.025 -0.284 0.335 0.161 0.872
Sofuoglu et al. (2008) No AMP vs. PBO V & IC -0.664 0.241 0.058 -1.137 -0.192 -2.755 0.006
Spencer et al., 1998 Yes ATX vs. PBO IC 0.320 0.124 0.015 0.076 0.564 2.568 0.010
Strauss et al. (1984) No MPH vs. PBO V & IC 0.526 0.233 0.054 0.070 0.983 2.259 0.024
Studer et al. (2010) No MPH vs. PBO WM -0.140 0.207 0.043 -0.547 0.266 -0.678 0.498
Taylor & Russo (2000) Yes AMP vs. PBO IC & WM 0.317 0.135 0.018 0.052 0.582 2.341 0.019
Taylor & Russo (2001) Yes AMP vs. PBO IC 0.116 0.130 0.017 -0.137 0.370 0.899 0.369
Theunissen et al. (2009) No MPH vs. PBO V & IC -0.143 0.240 0.057 -0.612 0.327 -0.597 0.551
Turner et al. (2003) No MPH vs. PBO V, IC & WM 0.048 0.309 0.096 -0.558 0.654 0.155 0.877
Turner et al. (2005) Yes MPH vs. PBO V, IC & WM 0.052 0.173 0.030 -0.287 0.391 0.303 0.762
van der Schaaf et al. (2013) No MPH vs. PBO WM 0.038 0.136 0.019 -0.229 0.305 0.278 0.781
Ward et al. (1997) No AMP vs. PBO PS 0.332 0.545 0.297 -0.737 1.401 0.609 0.542
Wardle et al. (2013) No AMP vs. PBO WM & PS 0.273 0.066 0.004 0.144 0.402 4.160 0.000
Weitzner (1965) No AMP vs. PBO PS 0.299 0.339 0.115 -0.364 0.963 0.884 0.377
Whiting et al. (2008) No AMP vs. PBO V -0.144 0.315 0.099 -0.761 0.474 -0.456 0.649
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Meta Analysis
Meta Analysis
  
106
 
Outlier Evaluation 
Studies with effect sizes falling outside 3 standard deviations (SD = 0.206) of 
the mean (g < -0.479 or g > 0.759) were examined as potential outliers. Two studies 
were identified under this criterion: Sofuoglu et al. (2008), g = -0.664, 95% CI[-1.137, 
-0.192], and Duke & Keeler (1968), g = -0.545, 95% CI[-1.173, 0.082]. Table 9 
displays the mean effect sizes with inclusion of all studies, as well as with the removal 
of each individual study and the removal of both studies potentially skewing the mean 
effect size in a negative direction.  
Table 9 
Outlier Summary of ADHD Medication and Abilities of Focused Behavior 
Analysis k Model g 95% CI p Q (df) LCL UCL 
All studies 74 
Fixed 0.148 0.115 0.181 <.001 
120.770** 
(73) 
Random 0.140 0.094 0.186 <.001  
Sofuoglu et 
a. (2008) 
removed 
73 Fixed 0.152 0.119 0.185 <.001 
109.366* 
(72) 
Random 0.146 0.102 0.190 <.001  
Duke and 
Keeler 
(1968) 
removed 
73 
Fixed 0.150 0.117 0.183 <.001 116.063
*
 
(72) 
Random 0.143 0.098 0.189 <.001  
Both studies 
removed 71 
Fixed 0.154 0.121 0.187 <.001 
104.606* 
(72) 
Random 0.149 0.106 0.193 <.001  
Notes. * p < .01; ** p < .001. 
Duke and Keeler (1968) used AMP, as well as placebo, as a control for 
investigating the cognitive effects of psilocybin, a drug that has similar effects to 
Lysergic Acid Diethylamide (LSD). The researchers concluded that both psilocybin 
and AMP resulted in impairments in performance on the TMT. The removal of this 
study resulted in only a slight increase in the mean effect size (g = 0.143) compared to 
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the original mean effect size of g = 0.140. Descriptive information concerning the 
second study potentially skewing the results in a negative direction (Sofuoglu et al., 
2008) was described in the previous meta-analysis that included all cognitive 
variables. The removal of this study from the analysis also resulted in only a minimal 
increase in the mean effect size to g = 0.146. When both studies with extreme negative 
effect sizes were removed, the increase in the mean effect size to g = 0.149 was also 
minimal. Therefore, both of these studies were maintained. 
Publication Bias 
Analysis of publication bias indicated minimal risk with a Rosenthal’s N of 
669 to lead to a p-value at or above an alpha of .05 and some risk with an Orwin’s N 
of 5 to reduce the measure of effect to 0.10. Under the fixed effects model, trim and 
fill analysis did not suggest the imputation of any studies to reduce positive bias; 
however, one study was identified for imputation due to negative bias resulting in a 
slight increase in the mean effect to g = 0.146, 95% CI [0.098, 0.194] (see Figure 3). 
Egger’s regression was not significant [B = -0.240, SE = 0.362, t(72) = 0.665, 95% CI 
[-0.961, 0.480], p = .254] represented by the symmetry shown in the funnel plot, 
which also indicates minimal bias.  
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Figure 3 
Funnel Plot with Observed Studies for Abilities of Focused Behavior 
 
Moderator Analysis 
The significant Q statistic indicated heterogeneity among studies, suggesting 
the potential for moderator variables. Effect sizes and moderator analyses identified a 
priori were compared across studies for ADHD medication and Abilities of Focused 
Behavior (see Table 10). ANOVA analog revealed significant influence of 
randomization of groups, Q(1) = 6.693, p = .010, where significantly larger mean 
effect sizes were found for studies reporting randomization of groups (g = 0.182) than 
studies that did not report randomization (g = 0.042). Homogeneity tests revealed 
significant results for studies that did not report randomization, Q(22) = 42.600, p = 
.005, but not for studies that included groups that were randomized, Q(50) = 62.736, p 
= .107.  
Significant differences were also revealed for inclusion of other drugs, Q(1) = 
4.144, p = .042; studies that investigated additional drugs resulted in smaller effect 
sizes (g = 0.052) compared to studies that investigated only one drug (g = 0.172). 
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Homogeneity tests were significant for both types of studies (included other drugs: 
Q(20) = 41.184, p = 0.004; did not include other drugs: Q(52) = 70.841, p = .042).  
Although not significant, trend level differences were revealed between doses, 
where low doses resulted in larger effect sizes (g = 0.165) than high doses (g = 0.057) 
of medication. Meta-regression and analog to ANOVA did not reveal any other 
significant moderator variables.  
Table 10 
Effect Sizes and Moderator Analyses for Abilities of Focused Behavior 
Variable k g SE 95% CI p LCL UCL 
Mean Effect Size       
Fixed 74 0.148 0.017 0.115 0.181 <.001a 
Random 74 0.140 0.024 0.094 0.186 <.001a 
Homogeneity Q(73) = 120.770, p < .001a    
ADHD Status       
Yes 14 0.172 0.042 0.089 0.254 418 
No 60 0.131 0.028 0.076 0.185  
Sample 
Characteristics       
Misc. Adults 60 0.134 0.027 0.082 0.186 .497 
University 
Students 10 0.203 0.058 0.088 0.317  
Elderly 
Adults 4 0.092 0.105 0.097 0.189  
Recruitment 
Characteristics       
University 22 0.130 0.002 0.041 0.220 .083 
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Table 10 
Effect Sizes and Moderator Analyses for Abilities of Focused Behavior 
Variable k g SE 95% CI p LCL UCL 
Community 16 0.258 0.047 0.166 0.351  
Clinic 10 0.151 0.048 0.058 0.244  
Military 1 -0.052 0.114 -0.275 0.171  
Clinic & 
Community 2 0.031 0.225 -0.409 0.472  
University & 
Community 5 0.091 0.050 -0.007 0.189  
NR 18 0.089 0.058 -0.024 0.202  
Study Design       
Crossover 65 0.144 0.025 0.094 0.193 .350 
Parallel 9 0.076 0.068 -0.057 0.209  
Learning/Practice 
Practice or 
Training Effects  
      
Yes 26 0.145 0.035 0.077 0.213 .804 
No 48 0.134 0.032 0.072 0.195  
Randomized       
Yes 51 0.182 0.024 0.136 0.228  
.010a 
No Report 23 0.042 0.049 -0.054 0.138  
Counterbalanced       
Yes 27 0.151 0.038 0.077 0.226 .698 
No Report 47 0.132 0.030 0.072 0.192  
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Table 10 
Effect Sizes and Moderator Analyses for Abilities of Focused Behavior 
Variable k g SE 95% CI p LCL UCL 
Medication 
Administration       
Fixed 67 0.138 0.026 0.088 0.189 .879 
Titrated 7 0.148 0.057 0.035 0.260  
Medication Dose       
Low 55 0.165 0.023 0.119 0.211 .096 
High 19 0.057 0.061 -0.062 0.176  
Medication       
AMP 23 0.121 0.043 0.037 0.206 .887 
MPH 44 0.149 0.029 0.093 0.206  
LDX 1 0.305 0.191 -0.069 0.679  
ATX 5 0.096 0.137 -0.172 0.364  
AMP & MPH 1 0.161 0.203 -0.237 0.559  
Medication 
Activation Type       
Short-acting 66 0.141 0.024 0.094 0.189 .918 
Medium or 
Long-acting 8 0.131 0.099 -0.062 0.324  
Timing of Dose 
Activation       
Prior 11 0.167 0.040 0.088 0.246 .622 
During 47 0.119 0.001 0.058 0.181  
  
112
 
Table 10 
Effect Sizes and Moderator Analyses for Abilities of Focused Behavior 
Variable k g SE 95% CI p LCL UCL 
After 8 0.224 0.088 0.051 0.397  
NR 8 0.145 0.005 0.008 0.282  
Inclusion of Other 
Drugs       
Yes 21 0.052 0.053 -0.052 0.157 .042a 
No 53 0.172 0.024 0.124 0.219  
Inclusion of Non-
behavioral 
Measures 
      
Yes 26 0.139 0.039 0.063 0.215 .984 
No 48 0.140 0.030 0.082 0.199  
Significant and 
Non-significant 
Findings 
      
Yes 69 0.132 0.024 0.084 0.179 .194 
No 5 0.271 0.105 0.066 0.476  
 
 
Variable k QR B SE B 95% CI p LCL UCL 
Study Year 74 1.43 0.002 
0.002 
-0.001 0.006 .232 
Demographics    
 
   
Mean Age 56 0.29 0.001 
0.002 
-0.003 0.005 .588 
% Female 69 0.44 0.001 0.001 
-0.001 
0.002 .509 
Years of 
Education 11 2.63 
-
0.084 
0.052 
-0.186 0.018 .105 
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Variable k QR B SE B 95% CI p LCL UCL 
Baseline 
Cognitive 
Functioning 
13 0.27 0.002 
0.004 
-0.006 0.011 .602 
Number of 
Sessions 74 1.67 
-
0.015 
0.011 
-0.037 0.008 .196 
Number of Doses 74 0.43 0.022 
0.033 
-0.043 0.087 .510 
Days on 
Medication 74 0.02 
-
0.000 
0.002 
-0.004 0.004 .902 
Minimum 
Washout Days 
Between Sessions 
54 0.62 -0.007 0.009 -0.025 
0.011 
.431 
 
Note. a indicates significance of mean effect size. 
Missing Data 
 Thirty-four studies were excluded from the analysis involving the effects of 
ADHD medication on neurocognitive enhancement of abilities of focused behavior 
(see Appendix C). Findings from these studies included results that were mixed, i.e., 
including positive significant differences and non-significant findings (k = 7; 20.59%), 
results that revealed significant positive benefits (k = 12; 34.29%), results that 
indicated significant negative effects (k = 1; 2.94%), and results that were reported to 
be non-significant (k = 12; 35.29%). Two studies did not provide enough information 
to report findings. 
Neurocognitive Enhancement of Learning & Memory 
Twenty-nine studies that investigated the neurocognitive enhancement of 
prescription stimulant medication included learning and memory as an outcome 
variable. These measurements included both declarative memory – tested immediately 
after learning (k = 18), tested with a short delay after learning (k = 11), or tested with a 
long delay after learning (k = 9) – and non-declarative memory (k = 6). Effect sizes 
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were calculated based on findings from a total of 846 participants. Studies investigated 
the effects of AMP (k = 14), MPH (k = 14), and LDX (k = 1) on enhancement of 
learning and memory among adults with ADHD (k = 4) and adults without ADHD (k 
= 25). Table 11 displays the descriptive data and ES estimates (Hedge’s g) from each 
of the 29 studies. The studies generated a statistically significant mean effect size of g 
=0.152 (SE = 0.052, 95% CI [0.050, 0.254], p = .004) under a random effects model 
analysis, with effect sizes ranging from g = -1.226 to g = 3.937. A fixed effects model 
yielded mean effect sizes in the reverse direction compared to those found with the 
random effects model (g = -0.060, SE = 0.011, 95% CI [-0.081, -0.038], p < .001). The 
heterogeneity of variance analysis was significant, Q (28) = 125.533, p <.001.
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Table 11 
ADHD Medication Neurocognitive Effects on Learning and Memory and Mean Results 
 
Notes. AMP = Amphetamine; DM-I = Declarative Memory – Immediate; DM-D = Declarative Memory Delayed; DM-L = 
Declarative Memory Long-Term; LDX = Lisdexamfetamine Dymesylate; MPH = Methylphenidate; NDL = Non-
Declarative Learning; PBO = Placebo. 
Study name ADHD Comparison Outcome Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
Ballard et al. (2013) No AMP vs. PBODM-L 0.277 0.134 0.018 0.015 0.539 2.073 0.038
Ballard et al. (2014) No AMP vs. PBODM-L -0.087 0.012 0.000 -0.110 -0.064 -7.442 0.000
Ben-Itzhak et al. (2008) No MPH vs. PBODM-I 0.061 0.125 0.016 -0.185 0.306 0.483 0.629
Breitenstein et al. (2004) No AMP vs. PBONDL 0.515 0.307 0.095 -0.088 1.118 1.675 0.094
Brignell et al. (2007) No MPH vs. PBODM-I & DM-D 0.251 0.347 0.120 -0.429 0.931 0.724 0.469
Burns et al. (1967) No AMP vs. PBONDL -1.226 0.555 0.308 -2.313 -0.139 -2.211 0.027
Chevassus et al. (2013) No MPH vs. PBODM-I -0.006 0.171 0.029 -0.342 0.329 -0.036 0.971
DuPaul et al. (2012) Yes LDX vs. PBO DM-I & DM-D -0.111 0.117 0.014 -0.340 0.117 -0.953 0.341
Finke et al., 2010 No MPH vs. PBODM-I 0.108 0.192 0.037 -0.269 0.484 0.559 0.576
Fleming et al. (1995) No AMP vs. PBODM-I 0.086 0.086 0.007 -0.083 0.256 1.000 0.317
Gilbert et al. (1973) No MPH vs. PBODM-I -0.217 0.130 0.017 -0.472 0.038 -1.665 0.096
Ilieva et al. (2013) No AMP vs. PBODM-D -0.009 0.099 0.010 -0.203 0.185 -0.090 0.928
Izquierdo et al. (2008) No MPH vs. PBODM-L 3.937 1.128 1.272 1.726 6.148 3.491 0.000
Kinsbourne et al.(2001) Yes MPH vs. PBODM-I 0.243 0.207 0.043 -0.164 0.650 1.172 0.241
Kornetsky (1958) No AMP vs. PBONDL -0.100 0.126 0.016 -0.346 0.146 -0.799 0.424
Linssen et al. (2014) No MPH vs. PBODM-I, DM-D & DM-L 0.110 0.163 0.026 -0.209 0.428 0.676 0.499
Makris et al.(2007) No AMP vs. PBONDL 0.531 0.209 0.043 0.122 0.939 2.544 0.011
Schlösser et al. (2009) No MPH vs. PBONDL 0.100 0.149 0.022 -0.191 0.392 0.676 0.499
Turner et al. (2003) No MPH vs. PBODM-I 0.284 0.310 0.096 -0.324 0.891 0.914 0.361
Turner et al. (2005) Yes MPH vs. PBODM-I & DM-D 0.026 0.122 0.015 -0.212 0.265 0.215 0.829
Unrug et al. (1997) No MPH vs. PBODM-I & DM-D 0.330 0.177 0.031 -0.017 0.676 1.865 0.062
van der Schaaf et al. (2013)No MPH vs. PBONDL 0.385 0.160 0.026 0.071 0.698 2.403 0.016
Verster et al. (2010) Yes MPH vs. PBODM-I & DM-D 0.106 0.152 0.023 -0.193 0.404 0.695 0.487
Weitzner (1965) No AMP vs. PBODM-I 0.139 0.338 0.114 -0.523 0.801 0.412 0.681
Whiting et al. (2008) No AMP vs. PBODM-L 1.423 0.343 0.117 0.751 2.094 4.153 0.000
Zeeuws & Soetens (2007)No AMP vs. PBODM-I, DM-D & DM-L 0.154 0.110 0.012 -0.063 0.370 1.393 0.164
Zeeuws et al. (2010a) No AMP vs. PBODM-I, DM-D & DM-L 1.117 0.201 0.041 0.723 1.512 5.549 0.000
Zeeuws et al. (2010b)a No AMP vs. PBODM-I, DM-D & DM-L 0.089 0.174 0.030 -0.252 0.430 0.513 0.608
Zeeuws et al. (2010b)b No AMP vs. PBODM-I, DM-D & DM-L 0.010 0.159 0.025 -0.302 0.322 0.063 0.950
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Meta Analysis
Meta Analysis
  
116
 
Outlier Evaluation 
Studies with effect sizes falling outside 3 standard deviations (SD = 0.280) of 
the mean (g < -0.688 or g > 0.992) were examined as potential outliers. Four studies 
were identified under this criterion: Burns et al. (1967), g = -1.226, 95% CI [-2.313, -
0.139], Zeeuws et al. (2010a), g = 1.117, 95% CI [0.723, 1.512], Whiting et al. (2008), 
g = 1.423, 95% CI [0.751, 2.094], and Izquierdo et al. (2008), g = 1.128, 95% CI 
[1.726, 6.148]. Table 12 displays the mean effect sizes with inclusion of all studies, as 
well as with the removal of each individual study, the removal of the three studies 
(Zeeuws et al., 2010a; Whiting et al., 2008; Izquierdo et al., 2008) potentially skewing 
the mean effect size in a positive direction, and the removal of all studies.  
The first study that was examined as a potential outlier was conducted by 
Burns and colleagues in 1967 and was described previously. When this study was 
removed from the analysis, the mean effect was g = 0.161, resulting in only a slight 
increase from the original mean effect size of g = 0.152. Therefore, a decision was 
made to maintain the effect size from Burn et al. (1967). 
The remaining potential outlier studies resulted in mean effect sizes 
substantially larger than the present study’s mean effect size. As described previously, 
Izquierdo et al. (2008) and Zeeuws et al. (2010a) conducted studies resulting in large 
effect sizes for long-term memory. A third study (Whiting et al., 2008) examined the 
long-term effects of d-AMP on word memory. The removal of these studies 
individually resulted in the reduction of the mean effect size to g = 0.141 (Izquierdo et 
al., 2008), g = 0.111 (Zeeuws et al., 2010a), and g = 0.126 (Whiting et al., 2008). 
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When all three effect sizes were removed there was a large reduction in the mean 
effect size to g = 0.076 from g = 0.152. 
Table 12 
Outlier Summary of ADHD Medication and Learning and Memory 
Analysis k Model g 95% CI p Q (df) 
LCL UCL 
All studies 29 Fixed -0.060 -0.081 -0.038 <.001 125.533
**
 (28) 
Random 0.152 0.050 0.254 .004  
Burns et al. 
(1967) 
removed 
28 
Fixed -0.059 -0.081 -0.038 <.001 121.109** (27) 
Random 0.161 0.060 0.263 .002  
Zeeuws et 
al., (2010a) 
removed 
28 
Fixed -0.063 -0.085 -0.042 <.001 91.252** (27) 
Random 0.111 0.019 0.202 .018  
Whiting et 
al., 2008 
removed 
28 
Fixed -0.061 -0.083 -0.040 <.001 106.787** (27) 
Random 0.126 0.030 0.223 .010  
Izquierdo et 
al. 2008 
removed 
28 
Fixed -0.060 -0.082 -0.039 <.001 112.976** (27) 
Random 0.141 0.043 0.239 .005  
All studies 
with extreme 
positive 
effects 
removed 
26 
Fixed -0.065 -0.087 -0.044 <.001 59.830* (25) 
Random 0.076 -0.002 0.154 .057  
All studies 
removed 25 
Fixed -0.065 -0.086 -0.043 <.001 55.445* (24) 
Random 0.080 0.004 0.157 .039  
Notes. * p < .01; ** p < .001. 
 Outlier evaluation suggested that the effects from learning and memory 
measured with longer delays, i.e., long-term memory, resulted in effect sizes that were 
much larger than those from learning and memory measured with immediacy or short 
delays. Therefore, a decision was made to analyze long-term memory separately from 
immediate and delayed memory. Analyses were rerun to include only effect sizes from 
declarative and non-declarative learning and memory that was measured the same day 
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as learning. Effect sizes from measurements of long-term memory were analyzed as a 
narrow construct only and were not combined in the broad category of learning and 
memory. 
With long-term learning and memory removed, data were extracted from 24 
studies (k = 24) that investigated the neurocognitive effects of ADHD medication on 
declarative and non-declarative immediate and delayed learning and memory. Table 
13 displays the descriptive data and effect sizes (Hedge’s g) from each of the 24 
studies. The studies generated a statistically significant mean effect size of g =0.104 
(SE = 0.045, 95% CI [0.015, 0.192], p = .021) under a random effects model analysis, 
with effect sizes ranging -1.226 to 0.710. A fixed effects model resulted in a similar 
mean effect size to the random effects model (g = 0.082, SE = 0.030, 95% CI [0.023, 
0.192], p = .006). The heterogeneity of variance analysis yielded a significant Q 
statistic, Q (23) = 49.139, p =.004, indicating significant variability between studies.  
A second outlier evaluation was conducted and studies with effect sizes falling 
outside 3 standard deviations (SD = 0.220) of the mean (g < -0.557 or g > 0.765) were 
examined as potential outliers. The only study that met this criteria (Burns et al., 1967) 
was reviewed previously and maintained in the analysis. 
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Table 13 
ADHD Medication Neurocognitive Effects on Learning and Memory – Immediate and Delayed and Mean Results 
 
Notes. AMP = Amphetamine; DM-I = Declarative Memory – Immediate; DM-D = Declarative Memory Delayed; LDX = 
Lisdexamfetamine Dymesylate; MPH = Methylphenidate; NDL = Non-Declarative Learning; PBO = Placebo. 
Study name ADHD Comparison Outcome Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
Ben-Itzhak et al. (2008) No MPH vs. PBO DM-I 0.061 0.125 0.016 -0.185 0.306 0.483 0.629
Breitenstein et al. (2004) No AMP vs. PBO NDL 0.515 0.307 0.095 -0.088 1.118 1.675 0.094
Brignell et al. (2007) No MPH vs. PBO DM-I & DM-D 0.251 0.347 0.120 -0.429 0.931 0.724 0.469
Burns et al. (1967) No AMP vs. PBO NDL -1.226 0.555 0.308 -2.313 -0.139 -2.211 0.027
Chevassus et al. (2013) No MPH vs. PBO DM-I -0.006 0.171 0.029 -0.342 0.329 -0.036 0.971
DuPaul et al. (2012) Yes LDX vs. PBO DM-I & DM-D -0.111 0.117 0.014 -0.340 0.117 -0.953 0.341
Finke et al., 2010 No MPH vs. PBO DM-I 0.108 0.192 0.037 -0.269 0.484 0.559 0.576
Fleming et al. (1995) No AMP vs. PBO DM-I 0.086 0.086 0.007 -0.083 0.256 1.000 0.317
Gilbert et al. (1973) No MPH vs. PBO DM-I -0.217 0.130 0.017 -0.472 0.038 -1.665 0.096
Ilieva et al. (2013) No AMP vs. PBO DM-D -0.009 0.099 0.010 -0.203 0.185 -0.090 0.928
Kinsbourne et al.(2001) Yes MPH vs. PBO DM-I 0.243 0.207 0.043 -0.164 0.650 1.172 0.241
Kornetsky (1958) No AMP vs. PBO NDL -0.100 0.126 0.016 -0.346 0.146 -0.799 0.424
Linssen et al. (2014) No MPH vs. PBO DM-I & DM-D 0.104 0.168 0.028 -0.225 0.433 0.619 0.536
Makris et al.(2007) No AMP vs. PBO NDL 0.531 0.209 0.043 0.122 0.939 2.544 0.011
Schlösser et al. (2009) No MPH vs. PBO NDL 0.100 0.149 0.022 -0.191 0.392 0.676 0.499
Turner et al. (2003) No MPH vs. PBO DM-I 0.284 0.310 0.096 -0.324 0.891 0.914 0.361
Turner et al. (2005) Yes MPH vs. PBO DM-I & DM-D 0.026 0.122 0.015 -0.212 0.265 0.215 0.829
Unrug et al. (1997) No MPH vs. PBO DM-I & DM-D 0.330 0.177 0.031 -0.017 0.676 1.865 0.062
van der Schaaf et al. (2013)No MPH vs. PBO NDL 0.385 0.160 0.026 0.071 0.698 2.403 0.016
Verster et al. (2010) Yes MPH vs. PBO DM-I & DM-D 0.106 0.152 0.023 -0.193 0.404 0.695 0.487
Zeeuws & Soetens (2007)No AMP vs. PBO DM-I & DM-D 0.139 0.110 0.012 -0.077 0.355 1.264 0.206
Zeeuws et al. (2010a) No AMP vs. PBO DM-I & DM-D 0.710 0.169 0.029 0.379 1.041 4.201 0.000
Zeeuws et al. (2010b)a No AMP vs. PBO DM-I & DM-D -0.008 0.170 0.029 -0.341 0.325 -0.047 0.962
Zeeuws et al. (2010b)b No AMP vs. PBO DM-I & DM-D -0.009 0.154 0.024 -0.311 0.293 -0.058 0.953
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Meta Analysis
Meta Analysis
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Publication Bias 
Analysis of publication bias indicated minimal risk with a Rosenthal’s N of 36 
to lead to a p-value at or above an alpha of .05 and Orwin’s N of 25 to result in a mean 
effect size of g = 0.05 (this effect size was chosen considering the effect size was 
approaching the predetermined convention of g = 0.10). Trim and fill analysis 
indicated the potential for bias (see Figure 8), suggesting imputation of 6 studies that 
resulted in an mean effect size that approached zero (g =  0.019, 95% CI [-0.082, 
0.120]). Egger’s regression, however, was not significant (B = 0.947, SE = 0.844, t(22) 
= 1.122, 95% CI [-0.804, 2.698], p =.137).  
Figure 4 
Funnel Plot with Observed Studies for Learning and Memory – Immediate and 
Delayed 
 
Moderator Analyses 
The potential for the presence of moderating effects was indicated by the 
significant Q statistics across learning and memory constructs (indicating between 
study variance). Effect sizes and moderator analyses identified a priori were compared 
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displayed in Table 14. Although trend level (p < .10) differences between short-acting 
and long-acting agents were found for stimulant activation type, Q(1) = 3.296, p = 
.069, only 1 study examined long-acting agents, precluding conclusions between the 
two medication types. Similar results were revealed for medication activation timing, 
Q(3) = 6.428, p = .093; however when the 1 study that did not report medication 
administration timing was removed, results were not significantly different according 
to activation timing, Q(2) = 0.241, p = .886.  
A significant trend of decreasing effect sizes related to increased number of 
days on medication (B = -0.019, p = .036, R2 analog = 0.27) was revealed; however, 
this finding was limited by low variability, with only 4 of the 22 studies reporting 
more than 1 day (see Figure 5). Meta-regression also revealed a significant trend of 
increasing effect sizes (B = 0.006, p = .043, R2 analog = 0.17) for more recent 
publications (see Figure 6). Significant differences were not found for any of other the 
potential moderating categorical or continuous variables; however, note that there 
were not enough studies (k = 3) reporting number of years of education to run meta-
regression for this variable. 
Table 14 
Effect Sizes and Moderator Analyses for Learning and Memory – 
Immediate and Delayed 
Variable k g SE 95% CI p 
LCL UCL 
Mean Effect Size       
Fixed 24 0.082 0.030 0.023 0.142 .006a 
Random 24 0.104 0.045 0.015 0.192 .021a 
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Table 14 
Effect Sizes and Moderator Analyses for Learning and Memory – 
Immediate and Delayed 
Variable k g SE 95% CI p 
LCL UCL 
Homogeneity Q(23) = 49.139, p =.004a    
ADHD Status       
Yes 4 0.018 0.069 -0.118 0.154 .240 
No 20 0.121 0.053 0.017 0.226  
Sample 
Characteristics       
Misc. Adults 17 0.119 0.047 0.027 0.210 .543 
University 
Students 4 0.051 0.204 -0.349 0.450  
Elderly Adults 3 -0.027 0.127 -0.275 0.221  
Recruitment 
Characteristics       
University 6 0.037 0.056 -0.073 0.146 .497 
Community 8 0.214 0.100 0.018 0.410  
Clinic 2 0.082 0.105 -0.124 0.287  
Military 0      
Clinic & 
Community 0      
University & 
Community 2 0.230 0.268 -0.296 0.755  
NR 6 0.002 0.090 -0.174 0.177  
Study Design       
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Table 14 
Effect Sizes and Moderator Analyses for Learning and Memory – 
Immediate and Delayed 
Variable k g SE 95% CI p 
LCL UCL 
Crossover 19 0.114 0.043 0.029 0.198 .649 
Parallel 5 0.011 0.222 -0.425 0.446  
Randomized       
Yes 15 0.091 0.038 0.017 0.165 .992 
No Report 9 0.090 0.109 -0.123 0.303  
Counterbalanced       
Yes 12 0.093 0.076 -0.056 0.242 .877 
No Report 12 0.107 0.054 0.001 0.213  
Medication 
Administration       
Fixed 22 0.121 0.047 0.030 0.213 .265 
Titrated 2 -0.065 0.161 -0.381 0.250  
Medication Dose       
Low 18 0.131 0.058 0.017 0.246 .157 
High 6 0.014 0.059 -0.100 0.129  
Medication       
AMP 10 0.133 0.087 -0.037 0.304 .208 
MPH 13 0.093 0.047 0.002 0.185  
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Table 14 
Effect Sizes and Moderator Analyses for Learning and Memory – 
Immediate and Delayed 
Variable k g SE 95% CI p 
LCL UCL 
LDX 1 -0.111 0.117 -0.340 0.117  
ATX 0      
AMP & MPH 0      
Medication 
Activation Type       
Short-acting 23 0.117 0.046 0.026 0.207 .069 
Medium or 
Long-acting 1 -0.111 0.117 -0.340 0.117  
Timing of Dose 
Activation       
Prior 6 0.134 0.089 -0.039 0.308 .093 
During 13 0.104 0.065 -0.025 0.232  
After 4 0.155 0.085 -0.012 0.322  
NR 1 -0.217 0.130 -0.472 0.038  
Inclusion of Other 
Drugs       
Yes 9 0.056 0.098 -0.137 0.249 .546 
No 15 0.122 0.049 0.025 0.219  
Inclusion of Non-
behavioral 
Measures 
      
Yes 2 0.102 0.111 -0.116 0.320 .975 
No 22 0.106 0.049 0.009 0.202  
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Table 14 
Effect Sizes and Moderator Analyses for Learning and Memory – 
Immediate and Delayed 
Variable k g SE 95% CI p 
LCL UCL 
Significant and 
Non-significant 
Findings 
      
Yes 22 0.105 0.049 0.009 0.201 .993 
No 2 0.106 0.119 -0.127 0.340  
 
Variable k QR B SE B 95% CI p LCL UCL 
Study Year 23 4.09 0.006 0.003 -0.000 0.012 .043a 
Demographics        
Mean Age 19 0.08 -0.001 0.004 -0.008 0.006 .776 
% Female 21 0.14 -0.001 0.002 -0.004 0.003 .710 
Years of 
Educationb 3       
Baseline Cognitive 
Functioning 4 1.85 0.029 0.022 -0.013 0.072 .174 
Number of 
Sessions 24 0.16 0.008 0.019 -0.030 0.045 .688 
Number of Doses 24 0.01 0.007 0.068 -0.127 0.141 .916 
Days on 
Medication 23 4.37 -0.019 0.089 -0.036 
-
0.001 .036
a 
Minimum 
Washout Days 
Between Sessions 
17 0.03 0.002 0.013 -0.023 0.027 .872 
 
Notes. a indicates significance of mean effect size; b indicates limited power precluding 
meta-regression analysis. 
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Figure 5 
Scatter Plot of Number of Days on Medication and Mean Effect Sizes for Learning 
and Memory – Immediate and Delayed 
 
Figure 6 
Scatter Plot of Year of Publication on Medication and Mean Effect Sizes for Learning 
and Memory – Immediate and Delayed 
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Missing Data 
 Twenty-one studies were excluded from the analysis involving the effects of 
ADHD medication on neurocognitive enhancement of learning and memory (see 
Appendix C). Studies were excluded because of missing data critical for calculating 
effect sizes. Five studies (23.81%) reported findings that were mixed, including 
positive, negative, and/or non-significant findings. Six studies (28.57%) reported non-
significant findings and 7 studies (33.33%) reported findings that indicated a 
significant improvement from ADHD medication. The remaining 3 studies (14.29%) 
did not report enough information to interpret the direction of effects or significance of 
analyses. 
Neurocognitive Enhancement of Executive Function 
Executive function, including planning and decision-making (k = 5), as well as 
self-regulation (k = 15), was included as a cognitive outcome variable by 17 of the 
studies investigating the neurocognitive enhancement effects of ADHD medication. 
These studies examined the effects of AMP (k = 8), MPH (k = 8), and ATX (k = 1) on 
executive function among adults with (k = 5) and without (k = 12) ADHD, including a 
total of 592 participants. Findings were analyzed for executive function as one 
construct and also analyzed separately for planning and decision-making, self-
regulation, and inhibitory control. Table 15 displays the descriptive data and ES 
estimates (Hedge’s g) from each of the 17 studies. The studies resulted in a 
statistically significant mean effect size of g =0.127 (SE = 0.053, 95% CI [0.024, 
0.230], p = .016) under the random effects model, with effect sizes ranging from g = -
0.104 to g = 0.798. Under the fixed effects model, the mean effect size was slightly 
  128
 
reduced (g = 0.106, SE = 0.033, 95% CI [0.042, 0.170], p < .001). The heterogeneity 
of variance analysis was significant, Q (16) = 32.844, p =.008.
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Table 15 
ADHD Medication Neurocognitive Effects on Executive Function and Mean Results 
Notes. AMP = Amphetamine; ATX = Atomoxetine; MPH = Methylphenidate; PBO = Placebo; PD = Planning and 
Decision-Making; SR = Self-Regulation. 
 
Study name ADHD Comparison Outcome Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
Agay et al. (2010) Yes MPH vs. PBOPD 0.069 0.336 0.113 -0.590 0.728 0.205 0.838
Agay et al. (2014) Yes MPH vs. PBOPD -0.014 0.212 0.045 -0.430 0.402 -0.068 0.946
Chamberlain et al. (2007) Yes ATX vs. PBO SR 0.149 0.161 0.026 -0.167 0.464 0.924 0.355
Clatworthy et al. (2009) No MPH vs. PBOSR -0.026 0.196 0.038 -0.410 0.358 -0.133 0.894
Elliott et al. (1997) No MPH vs. PBOPD & SR 0.018 0.157 0.025 -0.289 0.325 0.117 0.907
Farah et al. (2009) No AMP vs. PBO SR 0.084 0.106 0.011 -0.124 0.292 0.792 0.428
Fleming et al. (1995) No AMP vs. PBO SR 0.092 0.160 0.026 -0.221 0.406 0.578 0.564
Ilieva et al. (2013) No AMP vs. PBO SR 0.157 0.074 0.005 0.013 0.301 2.131 0.033
Linssen et al. (2012) No MPH vs. PBOPD & SR 0.102 0.189 0.036 -0.268 0.473 0.541 0.588
Mattay et al. (1996) No AMP vs. PBO SR 0.082 0.206 0.043 -0.322 0.487 0.399 0.690
Rogers et al. (1999) No MPH vs. PBOSR 0.016 0.341 0.116 -0.652 0.684 0.047 0.963
Samanez-Larkin et al. (2013)No AMP vs. PBO SR 0.798 0.154 0.024 0.496 1.099 5.189 0.000
Taylor & Russo (2000) Yes AMP vs. PBO SR 0.384 0.140 0.020 0.108 0.659 2.732 0.006
Taylor & Russo (2001) Yes AMP vs. PBO SR 0.165 0.139 0.019 -0.108 0.437 1.185 0.236
Turner et al. (2003) No MPH vs. PBOPD & SR -0.104 0.310 0.096 -0.711 0.503 -0.336 0.737
van der Schaaf et al. (2013)No MPH vs. PBOSR -0.017 0.152 0.023 -0.315 0.281 -0.110 0.913
Wardle et al. (2013) No AMP vs. PBO SR -0.049 0.065 0.004 -0.178 0.079 -0.751 0.452
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Meta Analysis
Meta Analysis
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Outlier Evaluation 
Studies with effect sizes falling outside of 3 standard deviations (SD = 0.222) 
of the mean (g < -0.528 or g > 0.782) were examined as potential outliers. Only one 
study, conducted by Samanez-Larkin et al. (2013), met these criteria with a mean 
effect size of g = 0.798. Findings from this study indicated amphetamine-induced 
benefits for cognitive flexibility that varied in size according to the status of dopamine 
within a thalamocorticostrial network. Under both a random and fixed effects model, 
the removal of this study resulted in a reduction in the mean effect size to g = 0.073 
(SE = 0.033, 95% CI [0.008, 0.139], p = .028) that remained significantly different 
from zero. Considering this study explicitly examined the effects of AMP on cognitive 
flexibility, the effect size resulting from this study fell only slightly outside of the 
criteria, and results from the meta-analysis remained significant with its removal, a 
decision to maintain the effect size from Samanez-Larkin et al. was made. 
Publication Bias 
Rosenthal’s N to lead to a p-value at or above an alpha of .05 was 31 and 
Orwin’s N to reduce the measure of effect to g = 0.10 was 4. Although Trim and fill 
analysis did not suggest imputation for any studies to account for positive bias, the 
imputation of 6 studies that may have contributed to negative bias was suggested. The 
imputation of these studies (shown in Figure 7) resulted in an increased effect size of g 
= 0.190, 95% CI [0.094, 0.296]. Egger’s regression was not significant (B = 0.434, SE 
= 0.810, t(15) = 0.536, 95% CI [-1.291, 2.160], p = .300) indicating minimal 
publication bias.  
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Figure 7 
Funnel Plot with Observed Studies for Executive Function 
 
Missing Data 
 Three studies that met the study criteria, but were missing data critical for 
calculating effect sizes, were excluded from the analysis involving the effects of 
ADHD medication on neurocognitive enhancement of executive function (see 
Appendix C). Two studies reported findings that were non-significant and one study 
did not provide information on the task of executive function. All of the studies 
examined measures of self-regulation. 
Moderator Analyses 
The potential for the presence of moderating effects was indicated by the 
significant Q statistics (indicating between study variance). Effect sizes and moderator 
analyses identified a priori were compared across studies for EF enhancement of 
ADHD medication are displayed in Table 16. Significant results were not revealed by 
ANOVA analog or meta-regression.  
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Table 16 
Effect Sizes and Moderator Analyses for Executive Function 
Variable k g SE 95% CI p 
LCL UCL 
Mean Effect Size       
Fixed 17 0.106 0.033 0.042 0.170 <.001a 
Random 17 0.127 0.053 0.024 0.230 .016a 
Homogeneity Q(16) = 32.844, p = .008    
ADHD Status       
Yes 5 0.198 0.076 0.048 0.347 .377 
No 12 0.108 0.066 -0.021 0.238  
Sample 
Characteristics       
Misc. Adults 15 0.144 0.057 0.032 0.255 .472 
University 
Students 1 -0.017 0.152 -0.315 0.281  
Elderly 
Adults 1 -0.104 0.310 -0.711 0.503  
Recruitment 
Characteristics       
University 8 0.048 0.058 -0.065 0.162 .706 
Community 1 -0.017 0.152 -0.315 0.281  
Clinic 2 0.158 0.105 -0.048 0.364  
Military 0      
Clinic & 
Community 1 0.069 0.336 -0.590 0.728  
University & 
Community 1 0.157 0.074 0.013 0.301  
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Table 16 
Effect Sizes and Moderator Analyses for Executive Function 
Variable k g SE 95% CI p 
LCL UCL 
NR 4 0.270 0.208 -0.138 0.677  
Study Design       
Crossover 14 0.138 0.057 0.026 0.250 .450 
Parallel 3 -0.012 0.189 -0.383 0.359  
Randomized       
Yes 9 0.070 0.056 -0.039 0.180 .378 
No Report 8 0.160 0.047 0.006 0.189  
Counterbalanced       
Yes 6 0.046 0.041 -0.034 0.126 .144 
No Report 11 0.183 0.084 0.018 0.348  
Medication 
Administration       
Fixed 15 0.104 0.057 -0.007 0.215 .168 
Titrated 2 0.273 0.109 0.059 0.488  
Medication Dose       
Low 13 0.055 0.038 -0.020 0.130 .288 
High 4 0.264 0.193 -0.115 0.643  
Medication       
AMP 8 0.200 0.085 0.034 0.366 .217 
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Table 16 
Effect Sizes and Moderator Analyses for Executive Function 
Variable k g SE 95% CI p 
LCL UCL 
MPH 8 0.008 0.073 -0.167 0.464  
LDX 0      
ATX 1 0.149 0.161 -0.167 0.464  
AMP & MPH 0      
Medication 
Activation Type       
Short-acting 16 0.126 0.056 0.016 0.235 .895 
Medium or 
Long-acting 1 0.149 0.161 -0.167 0.464  
Timing of Dose 
Activation       
Prior 6 0.184 0.108 -0.027 0.395 .230 
During 8 0.074 0.064 -0.053 0.200  
After 1 -0.017 0.152 -0.135 0.281  
NR 2 0.330 0.130 0.076 0.585  
Inclusion of Other 
Drugs       
Yes 3 0.253 0.095 0.067 0.439 .186 
No 14 0.106 0.058 -0.009 0.221  
Inclusion of Non-
behavioral 
Measures 
      
Yes 3 0.297 0.279 -0.250 0.844 .432 
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Table 16 
Effect Sizes and Moderator Analyses for Executive Function 
Variable k g SE 95% CI p 
LCL UCL 
No 14 0.076 0.034 0.009 0.143  
Significant and 
Non-significant 
Findings 
      
Yes 17 0.127 0.053 0.024 0.230 1 
No 0      
 
 
 
Variable k QR B SE B 95% CI p LCL UCL 
Study Year 17 0.02 0.001 0.008 -0.015 0.017 .898 
Demographics        
Mean Age 15 0.01 0.002 0.007 -0.011 0.014 .820 
% Female 16 0.47 0.002 0.002 -0.003 0.006 .493 
Years of 
Educationb 3       
Baseline 
Cognitive 
Functioning 
5 0.45 -0.008 0.012 -0.030 0.015 .501 
Number of 
Sessions 17 0.00 -0.001 0.035 -0.070 0.068 .973 
Number of Doses 17 2.36 -0.098 0.064 -0.222 0.027 .124 
Days on 
Medication 17 1.43 0.025 0.021 -0.016 0.067 .231 
Minimum 
Washout Days 
Between Sessions 
13 1.64 -0.037 0.029 -0.094 0.020 .201 
 
Notes. a indicates significance of mean effect size; b indicates limited power precluding 
meta-regression analysis. 
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Summary of Neurocognitive Enhancement of Broad Constructs 
Table 17 displays the mean effect sizes for ADHD medication on cognition 
overall, as well as on abilities of focused behavior, learning and memory, and 
executive function described in the previous sections. Mean effect sizes were small for 
each construct. 
Table 17 
Summary of ADHD Medication and Cognition 
Outcome k Model g 95% CI p Q (df) 
LCL UCL 
Cognition 
Overall 
91 Fixed -0.005 -0.023 0.014 .621 
300.435** 
(90) 
 Random 0.147 0.095 0.199 <.001  
Abilities 
of Focused 
Behavior 
74 Fixed 0.148 0.115 0.181 <.001 
120.770** 
(73) 
 Random 0.140 0.094 0.186 <.001  
Learning 
and 
Memory – 
Immediate 
and 
Delayed 
24 Fixed 0.082 0.023 0.192 .006 
49.139* 
(23) 
 Random 0.104 0.015 0.192 .021  
Executive 
Function 
17 Fixed 0.106 0.042 0.170 <.001 
32.844* 
(16) 
 Random 0.127 0.024 0.230 .005  
Notes. * indicates p < .01; * indicates p < .001. 
Neurocognitive Enhancement by Narrow Constructs  
The remainder of the results is presented according to the ten narrow constructs 
encompassing abilities of focused behavior, learning and memory, and executive 
function. 
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Neurocognitive Enhancement of Narrow Constructs of Abilities of Focused 
Behavior 
Neurocognitive Enhancement of Vigilance 
Data were extracted from 24 studies that investigated the neurocognitive 
effects of prescription stimulants on vigilance, or sustained and focused attention. Data 
from a total of 624 participants were extracted from studies that examined the effects 
of AMP (k = 5), MPH (k = 17), LDX (k = 1), and ATX (k = 1) on vigilance among 
adults with (k = 9) and without (k = 15) ADHD. Table 18 displays the descriptive data 
and effect size estimates (Hedge’s g) from each of the 24 studies. Under the random 
effects model, the studies generated a mean effect size of g =0.037 that was not 
significantly different than zero (SE  = 0.047, 95% CI[-0.055, 0.128], p = .434), with 
effect sizes ranging from g = -0.327 to g = 0.615. A fixed effects model yielded 
similar results (g =0.016, SE  = 0.038, 95% CI[-0.057, 0.090], p = .664). Significant 
heterogeneity of variance was not revealed by the homogeneity analysis, (Q [23] = 
32.218, p =.096).  
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Table 18 
ADHD Medication Neurocognitive Effects on Vigilance Study and Mean Results 
 
Notes. AMP = Amphetamine; ATX = Atomoxetine; CPT = Continuous Performance Task; DV = Digit Vigilance; LDX = 
Lisdexamfetamine Dymesylate; MPH = Methylphenidate; PBO = Placebo; RVIP = Rapid Visual Information Processing; 
SART = Sustained Attention to Response Test; TOVA = Test of Visual Attention. 
Study name ADHD Comparison Outcome Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
Agay et al. (2010) Yes MPH vs. PBOTOVA -0.204 0.337 0.113 -0.863 0.456 -0.605 0.545
Agay et al. (2014) Yes MPH vs. PBOTOVA 0.046 0.157 0.025 -0.262 0.354 0.294 0.769
Barkley et al. (2005) Yes MPH vs. PBOCPT 0.039 0.171 0.029 -0.296 0.373 0.226 0.822
Boonstra et al. (2005) Yes MPH vs. PBOCPT -0.327 0.105 0.011 -0.533 -0.122 -3.127 0.002
Bron et al. (2014) Yes MPH vs. PBOCPT; TOVA 0.216 0.189 0.036 -0.154 0.587 1.146 0.252
Chamberlain et al. (2007)Yes ATX vs. PBO RVIP -0.122 0.209 0.044 -0.532 0.287 -0.585 0.559
Coons et al. (1981)a No MPH vs. PBOCPT 0.252 0.313 0.098 -0.362 0.865 0.804 0.421
Coons et al. (1981)b No MPH vs. PBOCPT; Oddball 0.105 0.281 0.079 -0.446 0.656 0.374 0.708
Costa et al. (2013) No MPH vs. PBOGo/No-Go -0.041 0.174 0.030 -0.381 0.299 -0.236 0.813
DuPaul et al. (2012) Yes LDX vs. PBO CPT 0.325 0.194 0.038 -0.056 0.706 1.672 0.094
Elliott et al. (1997) No MPH vs. PBORVIP 0.092 0.185 0.034 -0.271 0.455 0.497 0.619
Fleming et al. (1995) No AMP vs. PBO CPT -0.117 0.115 0.013 -0.343 0.109 -1.015 0.310
Hink et al. (1978) No MPH vs. PBOAuditory Attention 0.215 0.295 0.087 -0.363 0.793 0.730 0.465
Kollins et al. (2015) No MPH vs. PBOCPT 0.229 0.151 0.023 -0.066 0.524 1.521 0.128
Kratz et al. (2009) No MPH vs. PBOGo/No-Go 0.273 0.137 0.019 0.005 0.540 1.994 0.046
Levin et al. (2001) Yes MPH vs. PBOCPT -0.068 0.460 0.211 -0.969 0.834 -0.147 0.883
Rapoport et al. (1980) No AMP vs. PBO CPT 0.186 0.252 0.063 -0.307 0.679 0.739 0.460
Silber et al. (2006) No AMP vs. PBO DV -0.171 0.171 0.029 -0.506 0.165 -0.996 0.319
Sofuoglu et al. (2008) No AMP vs. PBO SART -0.051 0.183 0.034 -0.410 0.308 -0.278 0.781
Strauss et al. (1984) No MPH vs. PBOCPT 0.615 0.251 0.063 0.122 1.108 2.447 0.014
Theunissen et al. (2009)No MPH vs. PBOMackwoth Clock 0.043 0.156 0.024 -0.263 0.349 0.275 0.783
Turner et al. (2003) No MPH vs. PBORVIP -0.252 0.309 0.095 -0.857 0.354 -0.815 0.415
Turner et al. (2005) Yes MPH vs. PBORVIP 0.086 0.218 0.047 -0.340 0.513 0.397 0.692
Whiting et al. (2008) No AMP vs. PBO RVIP -0.144 0.315 0.099 -0.761 0.474 -0.456 0.649
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Meta Analysis
Meta Analysis
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Outlier Evaluation 
Studies with effect sizes falling outside 3 standard deviations (SD = 0.230) of 
the mean (g < -0.654 or g > 0.728) were examined as potential outliers. No studies met 
these criteria. Therefore, analyses were conducted maintaining effect sizes from all of 
the studies. 
Publication Bias 
Analysis of publication bias indicated minimal risk with a Rosenthal’s N of 24 
to lead to a p-value at or above an alpha of .05 an Orwin’s N of 64 to reduce the 
measure of effect to g = 0.01 (this effect size was chosen to represent an estimate 
approaching zero considering the minimal effect size, g = 0.037, the studies 
generated). Trim and fill analysis suggested the imputation of 8 studies to account for 
positive bias resulting in a mean effect size that signified small negative effects (g = -
0.079, 95% CI [-0.183, 0.025]) and Egger’s regression just missed significance (B = 
1.086, SE = 0.711, t(22) = 1.529, 95% CI [-0.387, 2.560], p = .070) (see Figure 8). 
These findings indicated the likelihood of positive publication bias within this 
analysis.  
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Figure 8 
Funnel Plot with Observed Studies for Vigilance 
 
 Moderator Analyses 
 Because the homogeneity analysis revealed a Q statistic that approached 
significance (p = .096), moderator analysis was conducted for variables identified a 
prior and for additional moderating variables. ANOVA analog revealed significant 
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did not reveal significant heterogeneity for adults, Q(18) = 22.157, p = .225 or 
students, Q(3) = 2.247, p =.523.  
Similar results were found for participant recruitment characteristics, Q(5) = 
11.932, p = .036, findings that are likely confounded with participant characteristics. 
Follow-up analyses with two-group ANOVA analogs revealed significantly larger 
effect sizes for studies conducting recruitment within university settings (k = 4; g = 
0.320, SE = 0.119, 95% CI [0.087, 0.553]) compared to studies where recruitment was 
conducted within communities (k = 7; g = -0.048, SE = 0.062, 95% CI [-0.169, 
0.074]), Q(1) = 7.507, p = .006, and also compared to studies that conducted 
recruitment within clinical settings (k = 6; g = -0.026, SE = 0.337, 95% CI [-0.863, 
0.456]), Q(1) = 4.606, p = .032. Significant differences were also revealed between 
studies that did not report recruitment settings (k = 5, g = 0.205, SE = 0.090, 95% CI 
[0.029, 0.381]) and studies that recruited participants within communities, Q(1) = 
5.364. None of the other recruitment variables showed significant differences; 
however, analyses were not conducted comparing military settings or community 
settings that were combined with other settings considering their small sample sizes. 
Homogeneity analyses did not reveal significant differences within participant 
recruitment groups.  
 Meta-regression revealed significant effects for age (k = 21; B = -0.019, SE = 
0.005, 95% CI [-0.029, -0.008], p = .001, R2 analog = 1.0) and gender distribution (k = 
22; B = -0.005, SE = 0.002, 95% CI [-0.010, --0.000], p = .032), R2 analog = 0.52) on 
measures of vigilance. Figures 9 and 10 show trends where a decrease in study effect 
size related to an increase in mean age and decrease in representation of females. A 
  
142
 
significant trend was also revealed for cognitive baseline (k = 8; B = 0.010, SE = 
0.004, 95% CI [0.002, 0.017, p =.014, R2 analog = 1.00). As can be seen in Figure 11, 
larger effect sizes associated with higher baseline scores of cognitive functioning. 
Finally, although lower numbers of days on medication was significantly related to 
higher effect sizes across studies (k = 24; B = -0.013, SE = 0.006, 95% CI [-0.025, -
0.001], p =.034, R2 analog = 0.63), this finding should be interpreted with caution 
given only 4 studies administered medication for more than one day. No other 
significant continuous or categorical variables were revealed by meta-regression or 
ANOVA analog. 
Figure 9 
Scatter Plot with Observed Studies for Vigilance and Age 
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Figure 10 
Scatter Plot with Observed Studies for Vigilance and Percent Female 
 
Figure 11 
Scatter Plot with Observed Studies for Vigilance and Baseline Cognitive Functioning 
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Missing Data 
 Eleven studies with insufficient data to calculate effect sizes were excluded 
from the analysis involving the effects of ADHD medication on neurocognitive 
enhancement of vigilance (see Appendix C). Four studies reported non-significant 
findings, 5 studies reported significant, positive effects, 1 study reported mixed 
findings, and 1 study did not provide enough information to report. 
Neurocognitive Enhancement of Inhibitory Control 
Data were extracted from 43 studies that investigated the neurocognitive 
effects of ADHD medication on inhibitory control, including 1,495 participants. These 
studies examined the neurocognitive effects of AMP (k = 12), MPH (k = 25), LDX (k 
= 1), and ATX (k = 5) on inhibitory control on adults with (k = 13) and without (k = 
30) ADHD. Table 19 displays the descriptive data and ES estimates (Hedge’s g) from 
each of the 43 studies. The random effects model analysis resulted in a statistically 
significant mean effect size of g =0.164 (SE = 0.036, 95% CI [0.094, 0.235], p < .001), 
with effect sizes ranging -0.402 to 0.639. Under the fixed effects model, the mean 
effect size was slightly reduced to g = 0.145 (SE = 0.036, 95% CI [0.101, 0.189], p < 
.001). The heterogeneity of variance analysis yielded a significant Q statistic, Q (42) = 
89.308, p < .001.
  
145
 
Table 19 
ADHD Medication Neurocognitive Effects on Inhibitory Control and Mean Results 
 
ADHD Study name Comparison Outcome Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
Yes Agay et al. (2010) MPH vs. PBO TOVA 0.176 0.336 0.113 -0.483 0.836 0.524 0.600
No Allman et al. (2010) AMP vs. PBO Antisaccade 0.329 0.079 0.006 0.175 0.483 4.194 0.000
No Allman et al. (2012) MPH vs. PBO Antisaccade -0.058 0.070 0.005 -0.196 0.080 -0.829 0.407
Yes Aron et al. (2003) MPH vs. PBO Stop-Signal 0.534 0.304 0.092 -0.062 1.130 1.757 0.079
No Barch & Carter (2005) AMP vs. PBO Stroop 0.192 0.120 0.014 -0.044 0.427 1.597 0.110
Yes Barkley et al. (2005) MPH vs. PBO CPT 0.167 0.123 0.015 -0.074 0.408 1.360 0.174
No Ben-Itzhak et al. (2008) MPH vs. PBO Go/No-Go 0.309 0.107 0.011 0.099 0.518 2.888 0.004
Yes Boonstra et al. (2005) MPH vs. PBO Stop-Signal; CPT 0.354 0.174 0.030 0.013 0.696 2.034 0.042
Yes Bron et al. (2014) MPH vs. PBO CPT; TOVA 0.277 0.183 0.033 -0.082 0.636 1.513 0.130
Yes Chamberlain et al. (2007) ATX vs. PBO Stop-Signal; CPT 0.585 0.225 0.051 0.144 1.027 2.599 0.009
No Chamberlain et al. (2009) ATX vs. PBO Stop-Signal 0.354 0.303 0.092 -0.240 0.948 1.169 0.242
No Chevassus et al. (2013) MPH vs. PBO Stroop 0.051 0.151 0.023 -0.245 0.346 0.337 0.736
No Clark et al. (1986) MPH vs. PBO Task of Attention 0.523 0.380 0.145 -0.222 1.268 1.376 0.169
No Coons et al. (1981)a MPH vs. PBO CPT -0.292 0.226 0.051 -0.736 0.152 -1.289 0.198
No Coons et al. (1981)b MPH vs. PBO CPT; Oddball 0.172 0.208 0.043 -0.236 0.579 0.825 0.409
No Costa et al. (2013) MPH vs. PBO Go/No-Go; Stop-Signal 0.061 0.094 0.009 -0.123 0.244 0.650 0.516
No de Bruijn et al. (2004) AMP vs. PBO Flanker 0.150 0.210 0.044 -0.263 0.562 0.711 0.477
Yes DuPaul et al. (2012) LDX vs. PBO CPT 0.285 0.187 0.035 -0.083 0.652 1.519 0.129
Yes Faraone et al. (2005) ATX vs. PBO Stroop 0.138 0.097 0.009 -0.052 0.327 1.426 0.154
No Fleming et al. (1995) AMP vs. PBO CPT 0.282 0.194 0.038 -0.099 0.663 1.453 0.146
No Graf et al. (2011) ATX vs. PBO Go/No-Go -0.402 0.148 0.022 -0.692 -0.112 -2.721 0.007
No Hester et al. (2012); Nandam et al. (2014) MPH vs. PBO Go/No-Go 0.168 0.167 0.028 -0.159 0.495 1.007 0.314
No Hink et al. (1978) MPH vs. PBO Auditory Attention 0.261 0.294 0.086 -0.315 0.837 0.888 0.375
No Idestrom & Schalling (1970) AMP vs. PBO Stroop -0.096 0.119 0.014 -0.330 0.138 -0.800 0.424
No Ilieva et al. (2013) AMP vs. PBO Go/No-Go; Flanker 0.047 0.104 0.011 -0.156 0.250 0.452 0.651
No Kollins et al. (2015) MPH vs. PBO CPT -0.015 0.102 0.010 -0.215 0.185 -0.144 0.885
No Kratz et al. (2009) MPH vs. PBO Go/No-Go 0.385 0.139 0.019 0.112 0.659 2.764 0.006
Yes Levin et al. (2001) MPH vs. PBO CPT -0.166 0.454 0.206 -1.055 0.723 -0.366 0.714
No Linssen et al. (2012) MPH vs. PBO Stop-Signal 0.289 0.323 0.105 -0.345 0.923 0.893 0.372
No Moeller et al. (2014) MPH vs. PBO Stroop 0.377 0.144 0.021 0.095 0.659 2.621 0.009
No Nandam et al. (2011) ATX vs. PBO Stop-Signal 0.639 0.226 0.051 0.196 1.082 2.825 0.005
No Pauls et al. (2012) MPH vs. PBO Stop-Signal 0.183 0.322 0.104 -0.448 0.814 0.569 0.570
No Rapoport et al. (1980) AMP vs. PBO Stroop -0.146 0.186 0.035 -0.510 0.218 -0.785 0.433
No Servan-Schreiber et al. (1998) AMP vs. PBO Flanker 0.637 0.247 0.061 0.154 1.121 2.585 0.010
No Silber et al. (2006) AMP vs. PBO DV 0.145 0.171 0.029 -0.190 0.480 0.849 0.396
No Sofuoglu et al. (2008) AMP vs. PBO SART -0.343 0.186 0.035 -0.708 0.023 -1.838 0.066
Yes Spencer et al., 1998 ATX vs. PBO Stroop 0.320 0.124 0.015 0.076 0.564 2.568 0.010
No Strauss et al. (1984) MPH vs. PBO CPT 0.437 0.214 0.046 0.017 0.858 2.038 0.042
Yes Taylor & Russo (2000) AMP vs. PBO Stroop 0.447 0.133 0.018 0.186 0.708 3.362 0.001
Yes Taylor & Russo (2001) AMP vs. PBO Stroop 0.116 0.130 0.017 -0.137 0.370 0.899 0.369
No Theunissen et al. (2009) MPH vs. PBO Mackwoth Clock -0.329 0.323 0.104 -0.962 0.304 -1.019 0.308
No Turner et al. (2003) MPH vs. PBO RVIP 0.316 0.309 0.096 -0.290 0.922 1.021 0.307
Yes Turner et al. (2005) MPH vs. PBO RVIP 0.023 0.125 0.016 -0.222 0.269 0.187 0.852
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Meta Analysis
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Table 19 (continued) 
 
Notes. AMP = Amphetamine; ATX = Atomoxetine; CPT = Continuous Performance Task; DV = Digit Vigilance; LDX = 
Lisdexamfetamine Dymesylate; MPH = Methylphenidate; PBO = Placebo; RVIP = Rapid Visual Information Processing; 
SART = Sustained Attention to Response Test; TOVA = Test of Visual Attention. 
ADHD Study name Comparison Outcome Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
No Sofuoglu et al. (2008) AMP vs. PBO SART -0.343 0.186 0.035 -0.708 0.023 -1.838 0.066
Yes Spencer et al., 1998 ATX vs. PBO Stroop 0.320 0.124 0.015 0.076 0.564 2.568 0.010
No Strauss et al. (1984) MPH vs. PBOCPT 0.437 0.214 0.046 0.017 0.858 2.038 0.042
Yes Taylor & Russo (2000) AMP vs. PBO Stroop 0.447 0.133 0.018 0.186 0.708 3.362 0.001
Yes Taylor & Russo (2001) AMP vs. PBO Stroop 0.116 0.130 0.017 -0.137 0.370 0.899 0.369
No Theunissen et al. (2009)MPH vs. PBOMackwoth Clock -0.329 0.323 0.104 -0.962 0.304 -1.019 0.308
No Turner et al. (2003) MPH vs. PBORVIP 0.316 0.309 0.096 -0.290 0.922 1.021 0.307
Yes Turner et al. (2005) MPH vs. PBORVIP 0.023 0.125 0.016 -0.222 0.269 0.187 0.852
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Meta Analysis
Meta Analysis
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Outlier Evaluation 
Studies with effect sizes falling outside 3 standard deviations (SD = 0.236) of 
the mean (g < -0.544 or g > 0.872) were examined as potential outliers. No studies met 
these criteria. Therefore, analyses were conducted maintaining effect sizes from all of 
the studies. 
Publication Bias 
Analysis of publication bias indicated minimal risk with a Rosenthal’s N of 
454 to lead to a p-value at or above an alpha of .05 and Orwin’s N of 27 to reduce the 
measure of effect to g = 0.10. Trim and fill analysis suggested the imputation of 7 
studies resulting in a reduction in the mean effect size to g = 0.116, 95% CI [0.044, 
0.188] (see Figure 12). Egger’s regression approached significance (B = 0.710, SE = 
0.540, t(41) = 1.316, 95% CI [-0.380, 1.801], p = .098) indicating some risk for 
publication bias.  
Figure 12 
Funnel Plot with Observed Studies for Inhibitory Control  
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 Moderator Analyses 
 
Moderator analyses were conducted given the between-study variability 
indicated by the significant homogeneity of variance analysis. ANOVA analog did not 
reveal any significant moderator variables. However, differences between studies 
administering low and high doses approached significance, Q(1) = 3.414, p = .065, 
where low doses (k = 31, g = 0.206, SE = 0.041, 95% CI [0.125, 0.287]) resulted in 
larger mean effect sizes than high doses (k = 12, g = 0.060, SE = 0.068, 95% CI [-
0.073, 0.192]). Timing of dose activation also approached significance, Q(3) = 7.388, 
p = .061, so follow-up two-group ANOVA analogs were conducted to examine 
differences between individual groups. Results indicated significantly smaller effect 
sizes among studies that administered medication that was active prior to learning (k = 
5, g = 0.011, SE = 0.066, 95% CI [-0.119, 0.141]) compared to studies where 
medication was active during learning (k = 29, g = 0.175, SE = 0.047, 95% CI [0.083, 
0.267]), Q(1) = 4.077, p = .043, and also compared to studies where medication 
activation timing was not reported (k = 5, g = 0.264, SE = 0.032, 95% CI [0.090, 
0.217]), Q(1) = 6.972, p = .008. Significant differences were not revealed for any other 
variables concerning timing of medication activation including studies reporting 
medication activation timing that was active following learning (k = 4, g = 0.155, SE = 
0.126, 95% CI [-0.091, 0.401]). Homogeneity analyses indicated significant between-
study variability for studies reporting medication activation during learning, Q(28) = 
65.587, p < .001. Significant between-study variance was not revealed for any of the 
other variables related to medication activation timing. 
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As shown in Figure 13, a significant trend was revealed where age 
demonstrated a positive association with effect sizes (k = 34, B = 0.007, SE = 0.003, 
95% CI [0.001, 0.012], p = .020, R2 analog = 0.33). Although not significant, a trend 
(p < .10) was revealed for higher number of sessions relating to smaller effect sizes (k 
= 43, B = -0.043, SE = 0.023, 95% CI [-0.088, 0.003], p = .066, R2 analog = 0.11). 
Meta-regression and ANOVA analog did not reveal any other significant moderator 
variables. 
Figure 13 
Scatter Plot with Observed Studies for Inhibitory Control and Age 
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studies reported mixed results, 2 studies reported positive and significant findings, and 
2 studies did not report the findings related to inhibitory control. 
Neurocognitive Enhancement of Working Memory 
Data were extracted from 32 studies (895 participants) that investigated the 
neurocognitive effects of prescription stimulants on working memory. These studies 
explored the effects of AMP (k = 11), MPH (k = 20), and ATX (k = 1) among adults 
with (k = 5) and without (k = 27) ADHD. Table 20 displays the descriptive data and 
effect size estimates (Hedge’s g) from each of the 32 studies. The studies generated a 
statistically significant mean effect size of g =0.068 (SE = 0.028, 95% CI[0.014, 
0.123], p = .014), with effect sizes ranging -0.479 to 1.018. A fixed effects model 
yielded a similar average mean effect (g =0.054, SE = 0.019, 95% CI[0.017, 0.090] , p 
= .004). The homogeneity of variance analysis did not reveal yield a significant Q 
statistic, Q (31) = 39.284, p = .146, indicating minimal variability between studies. 
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Table 20 
ADHD Medication Neurocognitive Effects on Working Memory Study and Mean Results 
 
Notes. AMP = Amphetamine; ATX = Atomoxetine; DS = Digit Span; MPH = Methylphenidate; PBO = Placebo; RIP = 
Rapid Information Processing Task;SWM = Spatial Working Memory; TMT = Trail-Making Task; WM = Working 
Memory. 
 
ADHD Study name Comparison Outcome Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
Yes Agay et al. (2010) MPH vs. PBO DS 1.018 0.353 0.124 0.327 1.709 2.886 0.004
Yes Agay et al. (2014) MPH vs. PBO DS; WM Task 0.016 0.151 0.023 -0.280 0.311 0.103 0.918
No Barch & Carter (2005) AMP vs. PBO Dot-Letter Task 0.118 0.160 0.026 -0.195 0.431 0.739 0.460
No Brumaghim et al. (1987)a MPH vs. PBO Recall of Consonants 0.248 0.080 0.006 0.091 0.405 3.103 0.002
No Brumaghim et al. (1987)b MPH vs. PBO Recall of Consonants 0.240 0.090 0.008 0.064 0.416 2.673 0.008
No Campbell-Meiklejohn et al. (2012) MPH vs. PBO n-back 0.211 0.312 0.097 -0.400 0.821 0.676 0.499
Yes Chamberlain et al. (2007) ATX vs. PBO SWM 0.061 0.167 0.028 -0.265 0.388 0.367 0.713
No Chevassus et al. (2013) MPH vs. PBO DS 0.081 0.162 0.026 -0.236 0.399 0.502 0.615
No Clatworthy et al. (2009) MPH vs. PBO SWM 0.069 0.212 0.045 -0.346 0.484 0.328 0.743
No de Wit et al. (2002) AMP vs. PBO DS 0.189 0.104 0.011 -0.016 0.393 1.809 0.070
No Duke & Keeler (1968) AMP vs. PBO TMT-B -0.479 0.280 0.079 -1.028 0.071 -1.708 0.088
No Elliott et al. (1997) MPH vs. PBO SWM 0.000 0.216 0.047 -0.423 0.423 0.000 1.000
No Fillmore et al. (2005) AMP vs. PBO RIP 0.231 0.205 0.042 -0.171 0.633 1.128 0.259
No Fleming et al. (1995) AMP vs. PBO Spatial Delay Response 0.257 0.257 0.066 -0.247 0.761 1.000 0.317
No Gilbert et al. (1973) MPH vs. PBO DS -0.099 0.136 0.019 -0.366 0.168 -0.730 0.465
No Ilieva et al. (2013) AMP vs. PBO DS; n-back 0.009 0.112 0.013 -0.210 0.229 0.083 0.934
No Kollins et al. (2015) MPH vs. PBO n-back -0.213 0.211 0.044 -0.626 0.200 -1.010 0.313
No Linssen et al. (2012) MPH vs. PBO SWM -0.131 0.181 0.033 -0.486 0.224 -0.722 0.470
No Linssen et al. (2014) MPH vs. PBO SWM; Sternberg Memory -0.034 0.135 0.018 -0.299 0.232 -0.250 0.803
No Makris et al.(2007) AMP vs. PBO Number Recognition 0.026 0.026 0.001 -0.025 0.077 1.000 0.317
No Marquand et al. (2011) ATX vs. PBO SWM -0.025 0.196 0.038 -0.409 0.359 -0.127 0.899
No Mattay et al. (2000) AMP vs. PBO n-Back -0.138 0.237 0.056 -0.602 0.327 -0.580 0.562
No Mehta et al. (2000) MPH vs. PBO SWM 0.326 0.218 0.048 -0.101 0.754 1.497 0.134
No Oken et al. (1995) MPH vs. PBO DS -0.131 0.127 0.016 -0.379 0.118 -1.032 0.302
No Ramasubbu et al. (2012) MPH vs. PBO n-back 0.426 0.252 0.063 -0.068 0.920 1.692 0.091
No Silber et al. (2006) AMP vs. PBO DS; TMT-B 0.077 0.166 0.028 -0.249 0.403 0.461 0.644
No Studer et al. (2010) MPH vs. PBO Visual WM -0.140 0.207 0.043 -0.547 0.266 -0.678 0.498
Yes Taylor & Russo (2000) AMP vs. PBO DS 0.187 0.138 0.019 -0.083 0.457 1.356 0.175
No Turner et al. (2003) MPH vs. PBO DS; SWM 0.079 0.309 0.096 -0.526 0.685 0.257 0.798
Yes Turner et al. (2005) MPH vs. PBO n-back; SWM 0.047 0.176 0.031 -0.297 0.392 0.270 0.787
No van der Schaaf et al. (2013) MPH vs. PBO DS 0.038 0.136 0.019 -0.229 0.305 0.278 0.781
No Wardle et al. (2013) AMP vs. PBO n-back 0.013 0.089 0.008 -0.161 0.188 0.151 0.880
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Meta Analysis
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Outlier Evaluation 
Studies with effect sizes falling outside 3 standard deviations (SD = 0.158) of 
the mean (g < -0.407 or g > 0.543) were examined as potential outliers. Two studies 
met these criteria: Duke & Keeler (1968), g = -0.479 and Agay et al. (2010), g = 
1.018. Table 21 displays the mean effect sizes with the inclusion of all studies, with 
each of these studies removed, and with the removal of both studies. 
Table 21 
Outlier Summary of ADHD Medication and Working Memory 
Analysis k Model g 95% CI p Q (df) LCL UCL 
All studies 32 
Fixed 0.054 0.017 0.090 .004 
39.284 
(31) 
Random 0.068 0.014 0.123 .014  
Duke & 
Keeler 
(1968) 
removed 
31 
Fixed 0.056 0.019 0.093 .003 
35.661 
(30) 
Random 0.073 0.021 0.125 .006  
Agay et al. 
(2010) 
removed 
31 Fixed 0.051 0.014 0.088 .007 
31.787 
(30) 
Random 0.059 0.014 0.104 .010  
Both studies 
removed 30 
Fixed 0.053 0.016 0.090 .005 
28.202 
(29) 
Random 0.053 0.016 0.090 .005  
Notes. * p < .01; ** p < .001. 
Duke & Keeler’s (1968) study was described as a potential outlier in previous 
analyses; this study’s removal resulted in a minimal increase in the mean effect size to 
g =0.073 from g = 0.068. Agay et al. (2010) examined the effects of MPH on adults 
with and without ADHD in a parallel design study, reporting significant positive 
effects for working memory as measured by DS. A decision to maintain both studies 
in the subsequent analyses was made considering their minimal effects on mean effect 
sizes. 
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Publication Bias 
Analysis of publication bias indicated minimal risk with a Rosenthal’s N of 31 
to lead to a p-value at or above an alpha of .05 and Orwin’s N of 185 to reduce the 
effect size to g = 0.01. Trim and fill analysis suggested the imputation of 1 study, 
resulting in a slight reduction of the mean effect size to g = 0.062, 95% CI[0.001, 
0.121] (see Figure 14). Egger’s regression was not significant [B = 0.237, SE = 0.309, 
t(30) = 0.766, 95% CI [-0.394, 0.868], p = .225). Therefore, risk of publication bias 
appeared to be minimal for working memory. 
Figure 14 
Funnel Plot with Observed Studies for Working Memory 
 
Moderator Analyses 
Because the homogeneity variance analysis did not indicate significant 
heterogeneity between studies, only variables identified a priori concerning the 
present study’s hypotheses were explored as potential moderators. ANOVA analog 
and meta-regression did not reveal significance for ADHD status, activation timing of 
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learning, medication activation type, or baseline cognitive functioning (measured with 
intelligence tests and years of education).  
Missing Data 
 Eleven studies involving the effects of ADHD medication on neurocognitive 
enhancement of working memory were excluded from the analysis due to insufficient 
data for calculating effect sizes (see Appendix C). Six of the studies reported non-
significant findings and five reported significant benefits of ADHD medication for 
working memory. 
Neurocognitive Enhancement of Processing Speed 
Data were extracted from 18 studies that investigated the neurocognitive 
effects of ADHD medication on processing speed, resulting in a total of 558 
participants. Effect sizes resulted from studies examining the effects of AMP (k = 9), 
MPH (k = 8), and ATX (k = 1) on processing speed among adults without ADHD (k = 
18). Table 22 displays the descriptive data and effect sizes (Hedge’s g) from each of 
the 18 studies. Under the random effects model, the studies generated a statistically 
significant mean effect size of g =0.195 (SE = 0.060, 95% CI [0.077, 0.313], p = .001), 
with effect sizes ranging -0.612 to 0.607. The fixed effects model yielded a much 
larger mean effect size of g =0.306, SE = 0.025, 95% CI [0.257, 0.355], p < .001). The 
heterogeneity of variance analysis was significant, Q (17) = 73.499, p <.001, 
indicating significant between-study variance. 
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Table 22
 
ADHD Medication Neurocognitive Effects on Processing Speed Study and Mean Results 
 
Notes. AMP = Amphetamine; CRT = Choice Reaction Time; DSST = Digit Symbol Substitution Task; MPH = 
Methylphenidate; NR = Number Recognition; PBO = Placebo; SERS = Stimulus Evaluation Response Selection; SRT = 
Simple Reaction Test; TMT = Trail-Making Task; TRT = Total Choice Reaction Test. 
 
 
ADHD Study name Comparison Outcome Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
No Chevassus et al. (2013) MPH vs. PBO DSST; SRT; TRT 0.157 0.123 0.015 -0.084 0.397 1.276 0.202
No Coons et al. (1981)b MPH vs. PBO CRT 0.286 0.087 0.008 0.115 0.457 3.273 0.001
No Duke & Keeler (1968) AMP vs. PBO TMT-A -0.612 0.360 0.129 -1.317 0.093 -1.701 0.089
No Finke et al., 2010 MPH vs. PBO Whole-report Task 0.607 0.183 0.033 0.248 0.966 3.316 0.001
No Halliday et al. (1986)a MPH vs. PBO SERS 0.053 0.129 0.017 -0.201 0.306 0.407 0.684
No Halliday et al. (1986)b AMP, MPH vs. PBO SERS 0.161 0.203 0.041 -0.237 0.559 0.792 0.428
No Idestrom & Schalling (1970) AMP vs. PBO DSST -0.008 0.108 0.012 -0.221 0.204 -0.078 0.938
No Kornetsky (1958) AMP vs. PBO Simple Motor Response -0.117 0.137 0.019 -0.386 0.151 -0.855 0.392
No Linssen et al. (2011) MPH vs. PBO SRT 0.387 0.109 0.012 0.174 0.600 3.564 0.000
No Makris et al.(2007) AMP vs. PBO DSST 0.212 0.144 0.021 -0.070 0.494 1.475 0.140
No Muller et al. (2005) MPH vs. PBO Motor Reaction 0.039 0.124 0.015 -0.204 0.283 0.318 0.751
No Naylor et al. (1985) MPH vs. PBO SERS 0.264 0.132 0.017 0.005 0.524 2.000 0.046
No Oken et al. (1995) MPH vs. PBO Spatial Orientation; Visual Search 0.192 0.108 0.012 -0.020 0.404 1.774 0.076
No Samanez-Larkin et al. (2013) AMP vs. PBO DSST 0.262 0.085 0.007 0.095 0.430 3.066 0.002
No Silber et al. (2006) AMP vs. PBO DSST; TMT-A 0.051 0.123 0.015 -0.191 0.292 0.411 0.681
No Ward et al. (1997) AMP vs. PBO NR; DSST 0.332 0.545 0.297 -0.737 1.401 0.609 0.542
No Wardle et al. (2013) AMP vs. PBO DSST 0.532 0.042 0.002 0.450 0.615 12.678 0.000
No Weitzner (1965) AMP vs. PBO Digit Letter Coding 0.299 0.339 0.115 -0.364 0.963 0.884 0.377
-1.00 -0.50 0.00 0.50 1.00
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Outlier Evaluation 
Studies with effect sizes falling outside 3 standard deviations (SD = 0.256) of 
the mean (g < -0.569 or g > 0.959) were examined as potential outliers. Only one 
study (Duke & Keeler, 1968) met these criteria with a mean effect size of g = -0.612. 
The removal of this study resulted in a slight increase in the mean effect size to g = 
0.213 (SE = 0.059, 95% CI [0.097, 0.328], p < .001) from g = 0.195. Therefore, 
consistent to previous analyses, this study was maintained. 
Publication Bias 
Analysis of publication bias indicated minimal risk with a Rosenthal’s N of 
270 to lead to a p-value at or above an alpha of .05 and an Orwin’s N of 17 to reduce 
the measure of effect to 0.10. Although trim and fill analysis did not suggest the 
imputation of any studies to reduce positive bias, 8 studies were suggested for 
imputation to account for negative bias and resulted in an increase in the mean effect 
size to g = 0.382, 95% CI [0.260, 0.504]. Egger’s regression was significant [B = -
2.621, SE = 0.780, t(16) = 3.358, 95% CI [-4.276, -0.967], p = .002) which is 
displayed visually in Figure 15. These findings suggest minimal risk of publication 
bias within analyses examining processing speed. 
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Figure 15 
Funnel Plot with Observed Studies for Processing Speed 
 
Missing Data 
 Fourteen studies were excluded due to insufficient data from the analysis 
involving the effects of ADHD medication on neurocognitive enhancement of 
processing speed (see Appendix C). Two studies reported mixed findings, 1 study 
reported a significant negative effect, 4 studies reported non-significant findings, and 7 
studies reported significant and positive effects. 
Moderator Analyses 
 The significant Q statistic indicated between study variance so moderator 
analyses were conducted. ANOVA analog revealed significant differences for timing 
of dose activation, Q(3) = 7.873, p = .049; however, when the one study that did not 
report timing of dose activation (k = 1, g = -0.612, SE = 0.360, 95% CI [-1.317, 
0.093]) was removed from this analysis, significant differences were not found, Q(2) = 
3.047, p = .218. 
As shown in Figure 16, meta-regression revealed a significant trend for studies 
published more recently resulting in larger effect sizes (k = 18, B = 0.007, SE = 0.003, 
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95% CI[0.002, 0.012], p = .008, R2 = 0.53). No other significant variables were 
revealed by meta-regression; however, note that meta-regression could not be 
conducted for years of education or baseline cognitive functioning due to the low 
number of studies reporting them (k = 2 and k = 0, respectively). 
Figure 16 
Scatter Plot with Observed Studies for Processing Speed and Year of Publication 
 
Summary of Neurocognitive Enhancement of Narrow Constructs of Abilities of 
Focused Behavior 
Table 23 displays the mean effect sizes for ADHD medication on abilities of focused 
behavior overall, as well as on each underlying construct individually (vigilance, 
inhibitory control, working memory, and processing speed). Mean effect sizes were 
small for abilities of focused behavior overall, as well as for inhibitory control and 
processing speed, but they approached zero for vigilance and working memory. 
  
Regression of Hedges's g on Year of Publication
Year of Publication
1940.0 1950.0 1960.0 1970.0 1980.0 1990.0 2000.0 2010.0 2020.0 2030.0
H
ed
ge
s'
s 
g
1.00
0.80
0.60
0.40
0.20
0.00
-0.20
-0.40
-0.60
-0.80
  159
 
Table 23 
Summary of ADHD Medication and Abilities of Focused Behavior Findings 
Outcome k Model g 95% CI p Q (df) LCL UCL 
Overall 
74 Fixed 0.148 0.115 0.181 <.001 120.770** 
(73) 
 
 Random 0.140 0.094 0.186 <.001 
Vigilance 
24 Fixed 0.016 -0.057 0.090 .664 32.218 
(23)  Random 0.047 -0.055 0.128 .434 
Inhibitory 
Control 
43 Fixed 0.145 0.101 0.189 <.001 89.308
**
 
(42) 
 Random 0.164 0.094 0.235 <.001  
Working 
Memory 
32 Fixed 0.054 0.017 0.090 .004 39.284 
(31) 
 
 Random 0.068 0.014 0.123 .014 
Processing 
Speed 
18 Fixed 0.306 0.257 0.355 <.001 73.499** 
(17)  Random 0.195 0.077 0.313 .001 
Notes. * p < .01; ** p < .001. 
Neurocognitive Enhancement of Narrow Constructs of Learning and Memory 
Neurocognitive Enhancement of Declarative Learning and Memory – Immediate 
Data were extracted from 18 studies (567 participants) that investigated the 
neurocognitive effects of ADHD medication on declarative learning with immediate 
memory tests. Studies investigated AMP (k = 6), MPH (k = 11), and LDX (k = 1) 
among adults with (k = 4) and adults without (k = 14) ADHD. Table 24 displays the 
descriptive data and ES estimates (Hedge’s g) from each of the 18 studies. The studies 
generated a mean effect size of g =0.106 that just missed significance (SE = 0.054, 
95% CI [-0.000, 0.212], p = .051) under the random effects model, with effect sizes 
ranging from g = -0.217 to g = 0.935. A fixed effects model yielded similar findings 
that did reach statistical significance (g = 0.124, SE = 0.031, 95% CI [0.063, 0.186], p 
< .001). The heterogeneity of variance analysis yielded a significant Q statistic,  Q 
(17) = 59.878, p =.001. 
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Table 24 
ADHD Medication Neurocognitive Effects on Immediate Declarative Learning and Memory and Mean Results 
 
Notes. AMP = Amphetamine; CVLT = California Verbal Learning Test; GMT = Guild Memory Test; LDX = 
Lisdexamfetamine Dymesylate; MPH = Methylphenidate; PAL = Paired Associates Task; PBO = Placebo; PRM = Pattern 
Recognition Memory Task; RVALT = Rey Verbal Auditory Learning Task. 
ADHD Study name Comparison Outcome Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
No Ben-Itzhak et al. (2008) MPH vs. PBO Recognition of Object Orientation 0.061 0.125 0.016 -0.185 0.306 0.483 0.629
No Brignell et al. (2007) MPH vs. PBO Recognition of Story; Recall of Object 0.279 0.063 0.004 0.155 0.403 4.414 0.000
No Chevassus et al. (2013) MPH vs. PBO Recall of Pictures -0.006 0.171 0.029 -0.342 0.329 -0.036 0.971
Yes DuPaul et al. (2012) LDX vs. PBO CVLT -0.164 0.162 0.026 -0.481 0.153 -1.015 0.310
No Finke et al., 2010 MPH vs. PBO Whole-report 0.108 0.192 0.037 -0.269 0.484 0.559 0.576
No Fleming et al. (1995) AMP vs. PBO RAVLT; PAL 0.086 0.086 0.007 -0.083 0.256 1.000 0.317
No Gilbert et al. (1973) MPH vs. PBO GMT -0.217 0.130 0.017 -0.472 0.038 -1.665 0.096
Yes Kinsbourne et al.(2001) MPH vs. PBO PAL 0.243 0.207 0.043 -0.164 0.650 1.172 0.241
No Linssen et al. (2014) MPH vs. PBO RVLT; PAL 0.192 0.164 0.027 -0.130 0.513 1.170 0.242
No Turner et al. (2003) MPH vs. PBO PAL 0.284 0.310 0.096 -0.324 0.891 0.914 0.361
Yes Turner et al. (2005) MPH vs. PBO PRM 0.023 0.122 0.015 -0.215 0.262 0.192 0.848
No Unrug et al. (1997) MPH vs. PBO Recall of Vocabulary 0.218 0.175 0.031 -0.124 0.560 1.247 0.212
Yes Verster et al. (2010) MPH vs. PBO Recall and Recognition of Words 0.000 0.152 0.023 -0.298 0.298 0.000 1.000
No Weitzner (1965) AMP vs. PBO PAL 0.139 0.338 0.114 -0.523 0.801 0.412 0.681
No Zeeuws & Soetens (2007) AMP vs. PBO Recall of Words 0.114 0.110 0.012 -0.101 0.329 1.040 0.298
No Zeeuws et al. (2010a) AMP vs. PBO Recall of Words 0.935 0.182 0.033 0.579 1.292 5.142 0.000
No Zeeuws et al. (2010b)a AMP vs. PBO Recall of Words -0.082 0.173 0.030 -0.421 0.257 -0.473 0.636
No Zeeuws et al. (2010b)b AMP vs. PBO Recall of Words -0.070 0.154 0.024 -0.371 0.232 -0.454 0.650
-1.00 -0.50 0.00 0.50 1.00
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Outlier Evaluation 
Studies with effect sizes falling outside 3 standard deviations (SD = 0.229) of 
the mean (g < -0.581 or g > 0.793) were examined as potential outliers. Only one 
study (Zeeuws et al., 2010a, p = .065) met these criteria with a mean effect size of g = 
0.935. The removal of this study resulted in a slight reduction in the mean effect size 
to g = 0.074, SE = 0.040, 95% CI [-0.005, 0.153] from g = 0.106. Therefore, a 
decision to maintain this study was made, consistent to previous analyses. 
 Publication Bias 
Analysis of publication bias indicated minimal risk with a Rosenthal’s N of 34 
to lead to a p-value at or above an alpha of .05 and Orwin’s N of 20 to reduce the 
measure of effect to g = 0.05 (an estimate chosen to reflect a substantial decrease from 
the original mean effect size, g = 0.106). Trim and fill analysis did not suggest the 
imputation of any studies to account for positive bias; however, 5 studies were 
suggested for imputation to account for negative bias resulting in an increase in the 
mean effect size to g = 0.190, 95% CI [0.086, 0.295]. Egger’s regression was not 
significant (B = 0.523, SE = 0.980, t(16) = 0.534, 95% CI [-2.600, 1.554], p = .300) as 
evidenced by the symmetry shown in the funnel plot (see Figure 17). Findings suggest 
minimal publication bias within the analysis of declarative memory measured 
immediately after learning.  
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Figure 17 
Funnel Plot with Observed Studies for Immediate Declarative Learning and Memory 
 
Moderator Analyses 
Significant between study variability was present for studies exploring memory 
that measured immediately after learning, so moderator analyses were conducted. 
ANOVA analog revealed significant differences for stimulant administration type, 
Q(1) = 4.592, p = 0.032. Studies administering stimulant doses that were fixed (k = 16, 
g = 0.136, SE = 0.055, 95% CI [0.028, 0.245]) resulted in significantly larger mean 
effect sizes than studies administering titrated doses (k = 2, g = -0.123, SE = 0.108, 
95% CI [-0.333, 0.088]); however, this finding was underpowered considering the low 
number of studies administering titrated doses. A similar finding was revealed on a 
trend level (p < .10) for medication activation type, Q(1) = 2.790, p = 0.095, where 
studies administering short-acting medications (k = 17, g = 0.121, SE = 0.055, 95% CI 
[0.014, 0.228]) resulted in larger effect sizes than the one study administering long-
acting stimulants (k = 1, g = -0.164, SE = 0.052, 95% CI [-0.010, 0.193]). These 
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findings do not appear to be clinically meaningful given the small number of studies 
investigating medication that was titrated and long-acting agents. 
Differences between timing of medication activation approached significance, 
Q(3) = 7.681, p = 0.053. Similar to findings concerning medication activation and 
processing speed, however, when the one study that did not report medication 
activation timing was removed from this analysis (k = 1, g = -0.217, SE = 0.130, 95% 
CI [-0.472, 0.038]), results were not significant, Q(2) = 1.413, p = .493.  
Meta-regression revealed a significant trend of higher number of days on 
medication relating to smaller effect sizes (k = 18, B = -0.021, SE = 0.010, 95% CI[-
0.039, -0.002], p = .030, R2 = 0.32). Similar to previous findings related to this 
variable, however, this finding reflects low variability across studies where only 3 
studies reported more than 1 day of medication administration. No other significant 
variables were revealed by meta-regression or ANOVA analog. Furthermore 
education level and baseline cognitive functioning were not analyzed due to the low 
number of studies reporting these variables (k = 3). 
Missing Data 
Fourteen studies with insufficient data to calculate effect sizes were excluded 
from the analysis involving the effects of ADHD medication on immediate declarative 
memory (see Appendix C). One study reported impairments on memory related to 
medication, 6 studies reported findings that were non-significant, 5 studies reported 
positive effects that were significant, and 2 studies did not report results for memory 
measured immediately after learning. 
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Neurocognitive Enhancement of Declarative Learning and Memory – Delayed 
Data were extracted from 11 studies that investigated the neurocognitive 
effects of ADHD medication on declarative learning with delayed assessment (20 
minutes or longer but within the same day as learning) of memory. Taken together, 
these studies resulted in a total of 289 participants, investigating AMP (k = 5), MPH (k 
= 5), and LDX (k = 1) effects among adults with (k = 3) and without (k = 8) ADHD. 
Table 25 displays the descriptive data and ES estimates (Hedge’s g) from each of the 
11 studies. The studies resulted in a mean effect size of g = 0.126 that approached 
statistical significance (SE = 0.067, 95% CI [-0.005, 0.256], p = .060) under the 
random effects model, with effect sizes ranging from g = -0.058 to g = 0.169. A fixed 
effects model yielded findings with a slightly reduced and statistically significant 
mean effect size (g = 0.077, SE = 0.039, 95% CI [0.001, 0.153], p = .047). The 
heterogeneity of variance analysis was significant, Q (10) = 24.861, p = .006. 
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Table 25  
ADHD Medication Neurocognitive Effects on Delayed Declarative Learning and Memory and Mean Results 
 
Notes. AMP = Amphetamine; CVLT = California Verbal Learning Test; LDX = Lisdexamfetamine Dymesylate; MPH = 
Methylphenidate; PBO = Placebo; RVALT = Rey Verbal Auditory Learning Task. 
ADHD Study name Comparison Outcome Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
No Brignell et al. (2007) MPH vs. PBO Recall of Story (20 min.) 0.223 0.630 0.397 -1.012 1.459 0.354 0.723
Yes DuPaul et al. (2012) LDX vs. PBO CVLT (20 min.) -0.058 0.072 0.005 -0.199 0.082 -0.812 0.417
No Ilieva et al. (2013) AMP vs. PBO Recognition of Faces; Recognition of Words (120 min.) -0.009 0.099 0.010 -0.203 0.185 -0.090 0.928
No Linssen et al. (2014) MPH vs. PBO RVLT (30 min.) 0.016 0.171 0.029 -0.320 0.352 0.091 0.927
Yes Turner et al. (2005) MPH vs. PBO PRM (20 min.) 0.029 0.122 0.015 -0.209 0.268 0.239 0.811
No Unrug et al. (1997) MPH vs. PBO Recall of Vocabulary (20 min.) 0.441 0.179 0.032 0.091 0.792 2.470 0.014
Yes Verster et al. (2010) MPH vs. PBO Recall of Words (120 min.) 0.211 0.152 0.023 -0.087 0.510 1.389 0.165
No Zeeuws & Soetens (2007) AMP vs. PBO Recall of Words (30, 60 min.) 0.165 0.111 0.012 -0.052 0.381 1.489 0.136
No Zeeuws et al. (2010a) AMP vs. PBO Recall of Words (60 min.) 0.711 0.169 0.029 0.380 1.041 4.208 0.000
No Zeeuws et al. (2010b)a AMP vs. PBO Recall of Words (60 min.) -0.009 0.170 0.029 -0.342 0.325 -0.051 0.960
No Zeeuws et al. (2010b)b AMP vs. PBO Recall of Words (60 min.) -0.009 0.154 0.024 -0.310 0.292 -0.060 0.952
-1.00 -0.50 0.00 0.50 1.00
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Outlier Evaluation 
Studies with effect sizes falling outside 3 standard deviations (SD = 0.222) of 
the mean (g < -0.541 or g > 0.793) were examined as potential outliers. No studies met 
these criteria; therefore, effect sizes from all studies were maintained in the analyses 
concerning delayed assessment of declarative learning and memory. 
 Publication Bias 
Analysis of publication bias indicated minimal risk with a Rosenthal’s N of 12 
to lead to a p-value at or above an alpha of .05 and Orwin’s N of 16 to reduce the 
measure of effect to 0.05 (this estimate was selected given the mean effect size was 
already approaching g = 0.10). Trim and fill analysis suggested the imputation of 3 
studies resulting in a reduction in the mean effect size to g = 0.034, 95% CI [-0.122, 
0.189]). Egger’s regression approached significance (B = 1.933, SE = 1.134, t(9) = 
1.704, 95% CI [-0.633, 4.499], p = .061) and the funnel plot (see Figure 18) indicated 
some positive bias prior to imputation.  
Figure 18 
Funnel Plot with Observed Studies for Delayed Declarative Learning and Memory 
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 Moderator Analyses 
 Moderator analyses were conducted given the significant variability between 
studies indicated by the significant Q statistic. Significant differences were revealed 
for medication dose, Q(1) = 5.049, p = .025, where studies that administered lower 
medication doses resulted in larger mean effect sizes (k = 7, g  = 0.207, SE = 0.092, 
95% CI[0.027, 0.387]) than studies that administered higher medication doses (k = 4, 
g = -0.033, SE = 0.055, 95% CI [-0.141, 0.074]). ANOVA analog also revealed trend 
level (p < .10) differences for medication, Q(2) = 4.635, p = .099; however, when the 
only study examining LDX (k = 1, g = -0.058, SE  = 0.072, 95% CI [-0.075, 0.390]) 
was removed from the analysis, significant differences were not found, Q(1) = 0.003, 
p = .957. A similar finding was revealed for medication activation type, a variable that 
is confounded with medication, where a significant difference between short-acting (k 
= 10, g = 0.156, SE = 0.072, 95% CI [0.015, 0.298]) and long-acting (k = 1, g = -
0.058, SE = 0.051, 95% CI[-0.051, 0.148]) medication was revealed, Q(1) = 4.445, p = 
.035. Therefore, these findings do not reflect meaningful differences considering only 
one of the studies investigated a long-acting medication. ANOVA analog did not 
reveal any other significant variables.  
 No significant moderator variables were revealed by meta-regression. Note 
that meta-regression was not conducted for years of education and baseline cognitive 
functioning given only one study examined baseline cognitive functioning and no 
studies reported number of years of education. 
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Missing Data 
 Due to insufficient data critical for calculating effect sizes, eleven studies 
meeting this study’s eligibility criteria were excluded from the analysis involving the 
effects of ADHD medication on neurocognitive enhancement of delayed declarative 
memory (see Appendix C). Studies reported findings that were non-significant (k = 3), 
as well as significant with positive effects (k = 7). One study did not report enough 
information to interpret significance or direction of effects. 
Neurocognitive Enhancement of Declarative Learning & Memory – Long-term 
Data were extracted from 9 studies that investigated the neurocognitive effects 
of ADHD medication on declarative learning with long-term delays of assessment 
(longer than one day and up to two weeks delay after learning). Data from a total of 
236 participants represented studies investigating the effects of AMP (k = 7) and MPH 
(k = 2) among adults without ADHD (k = 9). Table 26 displays the descriptive data 
and mean effect sizes (Hedge’s g) from each of the 9 studies. The studies resulted in 
statistically significant mean effect size of g =0.499 (SE = 0.161, 95% CI [0.183, 
0.815], p = .002) under the random effects model, with effect sizes ranging -0.087 to 
3.937. A fixed effects model yielded mean effect sizes in the reverse direction 
compared to those found with the random effects model (g = -0.072, SE = 0.011, 95% 
CI [-0.094, -0.049], p < .001). The heterogeneity of variance analysis was significant, 
Q (8) = 103.264, p <.001. 
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Table 26  
ADHD Medication Neurocognitive Effects on Long-Term Declarative Learning Memory and Mean Results 
 
Notes. AMP = Amphetamine; MPH = Methylphenidate; PBO = Placebo; RVALT = Rey Verbal Auditory Learning Task. 
ADHD Study name Comparison Outcome Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
No Ballard et al. (2013) AMP vs. PBO Recall of Pictures (2 days) 0.277 0.134 0.018 0.015 0.539 2.073 0.038
No Ballard et al. (2014) AMP vs. PBO Recall of Pictures; Recognition of Words (2 days) -0.087 0.012 0.000 -0.110 -0.064 -7.442 0.000
No Izquierdo et al. (2008) MPH vs. PBO Retention of facts (2 days, 1 week) 3.937 1.128 1.272 1.726 6.148 3.491 0.000
No Linssen et al. (2014) MPH vs. PBO RVLT (1 day) 0.122 0.152 0.023 -0.176 0.420 0.803 0.422
No Whiting et al. (2008) AMP vs. PBO Recall of Names; Recognition of Names (1 week, 1 month) 1.423 0.343 0.117 0.751 2.094 4.153 0.000
No Zeeuws & Soetens (2007) AMP vs. PBO Recall of Words (1 day) 0.183 0.111 0.012 -0.035 0.400 1.647 0.100
No Zeeuws et al. (2010a) AMP vs. PBO Recall of Words (1 day, 1 week) 1.707 0.253 0.064 1.210 2.203 6.736 0.000
No Zeeuws et al. (2010b)a AMP vs. PBO Recall of Words (1 day, 1 week) 0.358 0.179 0.032 0.008 0.709 2.003 0.045
No Zeeuws et al. (2010b)b AMP vs. PBO Recall of Words (1 day, 1 week) 0.109 0.170 0.029 -0.224 0.442 0.643 0.520
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Meta Analysis
Meta Analysis
  170
 
Outlier Evaluation 
Studies with effect sizes falling outside of 3 standard deviations (SD = 0.222) 
of the mean (g < -0.950 or g > 1.948) were examined as potential outliers. Only one 
study met these criteria (Izquierdo et al., 2008, described previously), with a mean 
effect size of g = 3.937. When this study was removed from the analysis, the mean 
effect size was slightly reduced to g  = 0.429 (SE = 0.154, 95% CI [0.127, 0.731], p = 
.005) from the original mean effect size of g = 0.499. Therefore, a decision to maintain 
this study was made. 
Publication Bias 
Analysis of publication bias indicated minimal risk with a Rosenthal’s N of 43 
to lead to a p-value at or above an alpha of .05 and Orwin’s N of 35 to reduce the 
effect size to g = 0.10. Trim and fill analysis indicated the imputation of five studies, 
resulting in the reversal of the effect size direction (i.e., negative) and reduction in the 
mean effect size (g =  -0.025, 95% CI [-0.326, 0.274]). Furthermore, Egger’s 
regression was significant (B = 3.401, SE = 0.710, t(7) = 4.793, 95% CI [1.723, 
5.078], p < .001), which is represented by the asymmetry shown in the funnel plot (see 
19) indicating positive bias.  
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Figure 19 
Funnel Plot with Observed Studies for Long-term Declarative Learning and Memory 
 
 Moderator Analyses 
 Due to the small number of studies examining long-term declarative memory 
(k = 9), analyses to test for moderator variables were underpowered. For a number of 
variables (e.g., ADHD status, study design, medication type) analyses could not be 
conducted because no variability concerning those variables between studies was 
present. As such, moderator variables were only conducted for variables that had at 
least 3 studies per group; these included the study design variables of 
counterbalancing and randomization. ANOVA analog did not reveal significant 
differences for either variable. 
 Meta-regression was also conducted for variables reported by at least 3 studies 
(year of publication, age, gender distribution, number of sessions, number of days 
between sessions, and days on medication). Year of publication was associated with 
effect sizes on a trend level (k = 9, B = -0.124, SE  = 0.067, 95% CI [-0.255, 0.007], p 
= .064, R2 = 0.00), where more recent publications were related to smaller effect sizes. 
No other significant variables were revealed by meta-regression. 
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Missing Data 
 Eleven studies met eligibility criteria involving the effects of ADHD 
medication on neurocognitive enhancement of long-term declarative memory, but 
were excluded from the analysis due to insufficient data (see Appendix C). The 
majority of results from these studies indicated significant and positive effects of 
medication on long-term memory (k = 9). The remaining studies reported non-
significant findings (k = 1) or did not report adequate information to interpret findings 
(k = 1). 
Neurocognitive Enhancement of Non-Declarative Learning and Memory 
Data were extracted from 6 studies that investigated the neurocognitive effects 
of ADHD medication on non-declarative learning and memory, resulting in a total of 
120 participants without ADHD (k = 6). Four studies investigated the effects of AMP 
and 2 studies investigated the effects of MPH on non-declarative learning and 
memory. Table 27 displays the descriptive data and ES estimates (Hedge’s g) from 
each of the 6 studies. The studies resulted in a mean effect size of g =0.165 that was 
not statistically different than zero (SE = 0.151, 95% CI [-0.131, 0.461], p = .277), 
with effect sizes ranging from g = -1.226 to g = 0.531. The fixed effects model yielded 
similar results (g =0.145, SE = 0.074, 95% CI [0.001, 0.290], p = .048). The 
heterogeneity of variance analysis yielded a significant Q statistic, Q(5) = 17.128, p 
=.004. 
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Table 27 
ADHD Medication Neurocognitive Effects on Non-declarative Learning and Memory and Mean Results 
 
 
Notes. AMP = Amphetamine; AWL = Associative Word Learning; MPH = Methylphenidate; PBO = Placebo; RA = 
Repeated Acquisition of Response Sequences Task; SLT = Simple Learning Task. 
Study name ADHD Comparison Outcome Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
Breitenstein et al. (2004) No AMP vs. PBO AWL 0.515 0.307 0.095 -0.088 1.118 1.675 0.094
Burns et al. (1967) No AMP vs. PBO Learning Task -1.226 0.555 0.308 -2.313 -0.139 -2.211 0.027
Kornetsky (1958) No AMP vs. PBO SLT -0.100 0.126 0.016 -0.346 0.146 -0.799 0.424
Makris et al.(2007) No AMP vs. PBO RA 0.531 0.209 0.043 0.122 0.939 2.544 0.011
Schlösser et al. (2009) No MPH vs. PBO Probabalistic Decision-Making Task 0.100 0.149 0.022 -0.191 0.392 0.676 0.499
van der Schaaf et al. (2013) No MPH vs. PBO Reversal Learning 0.385 0.160 0.026 0.071 0.698 2.402 0.016
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Meta Analysis
Meta Analysis
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Outlier Evaluation 
Studies with effect sizes falling outside 3 standard deviations (SD = 0.370) of 
the mean (g < -0.945 or g > 1.275) were examined as potential outliers. Only one 
study met these criteria (Burns et al., 1967, described previously), with a mean effect 
size of g = -1.226. When this study was removed from the analysis, the mean effect 
size was increased to g  = 0.237 (SE = 0.130, 95% CI [-0.017, 0.492], p = .068) from 
the original mean effect size of g = 0.165. Considering the low number of studies (k = 
6) investigating the effects of ADHD medication on non-declarative learning and 
memory, a decision to maintain this study was made. 
Publication Bias 
Because the p-value for observed studies was not significant under the mixed 
effects model and approached p = .05 under the fixed effects model, Rosenthal’s N 
was calculated to be 0. Based on Orwin’s N, 3 studies with effect sizes of g = 0.0 
would reduce the mean effect size to g = 0.10. Trim and fill analysis did not suggest 
the imputation of any studies. Egger’s regression was not significant (B = -0.221, SE = 
2.224, t(4) = 0.099, 95% CI [-6.397, 5.954], p = .463) represented by the symmetry 
shown in the funnel plot (see Figure 20). These findings suggest minimal publication 
bias, but consistently small effect sizes. 
  
  175
 
Figure 20 
Funnel Plot with Observed Studies for Non-declarative Learning and Memory 
 
 Moderator Analyses 
 The small sample size included for non-declarative memory (k = 6) precluded 
the investigation of moderators. Therefore, moderator analyses were not conducted. 
Missing Data 
 Two studies missing critical data for the calculation of effect sizes were 
excluded from the analysis involving the effects of ADHD medication on 
neurocognitive enhancement of non-declarative memory (see Appendix C). One study 
reported findings that were mixed and one study reported non-significant findings. 
Summary of Neurocognitive Enhancement of Narrow Constructs of Learning 
and Memory 
Table 28 displays the mean effect sizes for ADHD medication on learning and 
memory immediate and delayed combined, as well as for each underlying construct 
individually (declarative memory that was measured immediately after learning, with 
short delays after learning or with long-term delays after learning, as well as non-
declarative learning and memory). Results suggest that effect sizes for declarative and 
-2.0 -1.5 -1.0 -0.5 0.0 0.5 1.0 1.5 2.0
0.0
0.1
0.2
0.3
0.4
0.5
0.6
St
an
da
rd
 
Er
ro
r
Hedges's g
Funnel Plot of Standard Error by Hedges's g
  176
 
non-declarative memory measured immediately after or with a short-delay after 
learning resulted in small effect sizes. Effect sizes for memory measured with long-
term delays (between 1 day and 2 weeks), however, resulted in effect sizes considered 
medium in size according to Cohen’s convention. 
Table 28 
Summary of ADHD Medication and Learning & Memory Findings 
Outcome k Model g 95% CI p Q (df) 
LCL UCL 
Overall 
(Immediate & 
Delayed Only) 
24 Fixed 0.082 0.023 0.192 .006 49.139
*
 
(23) 
 Random 0.104 0.015 0.192 .021  
Declarative - 
Immediate 
18 Fixed 0.124 0.063 0.186 <.001 59.878
*
 
(17) 
 Random 0.106 -0.000 0.212 .051  
Declarative - 
Delayed 
12 Fixed 0.077 0.001 0.153 .047 24.861
* 
(10) 
 Random 0.126 -0.005 0.256 .060  
Declarative - 
Long-term 
9 Fixed -0.072 -0.094 -0.049 <.001 92.253
** 
(8) 
 Random 0.499 0.183 0.815 .002  
Non-declarative 6 Fixed 0.145 0.001 0.290 .048 
17.128* 
(5) 
 Random 0.165 -0.132 0.461 .277  
Notes. * p < .01; ** p < .001. 
Neurocognitive Enhancement of Narrow Constructs of Executive Function 
Neurocognitive Enhancement of Planning and Decision-Making 
Data were extracted from 5 studies, resulting in a total of 153 participants, 
investigating the neurocognitive effects of ADHD medication on planning and 
decision-making. Studies explored the effects of MPH (k = 5) among adults with (k = 
2) and without (k = 3) ADHD. Table 29 displays the descriptive data and mean effect 
sizes (Hedge’s g) from each of the 5 studies. Both a fixed and random effects model 
resulted in a mean effect size of g =0.024 that was not significantly different than zero 
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(SE = 0.093, 95% CI [-0.158, 0.207], p = .795), with effect sizes ranging from g =  -
0.363 to g = 0.197. The heterogeneity of variance analysis was not significant, Q(4) = 
2.987, p =.560. 
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Table 29 
ADHD Medication Neurocognitive Effects on Planning and Decision-Making and Mean Results
 
 
Notes. IGT = Iowa Gambling Task; MPH = Methylphenidate; PBO = Placebo; NTOL = Tower of London Spatial Planning 
Task. 
Study name ADHD Comparison Outcome Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
Agay et al. (2010) Yes MPH vs. PBO IGT 0.069 0.336 0.113 -0.590 0.728 0.205 0.838
Agay et al. (2014) Yes MPH vs. PBO IGT -0.014 0.212 0.045 -0.430 0.402 -0.068 0.946
Elliott et al. (1997) No MPH vs. PBO NTOL 0.197 0.157 0.025 -0.112 0.505 1.251 0.211
Linssen et al. (2012) No MPH vs. PBO NTOL -0.051 0.173 0.030 -0.390 0.288 -0.295 0.768
Turner, Robbins, Clark, Aron, Dowson, & Sahakian (2003) No MPH vs. PBO NTOL; IGT -0.363 0.311 0.097 -0.973 0.247 -1.165 0.244
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Meta Analysis
Meta Analysis
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Outlier Evaluation 
Studies with effect sizes falling outside 3 standard deviations (SD = 0.208) of 
the mean (g < -0.599 or g > 0.648) were examined as potential outliers. None of the 
studies met these criteria; therefore, effect sizes from all studies were maintained. 
Publication Bias 
Because the mean effect size for planning and decision-making approached 
zero and the p-value for observed studies was not significant (p = .974), Rosenthal’s N 
was calculated to be 0. Based on Orwin’s N, 7 studies with effect sizes of g = 0.0 
would reduce the mean effect size to g = 0.01 (an estimate chosen given the mean 
effect size was approaching zero, g = 0.024). Trim and fill analysis did not suggest the 
imputation of any studies to account for positive bias; however, 1 study was suggested 
for imputation to account for negative bias. Egger’s regression was not significant (B 
= -1.602, SE = 1.296, t(3) = 1.236, 95% CI [-5.726, 2.523], p = .152) represented by 
the symmetry shown in the funnel plot (see Figure 21). These findings suggest 
minimal publication bias, but consistently small effect sizes. 
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Figure 21
 
Funnel Plot with Observed Studies for Planning and Decision-Making 
 
Moderator Analyses 
 The small sample size included for planning and decision-making (k = 5), as 
well as the non-significant findings from the homogeneity of variance analysis, 
precluded the investigation of moderators. Therefore, moderator analyses were not 
conducted. 
Missing Data 
 No studies were excluded from the analysis involving the effects of ADHD 
medication on neurocognitive enhancement of planning and decision-making due to 
insufficient data. 
Neurocognitive Effects of Self-Regulation 
Data were extracted from 15 studies, including a total of 556 participants, that 
investigated the neurocognitive effects of ADHD medication on self-regulation. 
Studies were conducted across populations of adults with ADHD (k = 3) and without 
ADHD (k = 12), examining the effects of AMP (k = 8), MPH (k =  6), and ATX (k = 
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1). Table 30 displays the descriptive data and ES estimates (Hedge’s g) from each of 
the 15 studies. The studies generated a statistically significant mean effect size of g 
=0.139 (SE = 0.059, 95% CI [0.023, 0.254], p = .0019with effect sizes ranging from g 
= -0.160 to g = 0.798. A fixed effects model yielded findings with a slightly reduced 
mean effect size (g = 0.108, SE = 0.033, 95% CI [0.043, 0.173], p = .001). The 
heterogeneity of variance analysis indicated significant between-study variance, Q 
[14] = 35.217, p =.001. 
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Table 30 
ADHD Medication Neurocognitive Effects on Self-Regulation and Mean Results 
 
Notes. AMP = Amphetamine; ATX = Atomoxetine; COWAT = Controlled Oral Word Association Test; IDED = Intra-
Extra Dimensional Set-Shift Task; MPH = Methylphenidate; PBO = Placebo; RAT = Remote Associations Task; WCST = 
Wisconsin Card Sorting Test. 
Study name ADHD Comparison Outcome Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
Chamberlain et al. (2007) Yes ATX vs. PBO IDED 0.149 0.161 0.026 -0.167 0.464 0.924 0.355
Clatworthy et al. (2009) No MPH vs. PBO Reversal Learning -0.026 0.196 0.038 -0.410 0.358 -0.133 0.894
Elliott et al. (1997) No MPH vs. PBO IDED; Verbal Fluency Test" -0.160 0.156 0.024 -0.465 0.145 -1.030 0.303
Farah et al. (2009) No AMP vs. PBO RAT; Embedded Figures; AUT; Draing Task 0.084 0.106 0.011 -0.124 0.292 0.792 0.428
Fleming et al. (1995) No AMP vs. PBO WCST; COWAT 0.092 0.160 0.026 -0.221 0.406 0.578 0.564
Ilieva et al. (2013) No AMP vs. PBO RAT; Embedded Figures 0.157 0.074 0.005 0.013 0.301 2.131 0.033
Linssen et al. (2012) No MPH vs. PBO IDED 0.256 0.205 0.042 -0.147 0.658 1.244 0.213
Mattay et al. (1996) No AMP vs. PBO WCST 0.082 0.206 0.043 -0.322 0.487 0.399 0.690
Rogers et al. (1999) No MPH vs. PBO IDED 0.016 0.341 0.116 -0.652 0.684 0.047 0.963
Samanez-Larkin et al. (2013) No AMP vs. PBO Switch Cost 0.798 0.154 0.024 0.496 1.099 5.189 0.000
Taylor & Russo (2000) Yes AMP vs. PBO COWAT 0.384 0.140 0.020 0.108 0.659 2.732 0.006
Taylor & Russo (2001) Yes AMP vs. PBO COWAT 0.165 0.139 0.019 -0.108 0.437 1.185 0.236
Turner et al. (2003) No MPH vs. PBO IDED 0.155 0.308 0.095 -0.450 0.759 0.501 0.616
van der Schaaf et al. (2013) No MPH vs. PBO Reversal Learning Shift -0.017 0.152 0.023 -0.315 0.281 -0.110 0.913
Wardle et al. (2013) No AMP vs. PBO WCST -0.049 0.065 0.004 -0.178 0.079 -0.751 0.452
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Meta Analysis
Meta Analysis
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Outlier Evaluation 
Studies with effect sizes falling outside 3 standard deviations (SD = 0.228) of 
the mean (g < -0.546 or g > 0.824) were examined as potential outliers. No studies met 
these criteria; therefore, effect sizes from all 15 studies were maintained in the 
analyses concerning self-regulation. 
Publication Bias
 
Analysis of publication bias indicated minimal risk with a Rosenthal’s N of 34 
to lead to a p-value at or above an alpha of .05 and Orwin’s N of 5 to reduce the effect 
size to g = 0.10. Trim and fill analysis did not suggest the imputation of any studies 
and Egger’s regression was not significant (B = 0.854, SE = 0.973, t(13) = 0.878, 95% 
CI [-1.248, 2.957], p = .198). Additionally, the symmetry shown in Figure 22 suggests 
the risk for publication bias was minimal.  
Figure 22 
Funnel Plot with Observed Studies for Self-Regulation 
 
 Moderator Analyses 
 Because the homogeneity analysis was significant, moderator analyses 
including variables identified a priori were conducted. ANOVA analog revealed 
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differences on a trend level (p < .10) between studies that utilized counterbalancing of 
treatment conditions (k = 5, g = 0.035, SE = 0.057, 95% CI[-0.078, 0.147]) and studies 
that did not report counterbalancing (k = 10, g = 0.217, SE = 0.086, 95% CI[0.048, 
0.387]), Q(1) = 3.099, p = .078. Homogeneity analyses indicated significant 
heterogeneity between studies that did not report counterbalancing treatment 
conditions, Q(9) = 20.855, p = 0.013; significant heterogeneity was not revealed for 
studies that did report counterbalancing methods, Q(4) = 6.234, p = .182. No other 
significant moderator variables were revealed with ANOVA analog or meta-
regression. Note that number of years of education was not analyzed in these analyses 
due the low number of studies reporting this variable (k = 2). 
Missing Data 
 Three studies with insufficient data for calculation effect sizes were excluded 
from the analysis involving the effects of ADHD medication on neurocognitive 
enhancement of self-regulation (see Appendix C). Findings from these studies 
indicated results that were non-significant. 
Summary of Neurocognitive Enhancement of Narrow Constructs of Executive 
Function 
Table 31 displays the mean effect sizes for the effects of ADHD medication on 
executive function overall, as well as its effects on the underlying constructs of 
executive function (planning and decision-making and self-regulation). Mean effect 
sizes resulting from measures of self-regulation were small, but mean effect sizes from 
measures of planning and decision-making approached zero. 
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Table 31 
Summary of ADHD Medication and Executive Function Findings 
Outcome k Model g 95% CI p Q (df) 
LCL UCL 
Overall 17 Fixed 0.106
 0.042 0.170 <.001 32.844* (16) 
 Random 0.127 0.024 0.230 .005  
Planning 
and 
Decision 
Making 
5 Fixed 0.024 -0.158 0.207 .795 2.987 (4) 
 Random 0.024 -0.158 0.207 .795  
Self-
Regulation 
15 Fixed 0.108 0.043 0.173 <.001 35.217* (14) 
 Random 0.139 0.023 0.254 .019  
Notes. * p < .01; ** p < .001. 
 
Summary of Neurocognitive Enhancement of All Cognitive Constructs 
Table 32 displays the mean effect sizes resulting from the random effects model for all 
cognitive constructs. Mean effect sizes were small for cognition, as well as the broad 
cognitive constructs of abilities of focused behavior, learning and memory, and 
executive function. Small effect sizes were also found for inhibitory control, working 
memory, processing speed, declarative learning and memory (immediate and delayed), 
and self-regulation. Vigilance, non-declarative memory, and planning and decision-
making resulted in mean effect sizes that were not significantly different from zero.  
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Table 32 
Summary of ADHD Medication and All Cognitive Constructs Under Random Effects 
Model 
Outcome k g 95% CI p 
LCL UCL 
Cognition Overall 91 0.147 0.095 0.199 <.001 
Abilities of Focused Behavior 74 0.140 0.094 0.186 <.001 
Vigilance 24 0.047 -0.055 0.128 .434 
Inhibitory Control 43 0.164 0.094 0.235 <.001 
Working Memory 32 0.068 0.014 0.123 .014 
Processing Speed 18 0.195 0.077 0.313 .001 
Learning & Memory (Immediate & 
Delayed Only) 24 0.104 0.015 0.192 .021 
Declarative - Immediate 18 0.106 -0.000 0.212 .051 
Declarative - Delayed 12 0.126 -0.005 0.256 .060 
Declarative - Long-term 9 0.499 0.183 0.815 .002 
Non-declarative 6 0.165 -0.132 0.461 .277 
Executive Function 17 0.127 0.024 0.230 .005 
Planning and Decision Making 5 0.024 -0.158 0.207 .795 
Self-Regulation 15 0.139 0.023 0.254 .019 
Notes. * p < .01; ** p < .001. 
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CHAPTER 6: Discussion 
 The primary indications for ADHD prescription stimulant medication are for 
the reduction of ADHD symptoms (impulsivity, hyperactivity, inattention), for 
individuals diagnosed with ADHD. Yet, an increasing number of college students, 
both with and without ADHD, have reported misusing these medications to enhance 
their academic functioning. Previous research examining the effects of ADHD 
medication on cognition has typically relied on small sample sizes and yielded mixed 
results. Therefore, the present study conducted 14 meta-analyses (k = 91) to explore 
the potential for ADHD medication as a neurocognitive enhancer, as well as 
influencing factors associated with its neurocognitive effects.  
Summary of Predictions 
Neurocognitive Enhancement Effects 
The first hypothesis that medications for the treatment of ADHD would 
demonstrate general positive effects on cognition was partially supported. When 
abilities of focused behavior (vigilance, inhibitory control, working memory, and 
processing speed), learning and memory (declarative and non-declarative), and 
executive function (planning and decision-making and self-regulation) were averaged 
together, a significant effect size for neurocognitive enhancement from ADHD 
medication was revealed (g = 0.15). This effect size is considered small based on 
Cohen’s convention and the effect sizes reported in the literature for ADHD 
medication efficacy. ADHD medication for neurocognitive enhancement among adults 
with and without ADHD, however, is not directly comparable to its use for ADHD 
symptoms. Although small, these effects are notable for their overall improvement in 
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cognitive performance, suggesting that ADHD medication may indeed enhance 
cognition in adults with and without ADHD. These overall general neurocognitive 
effects, however, appear to vary across cognitive constructs and may have been 
influenced by publication bias. Therefore, the findings suggest that ADHD medication 
may act as a neurocognitive enhancer for some but not all areas of cognition. 
Abilities of Focused Behavior 
ADHD medication appears to have a small, positive effect on abilities of 
focused behavior (g = 0.15). In particular, prescription stimulant medication showed 
consistent and positive effects for reducing impulsivity (inhibitory control, g = 0.16) 
and increasing processing efficiency (g = 0.20). Findings also revealed very small 
medication effects for improving working memory (g = 0.07). These findings are 
similar to those reported by previous meta-analyses and reviews (Ilieva et al., 2015; 
Linssen et al., 2014; Smith & Farah, 2011). It is important to note, however, that 
symptoms of ADHD are not necessarily associated with processing speed or working 
memory (Lovett & Leja, 2015). Therefore, the finding that ADHD medication holds 
potential for enhancing processing speed memory is a benefit that may fall outside the 
scope of its indications as a treatment for ADHD symptoms. 
The effects of ADHD medication on sustained attention, however, did not 
result in overall improvements (g = 0.03). This finding is somewhat surprising 
considering the extensive literature base documenting the efficacy of ADHD 
medication for the reduction of ADHD symptoms that include attention and focus (e.g. 
Faraone, 2012; Faraone & Biederman, 2002; Faraone & Buitelaar, 2010; Faraone and 
Glatt, 2010). This finding may indicate that the neurocognitive benefits of ADHD 
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medication for focused behaviors may hinge on some of the former constructs, most 
likely inhibitory control. An alternative explanation, however, is that the minimal 
effects on sustained attention were the result of ceiling effects in the related tasks, 
something that has been suggested to occur on tests of attention and inhibition 
(Chamberlain et al., 2006; Chamberlain et al., 2007; Costa et al., 2013; Wöstman et 
al., 2013). 
Learning and Memory 
ADHD medication resulted in small improvements in learning measured 
immediately or with a short delay following learning, with the present study revealing 
a significant and small effect size resulting from 23 studies (g =0.10). Although 
qualified by publication bias, results related to the narrow construct of long-term 
learning and memory indicated the potential for ADHD medication to improve 
memory retrieval days following medication administration and learning. In particular, 
findings from the present study support previous research (Advokat, 2010; Ilieva et al., 
2015; Smith & Farah, 2011) that has found that stimulants are most effective for 
enhancing memory consolidation, as opposed to encoding or retrieval.  
While declarative memory that was measured immediately after learning (i.e., 
within 20 minutes) or measured at a delayed time-point within the same day of 
learning (i.e., after 20 minutes within 1 day) resulted in small effects that approached 
statistical significance (g = 0.11, g = 0.13, respectively), declarative memory that was 
measured longer than a day after learning resulted in a significant medium effect size 
(g = 0.50). In sum, it appears that peak effects of ADHD medication may be especially 
beneficial for consolidation, resulting in improved retention in the days following 
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encoding; however, this finding should be interpreted cautiously given the high risk of 
publication bias. 
Regarding non-declarative memory, i.e., procedural and probabilistic learning 
that was gradual and unconscious, the present study’s findings support previous 
research (Smith & Farah. 2011) indicating mixed effects from ADHD medication. 
Unfortunately, few studies have explored non-declarative memory (k = 6) and nearly 
all of them have relied on measures of learning rates or reaction times, as opposed to 
learning consolidation or accuracy. Only two studies (Schlösser et al., 2009; van der 
Schaaf et al., 2013) examined measures of error or accuracy. Schlösser et al. (2009) 
reported significant effects for RT but not error (calculated to g  = 0.22 and g = -0.02, 
respectively), implicating an improvement in processing speed, but not necessarily 
learning. The other study, conducted by van der Schaff and colleagues (2013) resulted 
in a significant and small effect size (g = 0.21) for accuracy. Although the present 
study’s results suggested that ADHD medication has small effects (g = 0.16) on non-
declarative learning, this preliminary research may reflect small improvements in 
speed of processing. Furthermore, findings were not significantly different than an 
effect size of zero; however, this finding most likely reflects the small sample size (k 
= 6) included for non-declarative learning and memory. 
Executive Function 
A particularly interesting question that has been raised in the literature 
(Advokat, 2010; Smith & Farah, 2011) regarding prescription stimulants as 
neurocognitive enhancers is even if positive benefits are associated with prescription 
stimulant use in some areas of cognition, could they also be associated with 
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impairments of other components of cognition such as creativity and flexibility? 
Results from the present study suggest that ADHD medication does not impair 
executive function, at least for the component of self-regulation (cognitive flexibility, 
verbal fluency, and creativity). Indeed, findings from the present study actually 
supported small benefits of ADHD medication for abilities of self-regulation (g = 
0.14).  
The significant and small mean effect size concerning self-regulation provides 
preliminary support for Smith and Farah’s (2011) conclusion that prescription 
stimulants have a positive effect on cognitive control, a similar construct to self-
regulation that refers to regulation of cognitive processes in everyday situations that 
are not necessarily natural or intuitive. In particular, the authors explained that these 
effects were most robust for participants with lower overall scores, participants who 
had the catechol-O-methtransferase (COMT) genotype related to poorer executive 
function, or participants who reported difficulty with impulsivity. Similarly, Farah and 
colleagues (2009) reported that among healthy adults, those with lower baseline 
creativity actually received creative benefits from prescription stimulants. While the 
present study examined creativity in conjunction with other abilities of self-regulation, 
i.e., verbal fluency and cognitive flexibility, the results do support Farah’s conclusion. 
In fact, only 3 of the 15 studies measuring self-regulation resulted in negative effect 
sizes, and only 1 of these studies utilized measures related to creativity; the other 
studies examined flexibility and verbal fluency. 
A similar question concerns ADHD medication effects on planning and 
decision-making – do prescription stimulants lead to difficulty with planning or poorer 
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decision-making? Agay and colleague’s (2010) findings shed some light on this 
question, where for adults with ADHD, MPH was shown to have minimal to no 
effects on planning and decision-making (g = 0.069), but for adults without ADHD, 
MPH had negative effects (g = -0.240). Agay et al.’s 2014 study also found effects for 
adults with and without ADHD that were close to zero; however, results indicated a 
negative effect for both groups (g = -0.014 and g  = -0.175, respectively). The present 
study also found that ADHD medication had minimal to no effects on planning and 
decision-making (g = 0.024), although this finding is limited by the small number of 
studies examining this outcome (k = 5). While these results do not implicate any 
benefits for planning and decision-making from ADHD medication, they are notable 
in that these medications do not appear to impair these abilities. This finding is 
significant for college students taking prescription stimulants for enhancement of 
studying material that may require more complex thoughts and decisions. It also has 
significant implications for students taking prescription stimulants to “party,” “stay 
awake to party,” or “get high,” an additional motivation for stimulant misuse 
(Weyandt et al., 2013). These students may be engaging in other risky behaviors (e.g., 
drugs and alcohol) and it would be very concerning if these medications appeared to 
worsen their ability to make decisions.  
Medication Dose 
To test the second hypothesis – that higher doses of ADHD medication would 
result in greater effects – doses were coded as either “low” or “high.” Contrary to this 
hypothesis, dose level was not significant for the majority of analyses, indicating that 
variability of effects were not significantly influenced by level of medication dose. 
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Three exceptions to this finding, however, indicated differences between dose level for 
the narrow constructs of declarative learning and memory – delayed and inhibitory 
control, as well as the broad construct of abilities of focused behavior. Findings 
suggest that when there were differences between dose levels, lower doses of 
medication resulted in the greatest gains.  
It is possible that dose level was not a significant variable in the majority of 
analyses due to the averaging of doses and effect sizes across studies investigating the 
neurocognitive enchaining effects of multiple doses of ADHD medication. 
Specifically, effect sizes were averaged across doses for 17 of the included studies 
(although 2 studies only reported results with doses averaged together), which may 
have mitigated some of the effects of higher medication doses compared to lower 
doses. To explore this possibility, effect sizes for each dose in studies reporting 
multiple doses were calculated for cognition. Ideally differences between dose levels 
reported in each study would be assessed with ANOVA analog; however, 
approximately half of the studies reported a range of doses that all fell within the 
category of “low” leaving only a small number of studies available for comparison. 
Instead, effect sizes are displayed in Table 33 according to study and results for each 
dose. Visual inspection indicates that differences between effect sizes by dose were 
mixed, some were larger for higher doses compared to lower ones (e.g., Ward et al., 
1997; Wardle et al.), others were equivocal (e.g., Ballard et al., 2014), and a few were 
smaller for higher doses compared to lower ones (e.g., Idestrom & Schalling, 1970). 
When viewing only those studies that included low doses and high doses meeting 
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criteria for the current study’s conventions of low and high doses (shown with an 
asterisk in Table 33), results still appear mixed. 
Instead, this finding may support dose level effects following a U-shaped 
pattern, where the lowest and highest doses proffer the lowest effects and medium 
doses result in the most benefits. Indeed, a recent review indicated that for MPH, a U-
shaped pattern emerged for effects on working memory (Linssen et al., 2014). Yet the 
same review indicated that the most effective dose levels varied according to cognitive 
outcome. Specifically, optimal doses of MPH for processing speed were the lowest 
doses, for verbal learning and memory optimal doses followed a linear trend, and for 
reasoning and problem solving they were the highest doses (Linssen et al., 2014).  
A final, but related explanation for the equivocal findings across dose levels 
relates to variability across individuals. For example, medication is most effective 
when titrated according to individual assessment (Coghill et al., 2013) and some 
individuals appear to perform better with lower doses compared to higher ones. The 
same effect may be true for cognition.  
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Table 33 
Study Effect Sizes by Dose(s) 
Study  Constru
ct 
Dose A Dose B Dose C 
Dose  g SE Dose  g SE Dose  g SE 
Ballard et 
al. (2013) AMP* L&M 10-mg  0.260 0.133 20-mg  0.294 0.134    
Ballard et 
al. (2014) AMP* L&M 10-mg  -0.085 0.117 20-mg  -0.056 0.117    
Barkley et 
al. (2005) MPH AFB 10-mg 0.042 0.146 20-mg 0.164 0.147    
DuPaul et 
al. (2012) LDX* 
AFB; 
L&M 30-mg 0.087 0.174 50-mg 0.174 0.177 70-mg 0.052 0.177 
Fillmore et 
al. (2005) AMP AFB 7.5-mg 0.266 0.207 15-mg 0.197 0.204    
Ideström & 
Schalling 
(1970) 
AMP AFB; EF 5-mg -0.126 0.147 15-mg -0.002 0.145    
Kinsbourne 
et al. 
(2001) 
MPH L&M 5-mg 0.311 0.209 10-mg 0.204 0.206 20-mg 0.213 0.206 
Kollins et 
al. (2015) MPH* 
AFB; 
EF 10-mg -0.048 0.232 40-mg 0.042 0.231    
Kornetsky 
(1958) AMP 
AFB; 
L&M 5-mg -0.117 0.133 10-mg -0.106 0.133    
Linssen et 
al. (2011) MPH* PS 10-mg 0.203 0.105 20-mg 0.357 0.108 40-mg 0.600 0.113 
Linssen et 
al. (2012) MPH* 
AFB; 
EF 10-mg 0.014 0.232 20-mg 0.004 0.228 40-mg 0.092 0.214 
Makris et 
al. (2007) AMP 
AFB; 
L&M 
0.035-
mg/kg 0.212 0.146 
0.07-
mg/kg 0.225 0.150 
0.14-
mg/kg 0.252 0.136 
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Study  Constru
ct 
Dose A Dose B Dose C 
Dose  g SE Dose  g SE Dose  g SE 
Rapoport et 
al. (1980) AMP* AFB 
0.25-
mg/kg -0.24 0.252 
0.50- 
mg/kg 0.164 0.259    
Turner et 
al. (2003a) MPH* 
AFB; 
EF; 
L&M; 
20-mg -0.026 0.310 40-mg 0.150 0.310    
Ward et al. 
(1997) AMP AFB 5-mg 0.661 0.580 10-mg 0.930 0.600    
Wardle et 
al. (2013) AMP* 
AFB; 
EF 5-mg -0.042 0.072 10-mg 0.057 0.072 20-mg 0.141 0.072 
Notes. * = Study included doses falling in both categories of “low” and “high” according to the present study’s conventions.
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Timing of Medication Activation 
To investigate the third hypothesis – that the relationship between prescription 
stimulant, prostimulant, and nonstimulant ADHD medication and cognition would 
vary according to timing of dose, with activation of stimulant during learning 
processes yielding greater effects than activation at other times among adults with and 
without ADHD – studies were coded conducting assessments prior to, during, or after 
peak effects of medication would normally occur. Significant differences were not 
found among studies for timing of dose activation for the majority of cognitive 
constructs. For the narrow construct of inhibitory control, however, studies where 
medication was active prior to assessment resulted in significantly smaller effect sizes 
compared to studies where medication was active during assessment and studies that 
did not report the timing of activation. However, note that only 5 studies administered 
medication so it was active prior to learning that included inhibitory control as an 
outcome variable.  
These findings are likely the result of low variability in timing of dose, which 
is related to the inclusion of studies with high quality research designs. The vast 
majority of studies (k = 54) were coded as medication having peak effects during 
assessments. The other studies, 11 of which were coded as peak effects occurring after 
assessment and 17 of which prior to assessment, reported timing of learning and/or 
assessment that was close to being considered as occurring during peak effects. 
However, an additional explanation relates to the duration of stimulant effects. For 
example, although LDX demonstrates clinically significant effects within 2 hours, it 
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has been shown to be effective for as long as 13 hours (Biederman et al., 2007; Heal, 
Cheetham & Smith, 2009). 
Medication Activation Type 
Findings from the present study support the hypothesis that the relationship 
between prescription stimulant, prostimulant, and nonstimulant ADHD medication 
and cognition would be consistent across medication activation types (short-acting, 
medium-acting, or long-acting medications) among adults with and without ADHD. 
No differences that were clinically relevant were found between studies investigating 
short-acting (k = 83) compared to studies investigating medium or long-acting (k = 8) 
medication effects on cognition in general, or for abilities of focused behavior, 
learning and memory, and executive function. This finding is consistent with the 
literature examining the efficacy of ADHD medication, which suggests that a variety 
of medication activation types offer significant effects (Kooij et al., 2010). It should be 
noted, however, that the vast majority of studies investigated the cognitive effects of 
short-acting agents, limiting the validity of these findings.  
Baseline Cognitive Functioning 
The hypothesis that prescription stimulant, prostimulant, and nonstimulant 
medication ADHD effects on cognition would demonstrate a negative relation with 
baseline cognitive functioning of adults with and without ADHD was not supported in 
the present study. However, it is important to note that this hypothesis was more 
difficult to test than other hypotheses in the present study and merits further 
investigation. Only 3 of the 91 studies included in this study presented results 
separately for groups demonstrating lower and higher performance on cognitive 
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outcomes prior to medication administration. The results from these studies suggested 
that adults with lower cognitive baseline scores may experience more cognitive 
benefits from ADHD medication compared to adults with higher scores. Faraone and 
colleagues (2005) examined the effects of ATX on executive function in adults with 
ADHD over a ten-week treatment period and reported significant differences between 
placebo and treatment for adults with ADHD scoring below the normative mean for 
the Stroop-color word test at baseline, but not for adults with ADHD who scored 
above the mean at baseline. These differences resulted in effect sizes of g = 0.160 and 
g = -0.064, respectively. Finke at el. (2010) also assessed differences between adults 
scoring low and high at baseline, in this case examining the effects of MPH and 
modafinil on healthy adult’s visual processing speed. Participants scoring below the 
sample’s median were categorized as “low” and those scoring above the median were 
categorized as “high.” Similar to the previous study, significant differences were only 
found for the participants considered to be low at baseline between placebo and 
medication and not for participants considered to be high at baseline. Unfortunately, 
data were only reported for significant results so effect sizes between the two groups 
could not be compared; however effect sizes that were large in size for visual 
processing speed (g = 1.214) and small for visual short-term memory (g = 0.215) were 
calculated for participants performing low at baseline.  
A number of additional studies did not report sufficient descriptive data for the 
calculation of effect sizes, but investigated the differing effects of prescription 
stimulants for cognition taking into account participant cognitive baseline functioning. 
Although data were not reported separately for participants with low and high 
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cognitive baseline scores, Agay et al. (2014) also found that adults with and without 
ADHD who scored lower at baseline received the greatest benefits from MPH. 
Additionally, the effect of MPH on associative learning showed impairments for 
participants with high baseline working memory and benefits for participants with low 
baseline working memory in another study (van der Schaaf et al., 2013). Whiting et al. 
(2008), however, reported that improved word recognition and recall occurred for 
participants irrespective of baseline neuropsychological performance. 
Implications from a recent study using PET scans to measure the effects of 
MPH on brain glucose metabolism supported these findings and may help explain 
their mechanism of action. Findings suggested that MPH intake was associated with 
attenuated brain metabolism increases instigated by cognitive tasks, i.e. facilitating the 
focus of attentional resources during cognitive task, and that the largest effects were 
found for participants demonstrating the lowest brain metabolism at baseline. 
Participants with the lowest metabolic activation at baseline (indicating “optimal 
focusing”), however, made the fewest cognitive gains (Volkow et al., 2008). These 
results suggest that MPH may proffer the greatest benefits to individuals with baseline 
impairments or attention problems.  
Studies investigating the influence of genetic variants related to the val158met 
polymorphism of the catechol-O-methtransferase (COMT) genotype gene on ADHD 
medication cognitive effects have provided further insight on differences in cognitive 
baseline, but have demonstrated mixed results (Mattay et al., 2003; Wardle et al., 
2013). Findings from Mattay et al. (2003) also support a U inverted hypothesis where 
individuals with the COMT met/met gene appeared to exhibit higher baseline function, 
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resulting in impairments related to AMP, compared to individuals with the COMT 
val/val gene who exhibit lower baseline function and may benefit most from AMP. 
Similar to Volkow et al. (2008), this study found that for individuals with the val/val 
gene, AMP improved cognitive efficiency as evidenced by a reduced activity in brain 
regions associated with working memory. A replication of this study (Wardle et al., 
2013), however, did not support this finding and reported no significant interaction 
between COMT and AMP effects on performance on the WCST and n-back. 
Because baseline functioning specific to each cognitive variable was not 
available to test as a moderator, global measures of cognitive functioning at baseline 
were tested as potential moderators to further examine this hypothesis. Eighteen 
studies reported results that included a global measure of cognitive functioning prior 
to medication administration, but meta-regression did not reveal overall cognitive 
functioning as a significant moderator variable for cognition in general or for any of 
the broad constructs of cognition. Among the 8 studies reporting global intelligence 
scores that examined a measure of the narrow construct of vigilance, however, a 
significant trend was revealed where larger effect sizes were associated with higher 
scores of cognitive functioning. This finding may have occurred because of the limited 
variability among studies reporting of cognitive functioning, i.e., mean scores fell at or 
above the 70th percentile for all studies and many studies excluded participants with 
mean scores falling below average or low average.  
Future research should explore group differences between adults with lower 
baseline scores compared to those with higher baseline scores on tests of cognition. If 
only adults scoring low receive cognitive benefits from ADHD medication the vast 
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majority of college students misusing prescription stimulants for academic purposes 
may not actually receive any neurocognitive benefits. This finding would be important 
for developing interventions to prevent and intervene in prescription stimulant misuse 
on college campuses. 
ADHD Status 
The present study’s findings did not support the final hypothesis that the 
relationship between prescription stimulant, prostimulant, and nonstimulant ADHD 
medications and cognition would result in greater benefit for adults with ADHD 
compared to adults without ADHD. Differences between studies examining adults 
with ADHD compared to those examining adults without ADHD were not significant 
for cognition, or when analyzed separately for abilities of focused behavior, learning 
and memory, and EF.  
Considering that ADHD’s defining characteristics include clinically elevated 
levels of inattention and impulsivity, in addition to hyperactivity, the finding that 
effect sizes were equivocal for adults with and without ADHD for abilities of focused 
behavior (encompassing vigilance and inhibitory control) is particularly surprising. 
Yet, even studies exploring differences between adults with and without ADHD 
without medication on other measures of executive function have reported mixed 
results (Advokat, 2010). Specifically, a review investigating the cognitive effects of 
stimulants in adults with ADHD (Advokat, 2010) found that while some studies 
reported no differences between adults with and without ADHD on the NTOL 
(Gropper and Tannock, 2008; Riccio, Wolfe, Romine, Davis & Sullivan, 2004), other 
studies reported deficits among adults with ADHD (McLean et al., 2004; Young, 
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Morris, Toone, & Tyson, 2007). Furthermore, a meta-analysis (Boonstra et al., 2005) 
examining studies comparing differences between adults with ADHD and adults 
without ADHD on measures of executive function did not reveal significant 
differences on measures of vigilance (CPT attentiveness), inhibitory control (CPT 
errors of commission, Stroop Interference scores), processing speed (TMT-A), or 
working memory (TMT-B and DS forwards and backwards). However, adults with 
ADHD performed significantly worse on measures of verbal fluency (d = 0.62) and 
Stroop-Color Word score (d = 0.89), which the present study used to measure 
inhibitory control, but demonstrated significantly lower caution in response style on 
the CPT (d = -0.22). The findings from Boonstra’s study may indicate that differences 
between adults with and without ADHD are even more specific than the constructs 
used in the present study.  
It is also possible that differences between these two populations were 
confounded with differences between studies in general, requiring a more explicit 
examination of the differing neurocognitive effects of ADHD medication for adults 
with and without ADHD. Two studies included in the present study did compare the 
neurocognitive effects of ADHD medication on adults with and without ADHD. 
Specifically, Agay et al. (2010; 2014) included a sample of adults with ADHD and a 
sample of healthy controls in their study investigating the effects of MPH on 
vigilance, working memory and decision-making. While the present study included 
the results from the ADHD group only, when comparing individual results of 
medication effects on cognitive constructs, results appear mixed (see Table 33). 
Indeed, findings specific to Agay et al.’s most recent (2014) study were that regardless 
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of ADHD status, adults with lower cognitive baseline scores proffered the most 
cognitive effects from MPH. Conclusions about direct comparisons between adults 
with and without ADHD based on two studies are premature and further research is 
warranted to investigate any differences for the neurocognitive effects of ADHD 
medication between the two groups. 
Table 33 
Effect Sizes from Studies Including Adults with and without ADHD 
Construct 
Adults with ADHD Adults without ADHD 
Agay et al. 
(2010) 
Agay et al. 
(2014) 
Agay et al. 
(2010) 
Agay et al. 
(2014) 
WM g = 1.018 g = 0.016 g = 0.227 g = 0.250 
V g = -0.002 g = 0.062 g = 0.062 g = 0.170 
PD g = 0.069 g = 0.014 g = -0.240 g = -0.175 
Notes. WM = Working Memory; V = Vigilance; PD = Planning and Decision-Making. 
Additional Moderator Variables 
Even though there was a high degree of variability present among study effects 
– where ADHD medication demonstrated large, positive effects (g = 3.94) and large, 
negative effects (g = -1.23) on cognition – very few of the study’s potential 
moderating variables were significant across cognitive constructs. In particular, none 
of the variables explored as moderator variables for the effects of ADHD medication 
on cognition as a broad category were significant. This finding is consistent with 
previous research that has failed to uncover gender distribution or dose level effects 
across studies examining AMP and MPH effects on inhibitory control and episodic 
memory (Ilieva et al., 2015). When moderator variables were analyzed separately for 
the broad and narrow constructs of cognition, however, a number of meaningful 
variables were significant, shedding light on some of the between-study variability. 
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Study Descriptors and Research Design 
Significant differences were not found for the majority of variables related to 
research design (study design, number of wash-out days between sessions, learning or 
practice effects, and inclusion of non-behavioral measures). In particular, the finding 
that non-behavioral assessments (e.g., fMRI, PET) did not influence the present 
study’s effects is important to consider when comparing results from future studies, 
considering some meta-analyses and reviews (e.g., Coghill et al., 2013) have excluded 
studies with non-behavioral assessments to minimize additional confounding variables 
related to environment.  
Randomization of treatment groups, however, was associated with larger effect 
sizes for abilities of focused behavior. This finding may suggest differences between 
quality of studies. Furthermore, counterbalancing was associated with smaller effect 
sizes for self-regulation, which may reflect the importance of counterbalancing 
treatment conditions for accurate results. However, considering differences between 
counterbalancing status were only found among effect sizes of self-regulation, this 
finding could be an artifact of the small sample sizes within groups.  
It is also important to note that for some of the cognitive constructs (learning 
and memory as a broad construct, as well as declarative learning and memory – long-
term and processing speed), studies that were published more recently resulted in 
larger effect sizes. Indeed, two of the three extreme negative effect sizes identified by 
outlier examinations resulted from studies that were conducted prior to 1970 (Burns et 
al., 1967; Duke & Keeler, 1968). Whether this trend reflects an increase in publication 
bias or an improvement in study quality over the years is unclear. 
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Medication 
The majority of variables related to medication, including number of doses 
administered, medication type, and dose type, were not revealed as significant 
moderators. Note that differences between medication types (stimulant, pro-stimulant, 
or non-stimulant) could not be analyzed in the most analyses due to the low number of 
studies examining pro-stimulants (k = 1) and non-stimulants (k = 5).  
There was some indication, however, for an association between studies that 
administered medication for fewer number of days and larger effect sizes for the broad 
construct learning and memory, as well as the narrow categories of vigilance and 
declarative memory measured immediately after learning. However, these findings 
were limited by low variability (only 10 studies administered medication more than 
one day) precluding conclusions about the effect of prolonged medication use. If 
further research supports the finding that greater medication effects for neurocognitive 
enhancement are associated with single administration methods, college students who 
report misusing ADHD medication for academic reasons may actually benefit from 
infrequent and sporadic use of medication to enhance studying and increase 
performance.  
Regarding the inclusion of other drugs, studies that examined ADHD 
medication alone resulted in larger mean effect sizes for abilities of focused behavior 
than studies that included other drugs (e.g., MPH and psilocybin). This finding has 
meaningful implications for future research investigating the neurocognitive effects of 
prescription stimulants on abilities of focused behavior, suggesting such studies 
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should limit their investigation to ADHD medication. However, significant differences 
between these studies were not shown for any of the other constructs of cognition. 
Recruitment 
For cognition in general, studies that utilized recruitment methods employed 
within the community resulted in larger mean effect sizes than studies that recruited 
participants from universities or clinics for cognition (note that differences only 
approached statistical significance p < .10). However, because this finding was not 
replicated across the broad and narrow level constructs of cognition, these differences 
do not appear meaningful. Interestingly, the reverse finding was true for participant 
and recruitment characteristics’ association with effect sizes pertaining to the narrow 
construct of vigilance. Here, studies that included adult student samples and studies 
that employed recruitment strategies targeting universities resulted in larger effect 
sizes than studies examining other adult populations and studies recruiting within 
community or clinical settings. This finding may be the artifact of inadequate power 
considering the small number of studies examining students and reporting university 
recruitment (k = 4). It is also possible, however, that college and university students 
were less influenced by the ceiling effect associated with tests of attention, i.e., 
students may have had lower baseline scores than other participants. Indeed, the mean 
effect size for vigilance when including all studies was not significant, but the mean 
effect size for vigilance among studies that included students was significant (g = 
0.320, p = .007). It is therefore possible that neurocognitive benefits for vigilance, or 
sustained attention, are unique to college students who may have a higher degree of 
distractions in their environments. 
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Participant Demographics 
For cognition in general, and among the broad constructs of cognition, results 
did not differ by samples of varying ages or gender distributions. These findings 
suggest that prescription stimulants may provide cognitive benefits across populations 
varying in age and gender. However, findings regarding tasks of sustained attention 
suggest that ADHD medication may have greater neurocognitive benefits for younger 
adult males in academic settings. Interestingly, for inhibitory control, older 
populations appeared to benefit more from ADHD medication than younger 
populations. Although definitive conclusions about these findings are precluded by the 
limited variability of age and gender within studies, it is possible these findings also 
reflect differences in baseline functioning. 
Finally, although number of years of education did not emerge as a modifying 
variable for any cognitive constructs, findings were limited by the small number of 
studies reporting this variable (k = 15) and for some of the constructs (e.g., learning 
and memory) this variable could not be included in the meta-regression.  
Implications 
The present study revealed small effect sizes for studies investigating the 
effects of ADHD medication on cognition, but how meaningful are these effect sizes 
in settings outside of the laboratory? In particular, are these effects meaningful for 
college students engaging in illicit stimulant misuse for academic purposes? While 
results from this study cannot directly answer this question, it seems likely that the 
larger effects related to long-term learning and memory indicate these effects could be 
meaningful for college students. In particular, college students taking prescription 
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stimulants 1-3 hours prior to memory consolidation, are probably receiving the 
greatest benefit.  
The consistent and small effect sizes found for ADHD medication effects on 
inhibitory control also suggest that students who struggle with impulsivity may benefit 
from prescription stimulants. This finding is consistent with the literature base 
(Moeller et al., 2001) on characteristics of college students engaging in misuse of 
prescription stimulants, that has found those students more likely to take prescription 
stimulants illegally are also more prone to risk-taking behaviors (e.g., using other 
illegal drugs). It is surprising, however, that effects for inhibitory control were not 
more robust as ADHD medications are well known for yielding behavioral 
improvements associated with reductions in impulsivity, with meta-analyses revealing 
mean effect sizes between g = 0.31 and g = 0.74 for adults with ADHD (Faraone & 
Glatt, 2010). Yet, the present study found only small effects for inhibitory control that 
did not differ across studies investigating populations with and without ADHD. 
Less certainty exists regarding the clinical and educational relevance of some 
of the other variables of cognition, such as working memory, processing speed, and 
self-regulation. While tests of learning and memory are directly comparable to tests 
within academic settings, tests of focused behavior and executive function may be less 
comparable to tasks relevant to academics. The included studies conducted cognitive 
assessments in research laboratories, providing an environment quite unlike one in 
which college students would normally attempt to study, read or write. In fact, 
research accumulated over the past three decades has suggested ADHD medication 
results in minimal to no effects on the overall academic achievement in children with 
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ADHD, even though ADHD medication may increase attention, improve productivity, 
and boost some areas of academic performance (e.g., quizzes, homework completion) 
(Advokat, 2010; Lakhan & Kirchgessner, 2012). For example, among children with 
ADHD there is evidence to suggest prescription stimulant medication is associated 
with improvements in school performance productivity (i.e., permanent product 
measures) (Wigal et al., 2011), but improvements may only result in a 15% increase in 
academic achievement for medicated students compared to unmedicated students with 
ADHD (Gadow, 1983 as cited in Advokat, 2010). Researchers (Gadow, 1983 as cited 
in Advokat, 2010; Swanson et al., 1991 as cited in Advokat, 2010) have hypothesized 
that “cognitive toxicity” may explain the relative improvement in behavior compared 
to the minimal effects on academics, where the optimal doses for behavior 
improvements may be higher than that for academic enhancement and actually impair 
academics. In the college setting, however, preliminary research does not support the 
explanation of “cognitive toxicity,” with studies indicating comparable GPA 
performance of medicated college students with ADHD and unmedicated college 
students with ADHD (Advokat et al., 2011). Instead, research suggests that positive 
study habits, as opposed to ADHD medication, have shown promise for overcoming 
achievement gaps in college students with ADHD compared to those without ADHD 
(Advokat et al., 2011).  
While less is known about the optimal dose of ADHD medication for cognitive 
enhancement, previous research (Linssen et al., 2014) has suggested that for MPH, it 
may vary according to the specific type of cognition. Further, efficacy research 
examining ADHD medication for symptom management suggests it varies across 
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individuals and requires optimization of dose (Coghill et al., 2013; Vitiello, 2008). 
Although findings from the present study did not indicate significant differences 
between low and high doses of ADHD medication for most constructs of cognition, 
the limited variability of medication doses included in the present study precludes any 
definitive conclusions. Furthermore, medication doses included in the present study 
may not reflect the levels of medication college students are misusing. The literature 
on prescription stimulant misuse does not provide an indication of typical dose 
students misuse, but if higher doses could result in cognitive impairments (or worse, 
adverse health outcomes), college students would benefit from safety information and 
efficacy information regarding ADHD medication dose. Future studies investigating 
prescription stimulant effects on tasks involving actual academic assignments (e.g., 
essay composition, calculus problems), comparing doses optimal for behavior 
improvement to lower doses in adult populations would shed light on this issue.  
It is also worth noting that there are a number of interventions being explored 
for their potential as cognitive neuroenhancers that could serve as an alternative to 
ADHD medication. Among these are video games that have shown promise for 
enhancing processing speed (between d = 0.48 to d = 1.47; Dye, Gree, & Bavelier, 
2009) and computerized training programs tailored to improve cognitive abilities (e.g., 
Gist training, employed to improve abstract reasoning and generalize it to everyday 
life and Luminosity, a computerized brain game) (Chapman & Mudar, 2014; Hardy, 
Drescher, & Sarkar, 2011). Exercise has also been shown to benefit enhancement of 
cognition, with a recent meta-analysis revealing significant effect sizes for information 
processing (d = 0.091), attention (d = 0.416) and executive function (d = 0.189) 
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(Chang, Labban, Gapin, & Etnier, 2012). Furthermore, mindfulness practice has been 
demonstrated to relate to improvements in cognitive performance within school 
settings, with studies resulting in large mean effect sizes (g = 0.80) for measures of 
cognition that included attention, creativity, and academic grades (Zenner, 
Herrnleben-Kurz, & Walach, 2014). In light of these findings, some researchers 
(Moreau & Conway, 2013) have even called for the use of “specifically-designed 
sports” that combine movement and cognitive challenges to enhance cognition. While 
the present study’s findings revealed smaller effect sizes from ADHD medication for 
cognitive enhancement than these alternative interventions, the ease of taking a 
medication compared to long-term trainings and programs should not be overlooked. 
Even a small boost in enhancement may be meaningful when applied to an increase in 
a grade for college students (Ilieva et al., 2015), especially considering it can result in 
near immediate effects. 
Physiological Implications 
The present study suggests that prescription stimulants are neurocognitive 
enhancers that proffer small effects. The mechanism by which neurocognitive 
enhancement occurs, however, remains an empirical question. Stimulant use has been 
shown to associate with the normalization of brain activation patterns for adults with 
ADHD and an increase in efficiency of attentional resources for adults with and 
without ADHD (Weyandt et al., 2013). One study hypothesized that the association 
between MPH-induced dopamine increases and mathematical task motivation among 
healthy adults may lead to improvements in attention and performance, suggesting 
task motivation as a mechanism for cognitive benefits (Volkow et al., 2004).  
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Although studies investigating the morphological effects of stimulants among 
humans are scarce, studies conducted on animal models have reported findings that 
may indicate the potential for damage as a result of stimulant use (Weyandt et al., 
2013). For example, studies have reported oxidative brain damage in rats (Urban, 
Warehouse, & Gau, 2012) and synaptic alterations of thalamic nuclei and GABA 
transmission in mice (Goitia et al., 2013; Weyandt et al., 2013). One study (Schouw et 
al., 2013) found that oral administration of MPH was associated with reductions in 
DATS in the striatum, as well as blunted hemodynamic responses, in recreational 
users of d-AMP, indicating that recreational use of d-AMP may lead to DA 
dysfunction. These findings highlight the importance of considering the risk associated 
with prescription stimulant use for cognitive neuroenhancement; even if college 
students misusing prescription stimulants are receiving small neurocognitive benefits, 
they may also be vulnerable to associated dysfunctions.  
Numerous studies have also reported on the extensive side effects and potential 
for adverse outcomes related to ADHD medication (e.g., Heal & Pierce, 2006; Heal et 
al., 2009). The most common side effects induced by ADHD medication may include 
insomnia, appetite loss and anorexia, emotional lability, abdominal cramps, nausea 
and vomiting, dizziness, and nervousness, as well as changes in blood pressure and 
heart rate (Heal & Pierce, 2006; Weyandt et al., 2014). Of particular concern, a meta-
analysis examining appetite suppression as a side effect of MPH (Schachter, Pham, & 
King, 2001) reported that across 62 studies, appetite suppression was observed by 
45% of parents and teachers (Heal & Price, 2006). Given the significant difficulties 
college students experience with healthy eating (Kelly, Mazzeo, & Bean, 2013), the 
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side effect of appetite suppression could have cumulative negative consequences for 
college students. Finally, in a review exploring cardiovascular outcomes related to 
ADHD medication, nearly half of the studies reported significant effects (Rapport & 
Moffit, 2002) suggesting serious risk associated with ADHD medication misuse. 
Indeed, the potential for negative side effects and adverse outcomes from ADHD 
medication is concerning when considering its role as neurocognitive enhancers.  
Social and Ethical Implications 
Recently, a number of ethical and social issues related to ADHD medication as 
a neurocognitive enhancer have garnered attention in the literature (e.g., Dubljević, 
2013; Farah, 2004; Goodman, 2010). For example, critics of cognitive neuroenhancers 
have compared cognitive neuroenhancement to cheating, arguing that gains made 
under neuroenhancement cannot be claimed as the user’s own (Goodman, 2010). 
However, a recent survey of German students revealed only small correlations 
between the use of cognitive neuroenhancers and the acts of plagiarism and fabrication 
(Dubljević, Sattler, & Racine, 2014), suggesting users may not necessarily perceive 
cognitive neuroenhancement to be as unethical as acts generally considered to be 
cheating. Arguments about the equivalence of cognitive neuroenhancement to 
cheating resemble debates about the use of anabolic steroids and human growth 
hormone performance among professional athletes – that are now generally considered 
to be illegal in most professional sports leagues.  
Regarding the ethical implications related to research, concerns have been 
raised for neurocognitive enhancement research given the potential for only minimal 
benefits, impacting a select (academic, i.e., privileged) population (Farah, 2004). Even 
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more concerning, however, is the distinction between neuroenhancement and 
“neurocorrection,” which could be used as a way of coercing individuals holding less 
power (i.e., prison populations, children) (Farah, 2004, p. 423). For example, the use 
of prescription stimulants for neuroenhancement in children and adolescents without a 
diagnosis of a neurological disorder has been considered “unjustifiable” by some (Graf 
et al., 2013, p. 1258), considering the fiduciary responsibility of physicians and the 
potential for coercion within child populations, among other reasons. Indeed, 
considering previous research has concluded ADHD medication largely controls 
children with ADHD’s behavior and does not yield any academic benefits (Advokat, 
2010), coercion is a concern even for children diagnosed with ADHD. 
On the other hand, proponents of cognitive neuroenhancers that have weighed 
the relative risks associated with medication advocate for the regulation of extended-
release stimulants as neuroenhancers, with lower abuse potential and less severe side 
effects (Dubljević, 2013; Greely, 2013). Considering the present study’s findings that 
ADHD medication provides small, but significant cognitive effects across multiple 
domains of cognition, there does appear to be justification for prescriptions stimulants 
use as cognitive neuroenhancers. Irrespective of peoples' views on the issue, however, 
prescription stimulants are already being used illegally for the purpose of cognitive 
neuroenhancement at high rates. Therefore, the establishment of public policies 
surrounding this issue, whether restrictive or liberal, is of critical importance. As Farah 
aptly explained, “The question is therefore not whether we need policies to govern 
neurocognitive enhancement, but rather what kind of policies we need” (p. 424). 
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Limitations 
 The present study has a number of strengths that support its contribution 
towards uncovering the potential of ADHD medication as a neurocognitive enhancer. 
At present, this study is the only systematic meta-analysis examining the effects of 
ADHD medication including stimulant, pro-stimulant, and non-stimulants, on a wide-
range of cognitive outcomes for adults with and without ADHD. Studies were 
searched for and retrieved from multiple bibliographic databases in order to capture as 
much data as possible and minimize publication bias. This study was the first meta-
analysis to explore the effects of ADHD medication on executive function tasks 
addressing self-regulation (creativity, cognitive flexibility, and verbal fluency), as well 
as planning and decision-making. Unique to the present study was the inclusion of 
multiple moderator variables that have not been previously explored, such as 
participant ADHD status, timing of medication activation, and number of washout 
days between sessions in studies. Finally, a major strength of the present study 
involved the well-established methodology applied to calculate mean effect sizes and 
test for moderator variables, which allowed for standardized comparisons and a high 
level of power to test hypotheses. It is particularly important to emphasize that 
previous studies examining the neurocognitive effects of ADHD medication have 
relied on sample sizes that were likely underpowered. Indeed, the 91 studies included 
in the present study relied on small sample sizes (mean n = 30.53) and resulted in 
small effect sizes. Therefore, this meta-analytic study, which pooled weighted 
estimates of effects and resulted in more power than individual studies, contributed 
greatly to the literature. 
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A number of limitations are also important to note, however, relating to the 
study’s design and methodology, as well as the theoretical foundations guiding the 
coding of cognitive data, and related to studies investigating the cognitive effects of 
ADHD medication in general. First, a limitation concerning meta-analysis 
methodology concerns its potential to overlook important individual variation by 
focusing on between-study variance (Egger & Smith, 1998b). Meta-analysis is 
plagued by issues of limited power for moderator variable detection (Hedges & Pigott, 
2004). For example, findings from the present study that indicate most of the potential 
moderator variables were not significant may reflect a lack of power as opposed to 
lack of variability. Even when moderator variables are significant, however, they are 
often confounded with other variables that are difficult to untangle from one another. 
Other criticisms of meta-analysis have included its reliance on published studies that 
may not reflect cultural diversity found in research conducted in less developed 
countries, as well as its potential for inclusion bias stemming from predetermined 
study selection criteria that may be influenced by existing literature (Egger & Smith, 
1998a). 
 A related issue that is often raised regarding meta-analyses is the potential 
influence of publication bias on meta-analytic findings.  While the present study 
utilized a number of methods to measure and minimize publication bias (Egger’s 
regression index, the funnel plot, Duval and Tweedie’s trim and fill, Orwin’s adapted 
version of Rosenthal’s fail-safe N, and an assessment of publication bias as a 
moderating variable), a concern regarding the exclusion of missing data should be 
noted. One method for handling studies that report findings as “non-significant” is to 
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record a dummy variable with the effect size set to zero. Although the present study 
used this method for studies that included at least enough data to calculate one effect 
size within the outcome measures of one instrument, using this method for all missing 
data would have provided a more conservative estimate of effect sizes. Still, 
considering the large number of studies that provided data that revealed negative and 
minimal effects, the present study’s findings appear to be representative of both 
significant and non-significant study findings. 
 Previous meta-analyses examining the efficacy of ADHD medication for 
improvements in ADHD symptoms have found significant differences between studies 
using change scores, i.e. studies comparing baseline scores, and post-treatment (or 
endpoint scores), i.e. studies comparing changes between placebo and medication 
scores, as measurement outcome (Faraone et al., 2006). Because all but one of the 
studies included in the present study reported data to calculate endpoint scores, 
findings in the present study were based on differences between placebo and 
medication scores unless only change scores were available (the case for only two 
studies, Gilbert, 1973 and Naylor et al., 1985, which reported on differences between 
change scores in placebo versus medication samples). Some studies reported data to 
allow for calculation of effect sizes for both change scores and endpoint scores (21 of 
the 91 studies included here), but considering that nearly all studies reported data to 
calculate effect sizes from endpoint scores, the present study did not calculate effect 
sizes from change scores.  
 Another important consideration is the susceptibility of meta-analysis to 
overlook important influences, such as the social context of the study, the quality of 
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the study, and theoretical influences/implications (Lispey & Wilson, 2001). For 
example, in their meta-analysis assessing stimulant effects on ADHD 
symptomatology, Faraone & Glatt (2010) suggested that the systematic variability 
across methodology between classes of drugs may have produced misleading results. 
On the other hand, two recent reviews exploring the cognitive effects of prescription 
stimulant medication in children (Pietrzak et al., 2006) and in adults (Linssen et al., 
2014) suggested that the use of meta-analysis for these investigations would be 
inappropriate due to the variability across study methodology, participant 
characteristics, treatment conditions and neuropsychological instruments used across 
studies. Indeed, it is likely that clearer patterns would have emerged if the present 
study only included studies meeting more rigid criteria (e.g., specific measures only). 
 One potential criticism of the null findings regarding differences between 
adults with and without ADHD is the present study’s decision to group all ADHD 
participants together, as opposed to investigating the differences between subtypes of 
ADHD (predominantly hyperactive/impulsive, predominantly inattentive, and 
combined). A natural expectation would be that adults with predominantly 
hyperactivity/impulsivity would receive the greatest benefits for inhibitory control and 
adults with ADHD predominantly inattentive would receive the greatest benefits in the 
area of vigilance, although with considerable overlap. Unfortunately, studies 
investigating the cognitive effects of ADHD medication on samples of adults with 
ADHD did not provide descriptive data for subtypes separately, so the present study 
could not explore this hypothesis. Future research might focus on these differences in 
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order to clarify the magnitude of neurocognitive effects from ADHD medication 
according to ADHD subtype. 
Finally, although meta-analysis is a powerful method that may help uncover 
the true effect of an intervention (Kraemer et al., 1998), results are limited by the 
quality of available published studies. Many criticisms of meta-analysis stem from the 
decision to either maintain open inclusion criteria (leading to a variety of studies that 
may not be comparable) or to adopt rigid inclusion criteria (resulting in less 
meaningful findings because of the exclusion of potentially meaningful studies) 
(Kraemer et al., 1998). Although the present study utilized inclusion criteria to select 
studies meeting standards of quality, a wide variety of study designs and study 
methodology were included. Publications also varied in the amount of detail provided 
regarding study design and participants characteristics. Of particular importance was 
the lack of report of participant ethnicity in most studies. It is unclear why so few 
studies investigating the cognitive effects of ADHD medication reported participant 
ethnicity, but considering that those that did report participant ethnicity relied on 
predominantly white samples (e.g., Halliday et al., 1986; Halliday et al., 1994; 
Rapoport, Buschman, & Weingartner, 1980; Zeeuws, Deroost, & Soetens, 2010), it 
will be important for future research to include more ethnically diverse populations.  
Another important limitation related to studies investigating the cognitive 
effects of ADHD medication relates to the tests used to measure cognition. As 
described previously, there is a considerable amount of overlap between cognitive 
constructs, and the instruments designed to measure them are just one way of 
conceptualizing cognitive outcomes. A potential criticism of the present study is the 
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subjective nature of the coding of cognitive instruments and measures. For example, 
inhibitory control was categorized as an underlying construct of Abilities of Focused 
Behavior, but an argument could be made to categorize it as an Executive Function 
considering the overlap between response inhibition and self-regulation. Likewise, 
outcome variables from the WCST, which have been used to measure inhibitory 
control in other studies (e.g., Ilieva et al., 2015) were categorized as self-regulation in 
the present study. Similar issues concerning the ranking of specific measures within 
instruments exist. For example, previous meta-analysis has implicated the format of 
the Stroop task (computer versus card) as affecting effect sizes among populations 
with Schizophrenia (Westerhausen et al., 2011). Although the present study attempted 
to select the measures most pertinent to each cognitive construct, an abundance of 
measures were available across constructs and it is possible that the present study only 
captured some of the important findings in the literature. Fortunately, the present study 
attempted to account for categorization errors and construct overlap by analyzing the 
constructs across three levels ranging in scope from broad to narrow.  
It is interesting to note that when compared to the effect sizes resulting from a 
web-based cognitive training, the effect sizes in the present study appear minimal. 
Specifically, Hardy et al. (2011) investigated the cognitive effects of Luminosity, a 
web-based cognitive training, and reported that after 30 sessions of 20 minutes 
participants scored significantly higher on measures of divided attention, spatial 
working memory, and letter memory than at pretest. Compared to a small control 
group, effect sizes were g = 1.128, g = 0.377, and g = 0.113, respectively. Although 
impressive in size (particularly for divided attention), these effect sizes may have little 
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to no clinical utility given participants were being trained and tested with the same 
cognitive exercises. In other words, these effect sizes likely indicate that Luminosity is 
beneficial for improving scores on Luminosity and little else. Likewise, it is possible 
that many of the included studies examining the cognitive effects of prescription 
stimulants are measuring improvements in tests of cognition that do not relate to 
cognitive abilities most applicable to the motivations for cognitive neuroenhancement. 
Future Directions 
The present findings suggest that ADHD medication may act as a 
neuroenhancer across a range of cognitive constructs that include abilities of focused 
behavior, learning and memory, and executive function. These effects, although small, 
appear to be significant for adults of varying ages and may be comparable for men and 
women. Still, a number of questions remain unanswered about the effects of ADHD 
medication for cognition among varying populations that may help elucidate their 
mechanism of action. 
Research is warranted to further investigate a number of areas related to 
ADHD medication for cognitive enhancement. The potential for moderating effects of 
participant characteristics, particularly baseline cognitive functioning, COMT 
genotype variability, and ADHD status, need to be clarified. If only adults with lower 
baseline cognitive functioning scores, and/or adults with the COMT val/val, receive 
neurocognitive benefits from ADHD medication many college students misusing 
prescription stimulants are taking unnecessary risks with minimal results. Or worse, if 
ADHD medication actually impairs cognitive functioning for some adults, some 
college students may actually be worsening their ability to engage in higher-level 
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learning and thinking tasks. The variability in effect sizes across studies found in the 
present study suggests that ADHD medication may have differential affects that 
appear to be relatively unexplored.  
Furthermore, adults and children with ADHD have consistently demonstrated 
impairments on many of the tests used to measure cognition, in particular those that 
rely heavily on focused attention such as tasks of focused behavior and Stroop 
interference measures (Advokat, 2010). It is therefore plausible that low baseline 
performance scores and ADHD characteristics are confounding variables, so that if 
one group benefits from ADHD medication both groups will benefit. Based on these 
findings it will also be important to understand if college students who report misusing 
prescription stimulants for academic purposes are also more likely to have higher 
levels of ADHD symptoms and/or lower levels of baseline cognitive functioning. For 
example, one explanation proposed by researchers is that a proportion of prescription 
stimulant misusers may actually be self-medicating for undiagnosed attention 
difficulties (Weyandt et al., 2013; Peterkin, Crone, Sheridan, & Wise, 2010). If this is 
the case, these students may benefit from prescription stimulant medication for the 
purpose of reducing ADHD symptoms and should be encouraged to consult with their 
medical providers. 
Studies that directly investigate the neurocognitive effects of ADHD 
medication on academic tasks, including essay composition, high level math 
calculations, and tests of learning and memory relevant to college courses will help 
shed light on how meaningful the effects found in the present study are for 
prescription stimulant misuse. Although the present study’s findings are indeed 
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meaningful, limitations related to the external validity of the included measures limit 
the finding’s generalizability to populations in academic settings.  
Although the present study attempted to include as many constructs of 
cognition as possible, there are many other areas that should be investigated in relation 
to ADHD medication. For example, the construct of Executive Function encompasses 
much more than simple tasks of cognitive flexibility, verbal fluency and decision-
making tasks. ADHD medication may offer greater benefits for other areas of 
cognition, such as volition and motivation, the latter of which has been suggested to be 
a mechanism of prescription stimulants for neuroenhancement (Volkow et al., 2008). 
Furthermore, the finding that ADHD medication did not result in effect sizes 
significantly different than zero on tasks of non-declarative memory and planning and 
decision-making was based on a small number of studies, requiring further 
examination.  
Finally, further research is warranted to better understand the underlying 
statistical power of studies that have examined the effects of ADHD medication on 
neurocognitive enhancement. Sample sizes of the studies included in the present 
investigation ranged from n = 6 to n = 536; however, the vast majority of studies (k = 
72, 79.12%) relied on sample sizes that included less than 30 participants. Considering 
the consistently small effect sizes found in the present study, it is likely that these and 
previous studies examining cognition and ADHD medication have been greatly 
underpowered. Given this serious limitation in the field, a power analysis addressing 
these studies would inform future research and provide further clarity concerning the 
variability within the present study’s findings. 
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Conclusion 
The present study supports the potential for using ADHD medication for 
neurocognitive enhancement in particular domains of cognition for both adults with 
ADHD and adults without ADHD. Specifically, ADHD medication appears to have 
enhancing effects on inhibitory control, working memory, processing speed, 
immediate and delayed memory, and self-regulation, supported by small and 
significant effect sizes in each domain. Most notably, peak effects of ADHD 
medication may be especially beneficial for memory consolidation, resulting in 
improved retention in the days following encoding, supported by a significant, 
moderate mean effect size for long-term declarative learning and memory. ADHD 
medication had little to no effects on tasks measuring planning and decision-making 
and non-declarative learning and memory; however, this finding was limited by the 
small number of studies addressing these outcomes. Finally, ADHD medication does 
not appear to influence tasks requiring sustained attention when examined separately 
from inhibitory control, suggesting that improvements in attention may relate to 
improvements in impulsivity. 
These findings have significant implications for the ethical debate regarding 
prescription stimulants for cognitive neuroenhancement. The fact that ADHD 
medication can boost long-term memory and efficiency indicates that the large number 
of college students misusing prescription stimulants for academics may actually be 
receiving meaningful benefits. Still, further research is warranted to investigate the 
academic implications of prescription stimulant misuse, i.e., does enhancement of 
tasks of cognition translate to boosts in academic grades in the college setting? Still, 
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findings indicate the need for public policy addressing the use of prescription 
stimulant medication for neurocognitive enhancement is needed, especially 
considering the medical risks associated with prescription stimulant misuse.  
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APPENDICES 
Appendix A: Article Coding Scheme 
Variable Name Description/Instructions 
Study Descriptors 
Name of Study Enter full APA reference of study. 
Country of Researcher Enter country(ies) where authors are located. 
Year of Publication Enter 4 digit number of year of publication. 
Sample Descriptors 
Targeted Sample 1 = Adults 
2 = University Students 
3 = Elderly 
4 = Adults & University Students 
NR = Not Reported 
Recruitment Type Select: 
1 = Community 
2 = University 
3 = Clinic 
4 = Military 
5 = Community & Clinic 
6 = Community & University 
NR = Not Reported 
Sample Size Enter study sample size. 
Mean Age Enter mean age of all participants. 
Standard Deviation of Age Enter standard deviation of age of all 
participants. 
Age Range Enter age range of participants. 
Ethnicity Distribution Record ethnicity distribution of participants in 
percent. 
Gender Distribution Enter percent female of participants. 
Years of Education Enter mean number of years of education. 
Measure of Cognitive/Intellectual 
Abilities 
Record name of instrument used to measure 
cognitive abilities and mean standard score 
reported. 
ADHD Status Select: 
1 = Yes 
2 = No 
Special Groups Record any additional special groups examined 
in the study. 
Methods and Procedures 
Type of Outcome Score Select: Change Score / Post treatment Score  
Study Design Select: Parallel / Crossover 
Counterbalanced For crossover studies, were treatment and 
placebo groups counterbalanced?  
1 = Yes 
2 = No 
NR = Not Reported 
NA = Not Applicable 
Randomized Was participant selection randomized for 
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Variable Name Description/Instructions 
treatment and placebo groups?  
1 = Yes 
2 = No 
NR = Not Reported 
Number of Sessions For crossover studies, record number of sessions 
administered. 
Washout Days For crossover studies, record number of washout 
days between sessions. 
Pretreatment Training or Practice 
Session 
Select: 
1 = Yes 
2 = No 
Pretest Select: 
1 = Yes 
2 = No  
Non-behavioral Measures Record inclusion of fMRI, PET, EEG, etc. and 
select: 
1 = Yes 
2 = No 
ADHD Medication Descriptors 
Medication Administration Type Select: 
1 = Fixed 
2 = Titrated 
Medication Administration Days Record number of days participants were 
administered medication. 
Medication Select: 
1 = AMP (d-AMP, MAS) 
2 = MPH 
3 = LDX 
4 = ATX 
5 = AMP & MPH 
Medication Type Select: 
1 = Short-Acting 
2 = Medium or Long-Acting 
Number of Doses Administered Record number of doses administered within 
study. 
 
Dose Level Record exact dose(s) administered. For doses 
reported per kg, calculate dose by multiplying 
dose by 62kg. 
Mean Dose Level Average dose levels and then code based on the 
following criteria: 
1 = Low (AMP < 20mg, MPH < 40mg, LDX < 
50mg, ATX < 70mg) 
2 = High (AMP ≥ 20mg, MPH  ≥ 40mg, LDX ≥ 
50mg, ATX ≥ 70mg 
Timing of Dose Relative to Assessment Record number of minutes dose was 
administered prior to learning. Then code based 
on the following criteria: 
1 = Activated Before Learning (AMP < 2hrs, 
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Variable Name Description/Instructions 
MPH < 1hr, LDX < 2hrs, ATX < 1hr) 
2 = Activated During Learning (AMP 2-3hrs, 
MPH 1-2hrs, LDX 2-4hrs, ATX 1-2hrs) 
3 = Activated After Learning (AMP > 3hrs, 
MPH > 2hrs, LDX > 4hrs, ATX > 2hrs) 
Timing of Dose Relative to Delayed 
Assessment for Memory and Learning 
If memory and learning was measured, also 
record # of minutes dose administered prior to 
memory test 
Inclusion of Other Drugs Enter if study examined additional drugs to 
AMP, MPH, LDX, and ATX select: 
1 = Yes 
2 = No 
Results 
Reported Both Significant and Non-
significant Results 
Enter if study reported results for all measures, 
both significant and non-significant: 
1 = Yes 
2 = No 
Notes. AMP = Amphetamine; APA = American Psychological Association; ATX = Atomoxetine; fMRI = 
functional Magnetic Resonance Imaging; d-AMP = Dextro-amphetamine; EEG = Electroencephalogram; 
LDX = Lisdexamfetamine Dymesylate; MAS = Mixed Amphetamine Salts; MPH = Methylphenidate; PET 
= Positron Emission Tomography. 
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Appendix B: Test-Retest Reliability Coefficients by Construct and Measure 
Test-Retest Reliability Coefficients by Construct and Measure 
Task Measure Reliability (measure) Reference 
Vigilance and Inhibitory Control 
Antisaccades Antisaccade error 
 
.92 (error rate) Wöstmann et al. 
(2013) 
Change Task 
(extension of Stop-
Signal Task) 
RT (stop-signal)* 
Mean RT (stop-signal, 
change response)* 
RT SD (stop-signal, 
change response)* 
.50 (SST, mean 
go RT) 
Wöstmann et al. 
(2013) 
Continuous 
Performance Task 
(CPT) 
 
Omission .20 (omission) Buchsbaum & 
Sostek (1980) 
 Detectability/attentiven
ess (d’) 
.76 (d’) Connors (2000) 
 Commission .59 
(commission) 
Buchsbaum & 
Sostek (1980) 
 Hit RT .95* (hit RT) Connors (2000) 
 Interstimulus interval 
Vigilance decrement 
.85 
(interstimulus 
interval) 
Buchsbaum & 
Sostek (1980) 
 Variability/SE .66* 
(Variability) 
Connors (2000) 
Digit Vigilance Test  Accuracy 
Commission 
.66 (error scores) Kelland & Lewis 
(1996) 
 RT .91 (total time) Kelland & Lewis 
(1996) 
Flanker Difference/ratio 
between congruent and 
incongruent 
accuracy/error 
Incongruent 
accuracy/error 
.65 (incongruent-
congruent 
accuracy) 
Wöstmann et al. 
(2013) 
Go/No-Go No-Go Accuracy 
Commissions 
.84  
(commission) 
Wöstmann et al. 
(2013) 
Oddball Task Omission .20 (CPT 
omission) 
Buchsbaum & 
Sostek (1980) 
  231
Test-Retest Reliability Coefficients by Construct and Measure 
Task Measure Reliability (measure) Reference 
 Commission .59 (CPT 
commission) 
Buchsbaum & 
Sostek (1980) 
Mackworth Clock Test Accuracy .76 (CPT d’)  
Rapid Visual 
Information 
Processing (RVIP) 
Detectability/target 
sensitivity (A’) 
.49 (A’) Syväoja et al. 
(2014) 
 Commission 
Omission (B’) 
.83 (CPT B’) Connors (2000) 
 RT 
Latency 
.73 (TOVA RT) Llorente et al. 
(2001) 
Stop-Signal Task P(Response) 
SSRT 
 
.03 (SSRT) Wöstmann et al. 
(2013) 
Stroop Task  Interference errors 
Interference RT 
Incongruent 
score/errors 
.82 (median 
interference) 
Wöstmann et al. 
(2013) 
Sustained Attention to 
Response Test (SART) 
Errors 
RT 
.76 (commission) Robertson et al. 
(1997) 
Test of Variables of 
Attention (TOVA) 
Omission .51 (omission) Llorente et al. 
(2001) 
 Commission 
Accuracy over time (d’) 
.71 (commission) Llorente et al. 
(2001) 
 RT .73 (RT) Llorente et al. 
(2001) 
Miscellaneous Tasks 
of Attention 
Sensitivity (d') 
Error 
Bias (β) 
.20 (CPT 
omission) 
Buchsbaum & 
Sostek (1980) 
 RT variability .75 (RT 
variability) 
Llorente et al. 
(2001) 
Working Memory 
Digit Span (DS) Standard score 
Longest span 
 
.79 (SS) Calamia, Markon, 
& Tranel, (2013) 
Dot-Letter Task  Accuracy 
Positive fit 
Span length 
.68 (SWM errors) Lowe & Rabbit 
(1998) 
  232
Test-Retest Reliability Coefficients by Construct and Measure 
Task Measure Reliability (measure) Reference 
Omissions 
Between-search 
Within-search 
Absolute 
RT 
Latency of response 
n-back  Accuracy 
Omission 
Commission 
 
.519 (0-Back 
Accuracy) 
.493 (1-Back 
Accuracy)  
.538 (2-Back 
Accuracy) 
.732 (3-Back 
Accuracy) 
Hockey & Geffen 
(2004) 
 RT .857 (0-Back RT) 
.787 (1-Back RT)  
.691 (2-Back RT)  
.806 (3-Back RT) 
Hockey & Geffen 
(2004) 
Spatial Delay 
Response  
Accuracy .68 (SWM errors) Lowe & Rabbit 
(1998) 
Spatial Location  Accuracy 
RT 
.68 (SWM errors) Lowe & Rabbit 
(1998) 
Spatial Working 
Memory (SWM) 
Accuracy 
Strategy score  
Positive fit 
Between error 
Within error 
Total error 
Absolute error 
.68 (errors) Lowe & Rabbit 
(1998) 
Spatial Span (SS) Span length 
Errors 
.64 (span) Lowe & Rabbit 
(1998) 
Sternberg Memory 
Task 
Accuracy 
RT 
RT variability 
.93 (RT) Neubauer, 
Rieman, Mayer, 
& Angleitner 
(1997) 
Trail Making Test-B 
(TMT-B) 
RT .56 (RT) Neyens & 
Aldenkamp 
(1996) 
Visual Working 
Memory Task 
Accuracy .68 (SWM errors) Lowe & Rabbit 
(1998) 
Processing Speed 
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Task Measure Reliability (measure) Reference 
Choice Reaction Time 
Tests: 
-SERS 
-Choice Visual 
Attention  
-Choice Reaction Time 
Test  
Accuracy 
Omission 
Commission 
Standard score 
RT 
.911 (RT) May et al. (1986) 
Digit Symbol 
Substitution Task 
(DSST) 
Standard score .851 (SS) Calamia et al. 
(2013) 
 AUC .851 (SS) Calamia et al. 
(2013) 
Simple Reaction Time 
Tests : 
-CNV Stop Light 
Task 
-CNV Lines Task 
-SERS  
-Simple Motor 
Response  
-Motor Reaction 
Task  
-Simple Reaction 
Time Test  
-Visual Search 
Task 
-Spatial Orienting 
Task 
RT SD 
Distraction time 
Errors 
 
.881 (RT) May et al., 1986 
 
Trail Making Test-A 
(TMT-A) 
RT .33 (RT) Neyens & 
Aldenkamp, 1996 
Declarative Learning & Memory 
California Verbal 
Learning Test (CVLT) 
Level of recall trials 1-
5 
.749 (trials 1-5 
total) 
Calamia et al. 
(2013) 
 Level of delayed free 
recall short delay 
.652 (short delay 
free recall) 
Calamia et al. 
(2013) 
 Short delay retention .621 
(recognition) 
Calamia et al. 
(2013) 
Paired Associates 
Learning Test (PAL) 
Accuracy (mean, 
maximum) 
Errors 
.57 (memory 
score) 
 
Lowe & Rabbit 
(1998) 
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Task Measure Reliability (measure) Reference 
 
 Total trials .75 (average 
trials to success) 
Lowe & Rabbit 
(1998) 
Pattern Recognition 
Memory Task 
Accuracy 
Response Latency* 
.84 (shape 
recognition) 
Lowe & Rabbit 
(1998) 
Recall of Words, 
Pictures, Stories, 
Objects Recognition of 
Words, Pictures, 
Stories, Objects  
Recall 
Recognition 
Sensitivity (d’) 
Commission 
Intrusions 
Confabulations 
Response Bias (C) 
.77 (word 
retention) 
 
Murdock (1960) 
Rey Verbal Auditory 
Learning Task 
(RVALT) 
Trial Score 
A’ (Sensitivity) 
.344 (Trial 1) 
.481 (Trial 5) 
 
Uchiyama et al. 
(1995) 
 Error .414 (intrusion 
errors) 
Uchiyama et al. 
(1995) 
Non-Declarative Learning and Memory 
Probabilistic Learning  Accuracy 
Perseverative errors 
.74 (reversal 
error) 
Freyer et al. 
(2009) 
 Mean errors to criterion .23 (spontaneous 
error) 
Freyer et al. 
(2009) 
 Feedback sensitivity .03 (strategy 
change after 
probabilistic 
error) 
Freyer et al. 
(2009) 
 RT* 
Latency of response* 
.90 (RT for first 
correct response) 
Freyer et al. 
(2009) 
Repeated Acquisition 
of Response 
Sequences Task (RA) 
 
Correct response rate 
Incorrect response rate 
.74 (probabilistic 
learning, reversal 
error) 
Freyer et al. 
(2009) 
Learning Tasks RT* .90 (Probabilistic 
learning, RT for 
Freyer et al. 
(2009) 
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Task Measure Reliability (measure) Reference 
first correct 
response) 
Reversal Learning 
Tasks  
Reward accuracy 
 
.03 (probabilistic 
learning, strategy 
change after 
probabilistic 
error) 
Freyer et al. 
(2009) 
 Punishment accuracy 
Errors 
.74 (probabilistic 
learning, reversal 
Error) 
Freyer et al. 
(2009) 
Planning and Decision Making 
Iowa Gambling Task 
(IGT) 
 
Probability of accuracy 
Advantageous choices 
Disadvantageous 
choices 
Mean Attempt of 
moves 
Deliberation time* 
Latency of RT* 
.47 (fifth deck) Cardoso et al. 
(2010) 
Tower of London 
Spatial Planning Task 
(NTOL) 
Accuracy 
Mean attempt of moves 
Latency* 
RT* 
.70 (total score) Schnirman et al. 
(1998) 
Self-Regulation 
Alternative Uses Task Mean acore .883 (number of 
figures correctly 
identified) 
Kepner & 
Neimark (1984) 
Controlled Oral Word 
Association Test 
(COWAT) 
 
Fluency score .794 (score) Calamia et al. 
(2013) 
Drawing Task from 
the Abbreviated 
Torrance Test for 
Adults  
Total score .93 Kim (2006) 
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Task Measure Reliability (measure) Reference 
Group Embedded 
Figures Task  
Accuracy .883 (number of 
figures correctly 
identified) 
Kepner & 
Neimark (1984) 
Intra-Extra 
Dimensional Set-shift 
Task  (IDED) 
Accuracy 
Total 
Extra dimensional 
Perseverative 
Discrimination 
Reversal 
Latency* 
RT* 
.70 (total errors 
to ED shift) 
Lowe & Rabbit 
(1998) 
Probabilistic Learning Accuracy 
Perseverative errors 
.74 (reversal 
error) 
Freyer et al. 
(2009) 
 Mean errors to criterion .23 (spontaneous 
error) 
Freyer et al. 
(2009) 
 Feedback sensitivity .03 (strategy 
change after 
probabilistic 
error) 
Freyer et al. 
(2009) 
 RT* 
Latency of response* 
.90 (RT for first 
correct response) 
Freyer et al. 
(2009) 
Remote Association 
Task  
Accuracy .883 (number of 
figures correctly 
identified, 
Embedded 
Figures Task) 
Kepner & 
Neimark (1984) 
Switch Cost and 
Switch Setting Tasks  
Switch cost score 
RT* 
.616 (WCST, 
perseverative 
errors) 
Calamia et al. 
(2013) 
Verbal Fluency Test  Fluency .74 (phonemic 
fluency) 
Tombaugh, 
Kozak & Rees 
(1999) 
Wisconsin Card 
Sorting Test (WCST) 
Accuracy 
Fluency 
Failures 
Perseveration errors 
.616 
(perseverative 
errors) 
Calamia et al. 
(2013) 
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Test-Retest Reliability Coefficients by Construct and Measure 
Task Measure Reliability (measure) Reference 
 Number of categories .88 categories 
sorted  
Tate et al. (1998) 
 
Notes. * indicates split-half reliability; AUC = Area Under the Curve; SD = Standard Deviation; SE = 
Standard Error; RT = Reaction Time; SSRT = Stop-Signal Reaction Time; SS = Spatial Span; SWM = 
Spatial Working Memory. 
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Appendix C: Studies Excluded Due to Insufficient Data 
 
 
Studies Excluded Due to Insufficient Data 
Study Design ADHD Status N 
Medicatio
n (Dose) Instrument (Construct) Findings 
Aman, 
Vamos, & 
Werry (1984) 
Crossover No 12 MPH (0.3-
mg/kg) 
Short Term Memory (STM) 
task (DM-D) 
CPT (V, IC) 
Fewer commission errors under MPH compared to the placebo were found 
for the CPT. Omission errors were not significantly different across MPH 
and placebo groups, although there was a trend for better performance 
under MPH. Ceiling effects were present for the STM task; therefore, 
findings for that task were not reported. 
Anderer, 
Saletu, 
Semlitsch, & 
Pascual-
Marqui (2002) 
Crossover No 20 MPH (20-
mg) NR NR 
Asghar, 
Tanay, Baker, 
Greenshaw, & 
Silverstone 
(2003) 
Crossover No 25 AMP (25-
mg) SRT (PS) 
AMP significantly decreased reaction times at 30, 60, 90, 150 and 210 
minutes compared with placebo.  
Ballard (2013) Crossover No NR 
AMP (10, 
20-mg) 
 
Memory Retrieval (DM-L) 
AMP administered before retrieval testing showed no affect on memory 
and increased false recognition, but it improved preferential emotional 
memory when administered prior to learning without increasing false 
recognition. 
Bernard, 
Penelaud, 
Mocaer, & 
Donazzolo 
(2011)  
Crossover No 18 MPH (40-
mg) CRT (PS) 
MPH was associated with decreased recognition RT compared to PBO, but 
significant differences were not found for total RT or the difference 
between recognition RT and total RT. 
Brumaghim, 
& Klorman 
(1998) 
Crossover No 22 MPH (0.3-
mg/kg) PAL (DM-I) 
MPH did not significantly reduce the number of errors during learning or 
enhance recall. Further, MPH was not found to significantly affect reaction 
and motor times; however, the task design required participants to wait 
until submitting their response, not optimal for evaluating drug effects on 
RT. 
Bullmore et 
al. (2003) Parallel No 24 
MPH (20-
mg) 
Object-Location Learning 
task (WM) No significant differences were found between the MPH and PBO group. 
Bullmore et 
al. (2001) Crossover No 12 
MPH (40-
mg) 
PAL (DM)  
n-choice motor reaction (PS) NR 
Bye, Munro-
Faure, Peck, Crossover No 12 
AMP (2.5, 
5, 7.5-mg) Auditory Vigilance Test (V) 
No significant differences were reported for errors of omission or signal 
detection (sensitivity) between AMP and PBO groups; however, mean 
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Study Design ADHD Status N 
Medicatio
n (Dose) Instrument (Construct) Findings 
& Young 
(1973). 
values indicated better performance scores for the AMP group. 
Callaway 
(1983) Crossover No 16 
MPH (5, 
10, 20-mg) RT task (PS) 
Among the young women only, RT was speeded under 10 and 20 mg of 
MPH relative to placebo (not among the older women). 
Camp-Bruno 
& Herting 
(1994) 
Parallel No 31 MPH (20-
mg) 
Recall of Verbal Learning 
(DM-I, D) 
Selective Reminding Test 
(SRT) (DM-I, D) 
Vigilance Task (V, IC) 
Vigilance task perceptual sensitivity (an estimate of hit and false alarm 
rates) and conservatism in reporting occurrence of target were not 
significantly different across the MPH and placebo groups. Vigilance RT 
was significantly lower in the MPH group compared with the PBO group 
at the 2.5-hour time point. No significant PBO-MPH group differences in 
delayed-immediate free recall performance were observed. Selective 
reminding test sum performance, however, was improved in the MPH 
relative to the PBO group (other SRT measures were non-significant). No 
significant effects of MPH were found for Total Free Recall or Forced-
Choice Pairwise-Recognition test performance for either the Free Recall or 
Selective Reminding Test tasks. 
Chamberlain 
et al. (2006) Parallel No 60 
ATX (60-
mg) 
SSRT (IC) 
probabilistic learning task 
(NDL) 
ATX was found to enhance SSRT response times relative to placebo, but 
no significant differences were found for median Go response times. For 
probabilistic learning, no significant differences between ATX and placebo 
were found. 
Clark, Geffen, 
& Geffen 
(1986b) 
Crossover No 10 MPH (0.65-
mg/kg) Task of Attention (V) 
Increases in both error rate and target detection rates were found for 
measures of divided, but not focused attention, in the MPH condition 
compared to the PBO. Significant differences were not found for 
discrimination or response time. 
Cooper et al. 
(2005) Crossover No 32 
MPH (5, 
15, 45-mg) 
Working Memory Task 
(WM) 
CPT (V) 
RT and number of omissions significantly decreased with increasing MPH 
dose. 
Crabbe, 
Jarvik, Liston, 
& Jenden 
(1983) 
Crossover No 12 AMP (10-
mg) 
DS (WM) 
DSST (PS) 
There were no significant differences between AMP and PBO groups on 
measures of DS or DSST. 
de Wit, Crean, 
& Richards 
(2000) 
Crossover No 20 AMP (10, 20-mg) Stop-Go (IC) 
AMP did not significantly affect the % of failed stop trials nor stop RT. 
"Slow stoppers", however, compared with "fast stoppers" (median split of 
group), demonstrated increased stop RT speed on AMP compared with 
PBO. This effect was not observed in the faster group. 
Dodds et al. 
(2008) Crossover No 20 
MPH (60-
mg) Reversal Learning (SR) 
MPH did not have significant effects for number of consecutive errors 
preceding a switch (perseverative errors) or the probability of switching 
after erroneous feedback. 
Evans & 
(1964) Parallel No 60 
AMP (10-
mg) 
Guilford Test of Memory 
Span (WM) 
Guilford Test of Perceptual 
Speed (PS) 
On tasks of spatial orientation AMP showed improvements compared to 
PBO, but for perceptual speed significant differences were not found 
between AMP and PBO. 
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Study Design ADHD Status N 
Medicatio
n (Dose) Instrument (Construct) Findings 
Fisch, Groner, 
Groner, & 
Menz (1983) 
Crossover No 12 MPH (5, 10-mg) Letter identification (WM) 
MPH did not significantly affect the identification of rapidly presented 
strings of letters. 
Fitzpatrick, 
Klorman, 
Brumaghim, 
& Keefover 
(1988) 
Crossover No 20 MPH (17.5 
- 25.0- mg) Item Recognition (WM) 
RTs were speeded by MPH. MPH was associated with decreased non-
responses; however, a drug*session order interaction was found wherein 
errors decreased more if PBO was administered first than if MPH was 
administered first. 
Frankenhaeus
er & Post 
(1966) 
Crossover No 30 AMP (15-
mg) SRT (PS) Performance speed was significantly improved by AMP compared to PBO. 
Halliday et al. 
(1990) Crossover No 16 
AMP (10-
mg) SERS (PS) 
AMP speeded mean RT relative to placebo and did not interact with 
response or stimulus complexity. When RT was decomposed into 
processing (PT) and distraction time (DT), AMP decreased PT for hard 
responses, but for easy response, D-AMP decreased distraction time 
(TDT). When those effects were combined to simulate mean RT, they 
cancelled each other and the differential effects disappeared. 
Halliday et al. 
(1994) crossover No 13 
AMP (10-
mg) SERS (PS) 
AMP was associated with positive effects for response processing, 
stimulus evaluation and preprocessing. 
Hamidovic, 
Dlugos, 
Palmer, & de 
Wit (2010 
crossover No 152 AMP (5, 10-mg) DSST (PS) AMP was associated with "typical" effects on the DSST 
Hermens et al. 
(2007) Crossover No 32 
MPH (5, 
15, 45-mg) 
Oddball (IC) 
CPT (V) 
Mackworth Clock (V) 
Verbal Memory Recall (DM-
I, D) 
Switching of attention (SR) 
Paced auditory serial addition 
test (PS) 
Oddball RT: significant arithmetic trend of decreasing RT to correctly 
identified stimuli with increasing MPH.  
CPT-RT: significant decreasing ordinal trend with increasing dose of 
MPH.  
CPT-Total Errors and CPT-FN errors: significant logarithmic trends, 
where errors decreased with increasing dose of MPH.  
Mackworth Clock Task: increasing MPH dose was associated with an 
ordinal trend of decreased RT Variability, Total Errors, and FNs.  
Serial test: ordinal decreasing trend with increasing MPH. MPH had 
"virtually no impact on words recalled." Results not reported for other 
tasks. 
Honey et al. 
(2003)  Crossover No 23  
MPH (20-
mg) 
Object-location learning 
(WM) 
No significant effects of MPH on accuracy or response latency were 
found. 
Kennedy, 
Odenheimer, 
Baltzley, 
Dunlap, & 
Wood (1990) 
Crossover No 16 D-AMP (10-mg) 
Grammatical Reasoning (SR) 
Code Substitution (PS) 
Short-term Memory (WM) 
Grammatical Reasoning and Code Substitution were not significantly 
affected by AMP. AMP significantly improved performance on the Short-
Term Memory Test. 
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n (Dose) Instrument (Construct) Findings 
Klorman et al. 
(1984)a Crossover No NR 
MPH (20-
mg) CPT (V, IC) 
No significant effects of MPH on test performance or response time were 
found. 
Klorman et al. 
(1984)b Crossover No NR 
MPH (20-
mg) CPT (V, IC) 
MPH did not significantly affect response time or number of errors; 
however, for errors of omission a significant decrease in the MPH group 
was found. 
Klorman et al. 
(1984)c Crossover No NR 
MPH (20-
mg) CPT (V, IC) 
MPH was found to significantly reduce the rate of omissions. Rate of 
commission errors was also lower under MPH although this difference was 
not statistically significant. RT was also speeded under MPH. 
Kollins, Rush, 
Pazzaglia, & 
Ali (1998) 
Crossover No 10 
MPH-IR, 
MPH-SR 
(20-mg) 
DSST (PS) 
Circular Lights task (PS) 
IMPH-IR (20mg) was associated with significant increases in the number 
of circular lights responses and MPH-SR (20mg) was associated with 
significant decreases in correct trials on the DSST; however, MPH-SR 
(40mg) resulted in significant increases in the number of Circular Lights 
task responses. 
Kumari et al. 
(1997) 
Crossover 
and 
Parallel 
No 60 AMP (5-
mg) 
Procedural Learning Task 
(NDL) 
Mean procedural learning scores were not significantly different between 
placebo and AMP groups; however, RT was significantly reduced in the 
AMP group. 
Kupietz, 
Richardson, 
Gadow, & 
Winsberg 
(1980) 
Crossover No 9 MPH (5, 10-mg) 
Verbal Learning of 96 
Chinese characters (DM) 
Lower dose of MPH reduced the number of total errors for the 
simultaneous instruction method only. Both doses of MPH reduced the 
numbers of errors made in reaching item criterion under the simultaneous 
instruction method but not under progressive instruction, but no significant 
differences across doses were found. Errors made in achieving two-trial 
list criterion were significantly reduced with low dose of MPH compared 
to PBO but not the high dose of MPH. 
Martin, 
Corcoran, 
Zhang, & 
Katic (2014) 
Crossover Yes 18 
LDX (50-
mg/day) 
AMP-IR 
(20-
mg/day) 
Power of Attention (V) 
Composite Power of Attention scores for both LDX and AMP-IR were 
improved relative to placebo at all post-administration time points (except 
for 2 hours post admin for LDX and 1 hour post admin for AMP-IR) 
Mintzer & 
Griffiths 
(2007) 
Crossover No 18 
AMP (20, 
30-
mg/70kg) 
Episodic memory/meta-
memory (DM-D) 
n-back (WM) 
Sternberg (WM) 
DSST (PS) 
AMP (30 only) significantly improved performance on the DSST (number 
attempted) but did not significantly affect working memory or episodic 
memory but did increase d' on the recognition memory test (AMP 30 
only).  
Mulligan 
(2002) Crossover Yes 16 
MPH (0, 
0.2, 0.4-
mg/kg) 
n-back (WM) 
Results indicated significant group differences in accuracy and RT 
increased with greater WM load. Under PBO, the control group 
outperformed the ADHD group in accuracy performance at 2-back and in 
reaction time at 3-back. Group differences under PBO disappeared with 
administration of 0.4 mg/kg of MPH, and this dose was associated with 
improved performance for the ADHD group at low (1-back) to moderate 
(2-back) levels of WM load. Findings suggest that 0.4 mg/kg dose of MPH 
improves the working memory performance of ADHD adults at low to 
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n (Dose) Instrument (Construct) Findings 
moderate levels of WM load. 
Rush, Essman, 
Simpson, & 
Baker (2001)  
Crossover No 8 
AMP (10, 
20-mg) 
MPH (20, 
40-mg) 
DSST (PS) Significant effects on DSST performance were not found for the drug 
conditions. 
Slattum 
(1992). Crossover No 8 
D-AMP (5, 
10, 20-mg) CPT (V, IC) NR 
Soetens et al. 
(1995)a Crossover No 12 
D-AMP 
(10-mg) 
Word recall (DM-I, DM-D, 
DM-L) 
AMP significantly improved recall performance for both 1 sec and 4 sec 
word presentation time conditions, relative to PBO.  
Soetens et al. 
(1995)b Crossover No 18 
D-AMP 
(10-mg) Word recall - (DM-I, DM-L) Recall of words was enhanced with AMP. 
Soetens et al. 
(1995)c Crossover No 14 
AMP (10-
mg) 
Word recall (DM-I, DM-D, 
DM-L) 
AMP interacted with session order, with the strongest effects in sessions 2 
and 3. Additionally, an interaction between AMP and moment of 
administration emerged, with AMP administered before learning 
improving performance but not when administered after learning.  
Soetens et al. 
(1995)d  Crossover No 12 
AMP (10-
mg; 
injected 
intra-
muscularly) 
Word recall (DM-I, DM-D, 
DM-L) AMP significantly improved performance at 1-day delay recall. 
Soetens et al. 
(1995)e  Crossover No 12 
AMP (10-
mg) 
Word recall (DM-I, DM-D, 
DM-L) 
AMP significantly improved recognition performance compared with 
placebo at the 1-week retest (non-significant for immediate and 1-day 
delayed recognition). 
Soetens et al. 
(1993)a Crossover No 18 
AMP (10-
mg) 
Free recall of words (DM-I, 
L) 
Significant increases in recalled words were found for memory tested a 
day after learning, and non-significant increases were shown immediately 
after learning. 
Soetens et al. 
(1993)b  Crossover No 18 
AMP (10-
mg) 
Free recall of words (DM-I, 
D, L) 
Significant increases in recalled words were found with a 1-hour and 1-day 
delay, but no significant improvements were found for immediate recall. 
Soetens et al. 
(1993)c Crossover No 12 
AMP (10-
mg) 
Free recall of words (DM-I, 
D, L) Significant effects were found for recall after a 1, 2 and 3 days delayed. 
Tipper et al. 
(2005) Parallel No 17 
AMP (2, 5, 
12.5-mg) SMT (WM) 
There was no significant difference in RT between AMP and PBO groups, 
but significant memory load and session results were consistent with 
difficulty and practice effects, respectively.  
Wetzel et al. 
(1981)a Crossover No 12 
MPH (0.5-
mg/kg) 
PAL (DM-I, DM-L) 
Picture recognition (DM-I, 
DM-L) 
Story recall (DM-I, DM-L) 
For PAL, when learning occurred before drug administration, acquisition 
was identical on placebo and MPH. Retention 24 hours later was not 
affected by MPH. When PAL learning occurred after drug administration, 
MPH resulted in poorer recall during early acquisition trials but not later 
ones, presumably due to a ceiling effect. Picture recognition was not 
significantly affected by MPH. For Story recall, when learning occurred 
prior to drug infusion, no significant differences between MPH and PBO 
were found. When learning occurred after drug administration, MPH 
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impaired recall.  
Wetzel et al. 
(1981)b Crossover No 12 
MPH (0.1, 
0.25-
mg/kg) 
PAL (DM-I) 
Picture recognition (DM-I) 
Story recall (DM-I)" 
PAL retention was not significantly affected when learning occurred either 
prior to or after infusion of MPH. Picture recognition and story recall was 
not significantly affected by MPH, either before or after learning.  
 
Zhu et al. 
(2013) 
Crossover No 18 MPH (20-
mg) Go/No-Go Task (IC) 
Significant effects were not found between the MPH and PBO groups on 
Go or No-Go accuracy. 
Notes. ADHD = Attention-Deficit/Hyperactivity Disorder; AMP = Amphetamine; AMP-IR = AMP Immediate Release; ATX = Atomoxetine; CPT = Continuous Performance Task; CRT = 
Choice Reaction Test; DM = Declarative Memory; DM-I = Declarative Memory – Immediate; DM-D = Declarative Memory – Delayed; DM – L = Declarative Memory – Long-term; DS = 
Digit Span; DSST = Digit Symbol Substitution Task; IC = Inhibitory Control; MPH = Methylphenidate; MPH-IR = MPH Immediate Release; MPH-SR = MPH Sustained Release; NDL = 
Non-Declarative Learning; NR = No Report; PAL = Paired Associates Learning Task; PBO = Placebo; PS = Processing Speed; RT = Reaction Time; SERS = Stimulus Evaluation Response 
Selection; SMT = Sternberg Memory Task; SR = Self-Regulation; SRT = Simple Reaction Test; STM = Short Term Memory Task; V = Vigilance; WM = Working Memory. 
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Appendix D: Measures by Study and Narrow Cognitive Construct 
 
Study Instrument Measure(s) 
Vigilance 
Agay et al. (2010) TOVA Omissions 
Agay et al. (2014) TOVA Weighted average of RT, RT 
errors and performance quality 
over time 
Barkley et al. (2005) CPT Omissions 
Boonstra et al. (2005) CPT Sensitivity 
Bron et al. (2014) CPT Omissions 
 TOVA Discriminative ability 
Chamberlain et al. (2007) RVIP Proportion of targets detected 
Coons et al. (1981)a CPT Omissions 
Coons et al. (1981)b CPT (and oddball) Omissions 
Costa et al. (2013) Go/No-Go Go accuracy 
Oddball accuracy 
DuPaul et al. (2012) CPT Omissions, detectability 
Elliott et al. (1997) RVIP Accuracy 
Fleming et al. (1995) CPT Omissions 
Hink et al. (1978) Auditory Attention Correct positive hits 
Kollins et al. (2015) CPT Omissions 
Kratz et al. (2009) Go/No-Go Hit Rate 
Levin et al. (2001) CPT Omissions, composite measure 
of attentiveness 
Rapoport et al. (1980) CPT Omission Errors 
Silber et al. (2006) DV Accuracy 
Sofuoglu et al. (2008) SART Omissions 
Strauss et al. (1984) CPT Omissions, Sensitivity of 
detection 
Theunissen et al. (2009) Mackworth Clock Hits 
Turner et al. (2003) RVIP Sequence detection 
Turner et al. (2005) RVIP Target sensitivity 
Whiting et al. (2008) RVIP Hit rate 
Inhibitory Control 
Agay et al. (2010) TOVA Commissions 
Allman et al. (2010) Antisaccade Antisaccade Error 
Allman et al. (2012) Antisaccade Antisaccade Error 
Aron et al. (2003) Stop-Signal SSRT 
Barch & Carter (2005) Stroop Incongruent Errors 
Barkley et al. (2005) CPT Commissions 
Ben-Itzhak et al. (2008) Go/No-Go Go/No Go Accuracy 
Boonstra et al. (2005) Stop-Signal SSRT 
 CPT Commissions 
Bron et al. (2014) CPT Commissions 
 TOVA Commissions 
Chamberlain et al. (2007) Stop-Signal 
RVIP 
SSRT 
Commissions 
Chamberlain et al. (2009) Stop-Signal SSRT 
Chevassus et al. (2013) Stroop Stroop-Color word T 
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Study Instrument Measure(s) 
Clark et al. (1986a) Task of Attention Error Rate 
Coons et al. (1981)a CPT (2 versions) Commissions 
Coons et al. (1981)b CPT (and oddball) Commissions 
Costa et al. (2013) Go/No-Go No-Go errors 
 Stop-Signal SSRT 
de Bruijn et al. (2004) Flanker Errors 
 Go/No-Go Commissions 
Total correct 
DuPaul et al. (2012) CPT Commissions 
Faraone et al. (2005) Stroop Interference 
Fleming et al. (1995) CPT Commissions 
Graf et al. (2011) Go/No-Go Commissions on no-go 
incongruent 
Hester et al. (2012); 
Nandam et al. (2014) 
Go/No-Go No-Go accuracy 
Hink et al. (1978) Auditory Attention False positives 
Idestrom & Schalling 
(1970) 
Stroop Incongruent RT 
 
Ilieva et al. (2013) Go/No-Go 
Flanker 
Commissions 
Inhibition Cost 
Kollins et al. (2015) CPT Commissions 
Kratz et al. (2009) Go/No-Go Impulsivity Errors 
Levin et al. (2001) CPT Commissions 
Linssen et al. (2012) Stop-Signal SSRT 
Moeller et al. (2014) Stroop Interference 
Nandam et al. (2011) Stop-Signal SSRT 
Pauls et al. (2012) Stop-Signal SSRT (two versions) 
Rapoport et al. (1980) Stroop Commissions 
Servan-Schreiber et al. 
(1998) 
Flanker Incongruent Errors 
Silber et al. (2006) DV False Alarms 
Sofuoglu et al. (2008) SART Commissions 
Spencer et al., 1998 Stroop Interference T 
Strauss et al. (1984) CPT Commissions 
Taylor & Russo (2000) Stroop Stroop-Color Word T 
Taylor & Russo (2001) Stroop Interference 
Theunissen et al. (2009) Mackwoth Clock Stop RT 
Turner et al. (2003) RVIP False Alarms 
Turner et al. (2005) RVIP Response Bias 
Working Memory 
Agay et al. (2010) DS DS Forward 
DS Backward 
Agay et al. (2014) DS; WM Task DS Forward 
DS Backward 
SWM Errors 
SWM Strategy Score 
Barch & Carter (2005) Dot-Letter Task Accuracy 
Brumaghim et al. 
(1987)a 
Recall of 
Consonants 
Error rate 
Brumaghim et al. Recall of Error rate 
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Study Instrument Measure(s) 
(1987)b Consonants 
Campbell-Meiklejohn et 
al. (2012) 
n-back Hits 
Misses 
False Alarms 
Chamberlain et al. (2007) SWM Total Between-Search Errors 
Strategy Score 
Chevassus et al. (2013) DS DS  
Clatworthy et al. (2009) SWM SWM Errors 
de Wit et al. (2002) DS DS 
Duke & Keeler (1968) TMT-B RT 
Elliott et al. (1997) SWM Strategy Score 
Fillmore et al. (2005) RIP RIP Score 
Fleming et al. (1995) Spatial Delay 
Response 
Accuracy 
Gilbert et al. (1973) DS DS 
Ilieva et al. (2013) DS DS Backward  
DS Forward  
 n-back Omissions 
Kollins et al. (2015) n-back Accuracy 
Linssen et al. (2012) SWM Accuracy  
Absolute Errors 
Positive Fit 
Linssen et al. (2014) SWM Accuracy  
Absolute Errors 
Positive Fit 
Makris et al.(2007) Number 
Recognition 
Accuracy 
Marquand et al. (2011) SWM Accuracy for Rewarded 
Accuracy for Nonrewarded 
Mattay et al. (2000) n-back Accuracy 
Mehta et al. (2000) SWM Between-search errors Within-
search errors  
 n-back Hit rate 
False alarm rate 
Sensitivity 
Oken et al. (1995) DS DS Forwards 
DS Backwards 
Ramasubbu et al. (2012) n-back Accuracy 
Errors 
Misses 
Silber et al. (2006) DS DS Forwards 
DS Backwards 
 TMT-B  RT 
Studer et al. (2010) Visual WM Accuracy 
Taylor & Russo (2000) DS DS Forward 
DS Backward 
Turner et al. (2003) DS DS Forward 
DS Backward 
 SWM Strategy Score 
Between-search errors 
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Study Instrument Measure(s) 
Within-search errors 
 SSP Span length 
Total errors 
Turner et al. (2005) SWM Strategy score 
Between errors  
Within errors 
 n=back Span length 
Total errors 
van der Schaaf et al. 
(2013) 
DS  
DS Forward 
DS Backward 
Wardle et al. (2013) n-back Accuracy 
Processing Speed 
Chevassus et al. (2013) DSST DSST score 
 SRT RT 
 CRT RT 
Coons et al. (1981)b CRT Omissions 
Commissions 
RT 
Duke & Keeler (1968) TMT-A RT 
Finke et al., 2010 Whole-report Task Rate 
Halliday et al. (1986)a SERS RT 
Halliday et al. (1986)b SERS RT 
Idestrom & Schalling 
(1970) 
DSST DSST score 
Kornetsky (1958) Simple Motor 
Response 
RT 
Linssen et al. (2011) SRT Accuracy 
RT 
Makris et al.(2007) DSST Accuracy 
Trial Rate 
 DSST Number attempted 
Proportion correct 
Muller et al. (2005) Motor Reaction Errors 
Naylor et al. (1985) SERS RT 
Oken et al. (1995) Spatial Orientation 
Visual Search 
RT 
Errors 
Samanez-Larkin et al. 
(2013) 
DSST DSST score 
Silber et al. (2006) DSST DSST Score 
 TMT-A RT 
Ward et al. (1997) NR Latency 
 DSST Trial Rate 
Accuracy Rate 
Wardle et al. (2013) DSST AUC 
Weitzner (1965) Digit Letter Coding Errors 
Immediate Declarative Learning and Memory 
Ben-Itzhak et al. (2008) Recognition of 
object orientation 
Accuracy 
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Study Instrument Measure(s) 
Brignell et al. (2007) Recognition of 
story; Recall of 
object 
Accuracy 
Confabulations  
Errors 
Recognition 
Chevassus et al. (2013) Recall of pictures Recall  
DuPaul et al. (2012) CVLT Level of Recall Trial 1-5 Total 
Short Delay Retention 
Finke et al., 2010 Whole-report Rate 
Fleming et al. (1995) RAVLT Trial 1 
Trials 1-5 
  
PAL 
AB trial 1 
AB trials 1-3 
AC trial 1 
AC trials 1-3 
AB-AC 
Gilbert et al. (1973) GMT Paragraphs 
Paired Associates 
Designs 
Kinsbourne et al.(2001) PAL Accuracy 
Linssen et al. (2014) RVALT Mean score 
 PAL Maximum 
Mean 
Turner et al. (2003) PAL First trial memory score 
Total errors 
Total trials 
Turner et al. (2005) PRM Accuracy 
Unrug et al. (1997) Recall of 
vocabulary 
Recall 
Verster et al. (2010) Recall and 
recognition of 
words 
Recall 
Recognition 
 
Weitzner (1965) PAL Trials to criterion 
Zeeuws & Soetens 
(2007) 
Recall of words Recall accuracy 
Number of intrusions (errors)  
Zeeuws et al. (2010a) Recall of words Sensitivity 
Response Bias 
Zeeuws et al. (2010b)a Recall of words Response Bias 
Hits 
False Alarms 
Zeeuws et al. (2010b)b Recall of words Response Bias 
Hits 
False Alarms 
Delayed Declarative Learning and Memory 
Brignell et al. (2007) Recall of story (20 Recall 
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Study Instrument Measure(s) 
min.) 
DuPaul et al. (2012) CVLT (20 min.) Level of Recall Long-Delay 
Free 
Long-Delay Retention 
Ilieva et al. (2013) Recognition of 
faces; Recognition 
of words (120 min.) 
Recall accuracy 
Recognition accuracy 
Linssen et al. (2014) RVALT (30 min.) Mean Score Recall 
Sensitivity 
Turner et al. (2005) PRM (20 min.) Accuracy 
Unrug et al. (1997) Recall of 
vocabulary (20 
min.) 
Recall 
Verster et al. (2010) Recall of words 
(120 min.) 
Recall 
Recognition 
Zeeuws & Soetens 
(2007) 
Recall of words (30, 
60 min.) 
Recall accuracy 
Number of intrusions (errors)  
Zeeuws et al. (2010a) Recall of words (60 
min.) 
Sensitivity 
Response Bias 
Zeeuws et al. (2010b)a Recall of words (60 
min.) 
Response Bias 
Hits 
False Alarms 
Zeeuws et al. (2010b)b Recall of words (60 
min.) 
Response Bias 
Hits 
False Alarms 
Long-term Declarative Learning and Memory 
Ballard et al. (2013) Recall of pictures (2 
days) 
Hit Rate  
False Alarm Rate  
Ballard et al. (2014) Recall of pictures; 
Recognition of 
words (2 days) 
Recall 
Recognition 
Izquierdo et al. (2008) Retention of facts 
(2 days, 1 week) 
Retention 
Linssen et al. (2014) RVALT (1 day) Recall 
RT  
Sensitivity  
Whiting et al. (2008) Recall of names; 
Recognition of 
names (1 week, 1 
month) 
Recognition 
Zeeuws & Soetens 
(2007) 
Recall of words (1 
day) 
Recall accuracy 
Number of intrusions (errors)  
Zeeuws et al. (2010a) Recall of words (1 
day, 1 week) 
Sensitivity 
Response Bias 
Zeeuws et al. (2010b)a Recall of words (1 
day, 1 week) 
Hits 
False Alarms 
Response Bias 
Zeeuws et al. (2010b)b Recall of words (1 
day, 1 week) 
Hits 
False Alarms 
Response Bias 
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Study Instrument Measure(s) 
Measures by Study and Instrument of Non-Declarative Learning and Memory 
Breitenstein et al. (2004) AWL Learning Curve  
Burns et al. (1967) Learning Task Learning Rate 
Kornetsky (1958) SLT RT 
Makris et al.(2007) RA Response rate 
Accuracy 
Schlösser et al. (2009) Probabalistic 
Decision-Making 
Task 
Probability RT 
van der Schaaf et al. 
(2013) 
Reversal Learning  Accuracy 
Measures by Study and Instrument of Planning and Decision-Making 
Agay et al. (2010) IGT Number of advantageous 
choices 
Agay et al. (2014) IGT IGT dis 
FPGT dis 
Elliott et al. (1997) NTOL Movement rate 
Accuracy rate 
Linssen et al. (2012) NTOL Accuracy 
RT 
Turner et al. (2003) NTOL Move attempts 
Latency 
 
 IGT Probability of selecting most 
likely outcome 
Deliberation time  
Measures by Study and Instrument of Self-regulation 
Chamberlain et al. (2007) IDED Total errors 
Total reversal errors 
ED shift errors 
Clatworthy et al. (2009) Reversal Learning Errors 
Elliott et al. (1997)  
IDED 
 
Perseverative errors 
 Verbal Fluency Test Letter Fluency 
Category Fluency 
Farah et al. (2009) RAT Accuracy 
 Embedded Figures Accuracy 
 AUT Mean score 
 Drawing Task Mean score 
Fleming et al. (1995) WCST Number of categories 
Perseverative responses 
Failures 
 COWAT Fluency 
Ilieva et al. (2013) RAT Accuracy 
 Embedded Figures Accuracy 
Linssen et al. (2012) IDED Accuracy 
Mattay et al. (1996) WCST Conceptual level 
Accuracy 
Number of categories 
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Study Instrument Measure(s) 
Perseveration error 
Rogers et al. (1999) IDED Errors 
Accuracy 
Samanez-Larkin et al. 
(2013) 
SCT RT 
Switch Cost 
Taylor & Russo (2000) COWAT COWAT score 
Taylor & Russo (2001) COWAT COWAT score 
Turner et al. (2003) IDED Total errors  
ED errors 
van der Schaaf et al. 
(2013) 
Reversal Learning 
(shifting) 
Accuracy 
Wardle et al. (2013) WCST Perseverative errors  
Notes. AUC = Area Under the Curve; AUT = Alternative Uses Test; AWL = Associative Word 
Learning; COWAT = Controlled Oral Word Association Test; CPT = Continuous Performance Task; 
CRT = Choice Reaction Test; CVLT = California Verbal Learning Test; DVT = Digit Vigilance Task;  
DS = Digit Span; DSST = Digit Symbol Substitution Task; GMT = Guild Memory Test; IDED = 
Intra-Extra Dimensional Set-Shift Task; IGT = Iowa Gambling Task; PAL = Paired Associates 
Learning Task; PRM = Pattern Recognition Memory Task; RA = Repeated Acquisition of Response 
Sequences Task; RAT = Remote Associations Task; RIP = Rapid Information Processing Task; RT = 
Reaction Time; RVALT = Rey Verbal Auditory Learning Task; RVIP = Rapid Visual Information 
Processing; SART = Sustained Attention to Response Test; SCT = Switch Cost Task; SERS = 
Stimulus Evaluation Response Selection; SLT = Simple Learning Task; SRT = Simple Reaction Test; 
SSP = Spatial Span Task; SSRT = Stop-Signal Reaction Time; SWN = Spatial Working Memory; 
NTOL = Tower of London Spatial Planning Task; TOVA = Test of Visual Attention; TMT = Trail-
Making Task; WCST = Wisconsin Card Sorting Test; WM = Working Memory 
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